

## Curriculum Vitae

Anne Searls De Groot M.D.

DR.ANNIE.DEGROOT@GMAIL.COM

ANNIED@EPIVAX.COM

### Current Position

CEO/CSO EpiVax, Inc.	1998-present
Professor, Director Institute for Immunology and Informatics (URI)	2008-present

### Biography

Educated at **Smith College** (BA, 1978), Pritzker School of Medicine / **University of Chicago** (MD, 1983), Internal Medicine (New England Medical Center, 1986); additional training in immunoinformatics and vaccinology with Russell Howard and Jay Berzofsky at the **National Institutes of Health** (Laboratory for Parasitic Diseases and National Cancer Institute, 1986-89), followed by clinical training in infectious disease at **New England Medical Center** (1989-92). Board certified Internal Medicine (1986) and Infectious Disease (1992). Joined **Brown University Medical School**, and opened the TB/HIV Research Laboratory in 1992. Licensed EpiMatrix vaccine design technology from her laboratory at Brown and established **EpiVax** with Bill Martin, 1998. Invited to direct the activities of the **Institute for Immunology and Informatics** at University of Rhode Island, beginning October, 2008 and awarded \$13M to initiate research on epitope-driven vaccines at the Institute in 2009.

Recipient of a NFID-Eli Lilly Award, two RI Foundation awards and a **Commercial Innovation Award** (Slater Biomedical Foundation), given a **Genius Award** in Science and Technology by Esquire Magazine (2003) and honored by the RI Tech Collective (2006) for work on the GAIA HIV vaccine. Awarded **RI Woman Physician of the Year** in 2006, received the Alvan Fisher **Red Ribbon Award** for Medical Advocacy from AIDS project Rhode Island in December 2007 and the **Woman of Achievement Award**, 2008 from the YWCA for her work relating to Access to Care in Providence and West Africa. Founded (with other healthcare providers) **Clínica Esperanza/Hope Clinic** in 2007; raised funds to open the clinic in a dedicated space December 2010. Has published more than 120 research papers, chapters and reviews in addition to numerous essays and blogs. On May 22, 2009, was given the **Lifetime Achievement Award** at the Business Women Awards by Providence Business News. Featured as a **Top Doctor in Rhode Island** in the RI Monthly, May 2010. RI Bioscience Award from the Tech Collective in 2013. Mother of two young adults (Aminata 21, Zeno 24). **De Groot was one of five "Smith Medalists" in 2013.** The Smith College Medal is awarded to "those alumnae who, in the judgment of the trustees, exemplify in their lives and work the true purpose of a liberal arts education."

**According to the Smith Medal 2013 Press Release:** *Internationally known for her research on the immune system's response to vaccinations, Anne De Groot has explored the "genome-to-vaccine" approach to solving some of the world's biggest infectious disease problems. First at **Brown University** and now at **the University of Rhode Island**, she has introduced the next generation of researchers to the field. De Groot has dedicated her medical skills and research to expanding the availability of vaccines by founding the **Global Alliance to Immunize against AIDS (GAIA) Vaccine Foundation** that collaborates with clinics and laboratories in Mali, West Africa, and was part of a group of medical volunteers who founded the **Clínica Esperanza /Hope Clinic**, a community health center that offers free medical care and preventive health services to Rhode Island residents.*

**Education**

B.A., Smith College, Northampton, Massachusetts	1974-1978
M.D., Pritzker School of Medicine, University of Chicago	1979-1983

**Post-Graduate Training**

Residency in Internal Medicine	1983-1986
Department of Internal Medicine	
Tufts New England Medical Center, Boston Massachusetts	

**Fellowship in Parasitology and Vaccine Research** 1986-1989

National Research Service Award Fellow, National Institutes of Health  
Malaria Section, Laboratory of Parasitic Diseases, NIAID (Russell Howard, Michael Good)  
Metabolism Branch, NCI, National Institutes of Health (Laboratory of Jay A. Berzofsky)

**Fellowship in Infectious Disease** 1989-1992

Division of Geographic Medicine and Infectious Disease, Gerald Keusch (Chief)  
Tufts New England Medical Center, Boston Massachusetts, David Wyler (Lab Chief)

**Fellowship in Societies**

Fellow of the International Society for Vaccinology	Oct 2013-
---	-----------

**Graduate and Post-Graduate Honors/Awards**

Kraft Nutrition Fellow: Research on newborn nutrition in Zaire and South Africa	1983
National Research Service Award for malaria and HIV immunology research	1986-1989
NFID Eli Lilly Award for TB immunology research	1991-1992
Visiting Scholar Award, TMRC, RITM, Manila, the Philippines	1995
Woman in Science of the Year, Women and Infants Hospital Auxiliary Committee	2002
Esquire "Best and the Brightest 2003" (Science and Industry)	2003
Unsung Heroes of HIV Rhode Island HIV Prevention Planning Committee	2004
Rhode Island Woman Physician of the Year, 2006	2006
Dr. Al Fisher Red Ribbon Award, Medicine, AIDS Project Rhode Island	2007
YWCA "Woman of Achievement Award" (Health Care)	2008
Lifetime Achievement Award 2009 (Providence Business News)	2009
Bank of America "Local Hero" (for Clinica Esperanza/Hope Clinic)	2010

July 2014

“Top Doctor” in the Jewelry District, Providence RI (RI Monthly)	2010
Community Service Award (CEHC) from Dorcas Place	2012
Smith Medalist (Smith College Outstanding Alumna)	2013
Rhode Island Bioscience Award Winners	2013
Elected Fellow of the International Society for Vaccinology	2013

**Professional Licenses and Board Certification**

Internal Medicine	1987
Infectious Disease	1992
American Academy of HIV Medicine AAHIVM	2002

**Academic Appointments**

Clinical Instructor, Department of Medicine Division of Geographic Medicine and Infectious Diseases	1989-1991
Special Scientific Staff, Department of Medicine Division of Geographic Medicine and Infectious Diseases Tufts New England Medical Center	01/92-06/92
Assistant Professor of Medicine and Community Health Division of Biology and Medicine Joint appointment in the Department of Medicine and the Department of Community Health, Brown University School of Medicine	07/92-12/00
Assistant Professor of Community Health (Research) Vincent Mor, Ph.D. Chairman Division of Biology and Medicine Brown University School of Medicine	01/01- 06/02
Associate Professor of Community Health (Research) Vincent Mor, Ph.D. Chairman Division of Biology and Medicine Brown University School of Medicine	07/02-12/05
Adjunct Associate Professor of Medicine	01/06-03/08

Division of Biology and Medicine  
Brown University School of Medicine

Adjunct Associate Professor of Pediatrics 03/08-05/11  
Division of Biology and Medicine  
Brown University School of Medicine

**Current:** Professor, Biotechnology (Research) Sept 1, 2008-  
College of Environmental and Life Sciences  
John Kirby, Ph.D., Dean  
University of Rhode Island

**Current:** Director, Institute for Immunology and Informatics Sept 1, 2008-  
University of Rhode Island Biotechnology Program

**Hospital Appointments**

Assistant Director, HIV/AIDS Unit, Lemuel Shattuck Hospital 07/92-06/93  
Director, Dual Infection (HIV/TB) Clinic, Lemuel Shattuck Hospital 05/93-01/94  
Medical Staff, Geographic Medicine, Miriam Hospital, RI 07/92-present  
Medical Staff, Infectious Diseases, (HIV clinic) Memorial Hospital of RI 07/97-06/01  
Medical Staff, Rhode Island State TB Clinic (Roger Williams Hospital) 10/93-07/01  
TB Clinic Staff/ Miriam Hospital Rise Clinic (TB Clinic) 07/01-present  
Staff, HIV in Prisons Program, Yale University (York Institution for Women) 08/96-11/04  
Rhode Island Free Clinic (Volunteer MD) 01/03-07/07  
Clínica Esperanza Interim Medical Director, Olneyville, Rhode Island) (Volunteer) 07/07-present

**Other Appointments (Previous)**

Director, I.D. (HIV) Clinic for Female Inmates, 05/92- 01/96  
Massachusetts Correctional Institution at Framingham  
(under the MA Department of Public Health and the Shattuck Hospital)  
Yale HIV in Prison Program  
York Correctional Facility HIV Clinic Staff 01/96-11/04  
Medical Director, Clinica Esperanza/Hope Clinic 07/2007-present

**Other Appointments (Current)**

CEO, CSO **EpiVax Inc.** (Founding partner) 5/98-present

EpiVax is a specialized biotech company that holds the exclusive license to the EpiMatrix technology. The company is located at 146 Clifford Street, in Providence. Clients have included vaccine companies (Wyeth, Chiron), pharmaceutical companies (Genentech, Roche, Bristol Meyers Squibb, Amgen), other biotechnology companies (Sequella), the Department of Defense (BDRD, DARPA) and academic groups (CDC, Forsythe Institute, and the USAMRIID, NMRC, UMD, UCSF, SLU, UPitt, etc. (See <http://www.EpiVax.com>).

Founder and Co-Chief editor, **Infectious Diseases in Corrections Report (IDCR)** 7/98-7/2008

Formerly known as HIV Education/Prison Project Report (HEPP Report)

Monthly update on the management of Infectious Diseases (Hepatitis and HIV) specifically geared to address the needs of correctional health providers in prison settings. Yearly Budget \$250,000. 12 Employees and Contributors (Full and Part time). Circulation: >20,000 by facsimile and email. Website <http://www.HIVcorrections.org>

Founder and Scientific Director / **GAIA Vaccine Foundation** 5/01-present

GAIA (Global Alliance to Immunize against AIDS) is a non-profit (501C-3) organization that supports the development of a “Globally relevant, globally accessible” AIDS vaccine. EpiVax and Brown U. (Brown University Research Foundation) have agreed in principle to license the HIV vaccine that is currently being developed by the TB/HIV Research Lab in collaboration with EpiVax to GAIA. GAIA is seeking to fund further development of the vaccine through studies to be carried out in developing countries such as Mali, in West Africa. The GAIA Vaccine Foundation efforts are directed by the GAIA Board of Directors (See <http://www.GAIAvaccine.org>).

Founding member and Interim Medical Director, **Clinica Esperanza/ Hope Clinic.** 07/07- present

Clinica Esperanza/Hope Clinic is a community initiative-free clinic that offers free, high quality medical care and preventive health services to adults living in Rhode Island who do not have health insurance or cannot afford to purchase health care. Located in the Olneyville neighborhood of Providence, Clinica Esperanza patients receive care from an all-volunteer staff of highly trained and qualified physicians, nurse practitioners, nurses, medical assistants, medical students and interpreters.

**Editor/Editorial Boards**

Founder and Chief Editor Infectious Diseases in Corrections Report (IDCR)	1998-2008
Editor, AIDS Reader; Guest Editor (Prison series)	2000-2008
Guest Editor, Rhode Island Journal of Medicine (Clinical Trials series)	2000
Invited Editor for issue of Methods (Academic Press)	2004
Co-editor (with L. Moise) of Special Issue in Medicine and Health Rhode Island	2007

Editorial Board, Emerging Infectious Diseases	2001-2004
Editorial Board, Human Vaccines	2008-present
Editorial Board, Immunome Research	2004-2012
Editorial Board, Current Opinion in Immunology.	2012-2013

### University Committees

People's Health Colloquium, Working group on the Social and Community Contexts of Health Care; Brown University School of Medicine	1992-1993
Foreign Research Fellowship Committee, Brown U. Medical School	1996-1997
Fogarty ARTP, International Health Institute, Senior Executive Committee	1996-1998
URI Center for Biotechnology and Life Sciences Development Committee	2008-2009

### Other Committees

Expert Panel, Health Status of Soon-to-be-released Inmates Project	1999
<b>National Commission on Correctional Health Care</b>	
Advisory Panel, <b>World Health Organization</b> TB Programme	1998-2000
National AIDS Minority Council ( <b>NMAC</b> ) Prison Advisory Panel	2000-2004
<b>HRSA</b> Advisory Panel on Medical Case Management and Support Services to Individuals with HIV Disease Being Released from Federal or State Prisons	2002
Rhode Island Technology Council <b>BioGroup Steering Committee</b>	2004- present
Advisor to Public Health Watch HIV/AIDS Project, <b>Open Society Institute</b>	
Assessment of the United States response to its domestic HIV/AIDS epidemic	2005-2006
UN <b>Millennium Village Project Medical Advisor</b> (Peter Hotez, Sonia Sachs)	2006-present
<b>Entrepreneurship "Hot Team"</b> Providence Chamber of Commerce	Summer 2008
Co-Leader (with Barrett Bready) of Mayor Cicilline's <b>Biotech Jewelry District Initiative</b>	2007-2009
Smith College <b>Fulfill the Potential Project</b>	2008-present
Mayoral <b>Transition Team</b> (Providence, RI, Focus on Economy)	2010-2012
<b>Jewelry District Biotech Development Committee</b> (Providence)	2011-2012
<b>RI Bioscience Leaders</b> (Member)	2012-present

### Board Membership

International Immunomics Society	2003-present
Rhode Island Free Clinic Medical Advisory Board	2004-2007
Clinica Esperanza/Hope Clinic Medical Advisory Board	2007-present
International Vaccine Society Executive Board	2009- present

Urban Action Community Development Board 2010- present

**Membership in Societies**

Massachusetts Medical Society	current
Massachusetts Infectious Diseases Society	previous
Rhode Island Medical Society	current
Rhode Island Medical Women's Association	current
International Immunomics Society	current
International Vaccine Society (Fellow)	current
American Association of HIV Medicine	until 2010

**Languages**

English and French (Fluent); Spanish (Fluent Medical Spanish), Italian (Conversational)

**Primary Publications**

1. Quakyi IA, Otoo LN, Pombo D, Sugars LY, Menon A, A.S. DeGroot, Johnson AH, Alling D, Miller LH, and Good MF, **Differential nonresponsiveness in humans of candidate *Plasmodium falciparum* vaccine antigens**, *Am. J. Trop. Med. Hyg.*, 1989, Vol. 41, Issue 2, pp. 125-134.
2. A.S. De Groot, Johnson AH, Maloy WL, Quakyi IA, Riley EM, Menon A, Banks S M, Berzofsky JA, and Good MF, **Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein**, *J. Immunol.*, 1989, Vol.142, No.11, pp. 4000-4005.
3. Good MF, Kumar S, A.S. De Groot, Weiss WR, Quakyi IA, Dontfraid F, Smith FE, Cochran M, Berzofsky JA, Miller LH, **Evidence implicating MHC genes in the immunological nonresponsiveness to the plasmodium falciparum CS protein**, *Bulletin of the World Health Organization*, 68 Supplement: pp. 80-84, 1990.
4. A.S. De Groot, Hosmalin CM, Hughes A, Barnd SH, Hendrix D, Houghten CW, Shearer GM, Berzofsky JA, **Human Immunodeficiency Virus Reverse Transcriptase T Helper Epitopes Identified in Mice and Humans: Correlation with a Cytotoxic T Cell Epitope**, *J. Infectious Disease* 1991, Vol.164, pp.1058-1065.
5. A.S. De Groot, Scheib RG, McGowan K, Schmid CP, Lieberman J, Wyler DJ, **T-cell responses to *Mycobacterium tuberculosis* antigens in the HIV-infected host**. *Vaccines* 93, Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 251-257.
6. Meister GE, Roberts CGP, Berzofsky JA, A.S. De Groot, **Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from *Mycobacterium tuberculosis* and HIV protein sequences**, *Vaccine* 1995, Vol. 13, No. 6, pp. 581-591.
7. A.S. De Groot, Jesdale BM, Meister GE, Muni N, Roberts CGP, **Prediction of T Cell Epitopes for HIV vaccine development by computer-driven algorithm**, in *HIV Molecular Immunology Database* 1995, Bette Korber, Gerald Meyers eds., Los Alamos National Laboratories, New

- Mexico, pp. iv17-iv28.
8. Stevens J, Zierler S, Dean D, Goodman AK, Chalfen EM, A.S. De Groot, **Prevalence of prior sexual abuse and HIV risk-taking behaviors in incarcerated women in Massachusetts**, *J. Correctional Health Care*, 1995, Vol. 2, Issue 2, pp. 137-149.
  9. Stevens J, Zierler S, Cram V, Dean D, Mayer KH, A.S. De Groot, **Risks for HIV infection in incarcerated women**, *J. Women's Health*, 1995, Vol. 4, No. 5, pp. 569-577.
  10. A.S. De Groot, Carter EJ, Roberts CGP, Edelson BT, Jesdale BM, Meister GE, Houghten RA, Montoya J, Romulo RC, Berzofsky JA, and Ramirez BDLL, **A novel algorithm for the efficient identification of T cell epitopes: prediction and testing of candidate TB vaccine peptides in genetically diverse populations**, *Vaccines* 96, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 127-134.
  11. Roberts CGP, Meister GE, Jesdale BM, Lieberman J, Berzofsky JA, A.S. De Groot, **Prediction of HIV peptide epitopes by a novel algorithm**, *AIDS Research and Human Retroviruses*, 1996, Vol. 12, No. 7, pp. 593-610.
  12. A.S. De Groot, Jesdale BM, Szu E, Schafer JR, Chiczy RM, Deocampo G. **An interactive Web site providing major histocompatibility ligand predictions: application to HIV research**. *AIDS Res Hum Retroviruses*. 1997 May 1; 13(7):529-31.
  13. Jesdale BM, Deocampo G, Meisell J, Mullen L, Beall J, Marinello M, A.S. De Groot, **Matrix-based prediction of MHC-binding peptides: the EpiMatrix algorithm, reagent for HIV research**, *Vaccines* 97, pp. 57-64, Cold Spring Harbor Laboratory Press 1997.
  14. Nguyen, KB, Suri, PK, Shah, AM, Goldberg, M, De Groot, AS, and Knopf, PM. **Differential immune responses against a *Schistosoma mansoni* candidate vaccine antigen in three murine strains**. *Vaccines* 97, 1997, 213-217.
  15. Gampper, SNR, George JA, Carter EJ, Jesdale BM, Flanigan TP, Mayer KH, A.S. De Groot, **Co-infection with *M. tuberculosis* (Mtb) and HIV in high risk clinical care settings in Rhode Island**, *AIDS Care*, 1998, Vol. 10, No. 2, pp. 221-229.
  16. Santiago ML, Santiago EG, Hafalla JCR, Manalo, MA, Orantia, L, Cajima, MNB, Martin C, Cuaresma, C, Dominguez CE, Borromeo ME, A.S. De Groot, Flanigan TP, Carpenter CJ, Mayer KH, Ramirez B, **Molecular Epidemiology of HIV-1 Infection in the Philippines, 1985-1997: Transmission of Subtypes B and E and Potential Emergence of Subtypes C and F**, *J. AIDS and Hu Retrovirology*, 1998, Vol. 18, No. 3, pp. 260-269.
  17. Schafer JA, Jesdale BM, George JA, Kouttab NM, A.S. De Groot, **Prediction of well-conserved HIV-1 ligands using a Matrix-based Algorithm, EpiMatrix**, *Vaccine*, 1998, Vol. 16, No. 19, pp. 1880-1884.
  18. Fink MJ, Goodman, AK, Hight E, Miller- Mack E, A.S. De Groot, **Critical prevention, critical care: gynecological and obstetrical aspects of comprehensive HIV prevention and treatment among incarcerated women**. *J. Correctional Health Care*, 1998, Vol. 5, Issue 2, pp.201-223.
  19. A.S. De Groot, Leibel SR, Zierler S, **A Standard of HIV care for incarcerated women: Northeastern United States' Experiences**. *J. Correctional Health Care*, 1998, Vol. 5, Issue 2, pp. 139-177.
  20. Xia Jin, DF Nixon, CGP Roberts, Nixon DF, J Safrit, LQ Zhang, YX Huang, N Bhardwaj, B Jesdale, A.S. De Groot, RA Koup, **Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation**



- and computer-driven algorithm.** *AIDS Res Hu Retroviruses* Vol 16, No.1, pp. 67-76, January 2000.
21. A.S. De Groot, Bick, J, Thomas, D, Stubblefield, E, **HIV Clinical Trials in Correctional Settings: Right or Retrogression?** *AIDS Reader*. 2001; 11(1):34-40.
  22. Bond KB, Sriwanthana B, Hodge TW, De Groot AS, Mastro TD, Young NL, Promadej N, Altman JD, Limpakarnjanarat K, McNicholl JM. **An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1 infected Thais.** *AIDS Research and Human Retroviruses* 2001; 17(8):703-18.
  23. A.S. De Groot, H. Sbai, C. Saint-Aubin, W. Martin, A. Bosma, G. Skowron, K. H. Mayer **Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS.** *AIDScience* 1(2) June 22, 2001.
  24. A.S. De Groot, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C **From genome to vaccine: in silico predictions, ex vivo verification.** *Vaccine*. 2001 Aug 14;19(31):4385-95.
  25. A.S. De Groot, Saint Aubin, CS, Rayner, J, Martin, W. **Rapid Determination of HLA B\*07-ligands from the West Nile Virus genome.** *Emerging Infectious Diseases*, Vol. 7, No. 4, July–August 2001: 706-713.
  26. H. Sbai, A. Mehta, A.S. De Groot. **Use of T cell epitopes for vaccine development.** *Current Drug Targets - Infectious Disorders*, 2001, 1, 283-293.
  27. A.S. De Groot, H. Sbai, C. Saint Aubin, J.A. McMurphy, William Martin **Immuno-informatics: Mining the genome for Vaccine Components.** *Immunology and Cell Biology*. *Immunology and Cell Biology* (2002) 80, 255–269.
  28. A.S. De Groot, J. Rayner, W. Martin. **Modeling the immunogenicity of therapeutic proteins using T cell epitope mapping.** In: *Immunogenicity of Therapeutic Biological Products. Developments in Biologicals*. Fred Brown, Anthony Mire Suis, editors. Basel, Karger, 2003. Vol 112:71-80.
  29. W. Martin, A. Bosma, H. Sbai and A.S. De Groot. **The use of bioinformatics for identifying class I restricted T cell epitopes.** *Methods* (Epitope Mapping Issue). Bill Kwok, editor, *Methods* 29 (2003) 289–298.
  30. A.S. De Groot, Vishvanath Nene, Nagendra R. Hedge, S. Srikumaran, James Rayner and William Martin. **T Cell Epitope Identification for Bovine Vaccines: An Epitope Mapping Method for BoLA A-11.** *International Journal for Parasitology* (Thematic Issue on Vaccines, David Brake Editor, (Vol 33/5-6 pp 641-653). 2003.
  31. Lopes AR, Jaye A, Dorrell L, Sabally S, Alabi A, Jones NA, Flower DR, De Groot AS, Newton P, Lascar RM, Williams I, Whittle H, Bertoletti A, Borrow P, Maini MK. **Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection.** *J Immunol*. 2003 Jul 1; 171(1):307-16.
  32. De Groot A,S. Hakima Sbai, Bill Jesdale, W. Martin, C. Saint Aubin, H. Sbai, A. Bosma, Judy Lieberman, G.A. Skowron, Fadi Mansourati, Ken Mayer. **Mapping Cross-clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach.** *Vaccine* 21 (2003) 4486–4504. <http://www.sciencedirect.com/science/journal/0264410X>.
  33. Dong Y, Demaria S, Sun X, Santori FR, Jesdale BM, De Groot AS, Rom WN, Bushkin Y. **HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium**

- tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase.** Infect Immun. 2004 Apr; 72(4):2412-5.
34. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CC, Martin W. **Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.** Methods. 2004 Dec; 34(4):476-87 Bioinformatics in Vaccine Design.
  35. McMurry, J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. **Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes.** Tuberculosis (Edinb). 2005; 85(1-2):95-105.
  36. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, Martin W. **HIV vaccine development by computer assisted design: the GAIA vaccine.** Vaccine. 2005 Mar 18; 23 (7-18):2136-48.
  37. De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, Weiner D, Martin B. **Developing an epitope-driven tuberculosis (TB) vaccine.** Vaccine. 2005 Mar 18; 23(17-18):2121-31.
  38. Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. **Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy.** Vaccine. 2005 Aug 30.
  39. De Groot A.S., P.M. Knopf, Bill Martin. **De-immunization of therapeutic proteins by T cell epitope modification.** Mire-Sluis, A. Ed. State of the Art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability. Dev. Biol. Basel, Karger, 2005. Vol 122. pp 137-160.
  40. Inaba H, Martin W, De Groot AS, Qin S, De Groot LJ. **Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease.** J Clin Endocrinol Metab. 2006 Jun;91(6):2286-94. Epub 2006 Apr 4.
  41. Koita, OA, D. Dabitaou, I. Mahamadou, M. Tall, A. S. Dao, A. Tounkara, H. Guiteye, C. Noumsi, O. Thiero, M. Kone, D. Rivera, J. A. McMurry, W. Martin, De Groot AS. **Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island.** Human Vaccines, 2006 June; 2(3), 119-128.
  42. McMurry JA, S. Kimball, J. Lee, D. Rivera, W. Martin, D.B. Weiner, M. Kutzler, D.R. Sherman, H. Kornfeld, De Groot AS. **Epitope-Driven TB Vaccine Development : A streamlined approach using immunoinformatics, ELISpot assays, and HLA transgenic mice.** Current Molecular Medicine, Curr Mol Med. 2007 Jun;7(4):351-68.
  43. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, De Groot AS. **Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine.** Vaccine. 2007 Apr 20;25(16):3179-91.
  44. De Groot AS, Goldberg M, Moise L, Martin W. **Evolutionary deimmunization: An ancillary mechanism for self-tolerance.** Cell Immunol. 2007 Apr 17; Epub. Cellular Immunology. Volume 244, Issue 2, December **2006**, Pages 148-153. <http://dx.doi.org/10.1016/j.cellimm.2007.02.006>
  45. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. **Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.** Clin Immunol. **2007** Jul;124(1):26-32.

46. De Groot AS, L. Moise, W. Martin, F. Guirakhoo, and T. Monath. **Analysis of ChimeriVax Japanese Encephalitis (JE) virus Sequence for T cell epitopes and comparison to circulating wild type JE Virus strains.** Nov. 2007. Vaccine 25 (2007) 8077–8084.
47. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin WD, **De Groot AS.** **Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori.** Hum Vaccin. 2008 May-Jun;4(3):219-23. Epub 2010 May 8.
48. Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, **De Groot AS.** **Novel function of complement C3d as an autologous helper T-cell target.** Immunol Cell Biol. 2008 Mar;86(3):221-5.
49. **De Groot AS.** Rivera DS, McMurry JA, Buus S, Martin W, **Identification of Immunogenic HLA-B7 “Achilles’ heel” Epitopes Within Highly Conserved Regions of HIV.** Vaccine, 2008 26, 3059—3071.
50. Liso A, Colau D, Benmaamar R, **De Groot AS**, Martin W, Benedetti R, Specchia G, Martelli MP, Coulie P, Falini B. **Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules..** Leukemia, 2008, Feb;22(2):424-6.
51. De Groot A.S., L. Moise, J.A. McMurry, Erik Wambre, Laurence Van Overvelt, Philippe Moingeon, W. Scott, W. Martin, **Activation of Natural Regulatory T cells by IgG Fc-derived Peptide “Tregitopes”.** Blood, 2008,112: 3303. <http://tinyurl.com/ASDeGroot-Blood-2008>.
52. Moise L., McMurry JA, Buus S., Frey S., Martin WD and **De Groot AS.** **In Silico-Accelerated Identification of Conserved and Immunogenic Variola/Vaccinia T-Cell Epitopes.** <http://dx.doi.org/10.1016/j.vaccine.2009.06.018> Vaccine, 2009 Oct 30;27(46):6471-9. Epub 2009 Jun 24.
53. Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, Martin W, De Groot AS. **Epitope-based vaccination against pneumonic tularemia.** Vaccine. 2009 Aug 27;27(39):5299-306. Epub 2009 Jul 17.
54. **De Groot AS**, Ardito M. McClaine E. Moise, L. Martin W. **Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-09 Conventional Influenza Vaccine.** Vaccine. 2009 Sep 25;27(42):5740-7. PMID: 19660593.
55. Inaba H, Martin W, Ardito M, De Groot AS, De Groot LJ. **The role of glutamic or aspartic Acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in graves' disease.** J Clin Endocrinol Metab. 2010 Jun;95(6):2909-16. Epub 2010 Apr 14.
56. Cohen T., Moise, L. Ardito M., Martin W.D., De Groot AS. **A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: iTEM (individualized T Cell Epitope Measure).** J Biomed Biotechnol. 2010. pii: 961752. Epub 2010 Jul 18. doi: 10.1155/2010/961752.
57. Moise L, Buller RM, Schriewer J, Lee J, Frey S, Weiner DB, Martin W, De Groot AS. **VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.** Vaccine. 2011. Jan 10;29(3):501-11. Epub 2010 Nov 4.
58. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee, J, Rogers AB, Martin W, De Groot AS. **HelicoVax: Epitope-based therapeutic H. pylori vaccination in a mouse model of gastric cancer.** Vaccine. 2011. Mar 3;29(11):2085-91.

59. Schanen, Brian C. , De Groot AS, Moise L, Ardito M, McClaine E., Martin, WB, Vaughan Wittman, William L. Warren, and Donald R. Drake III\* **Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus.** *Vaccine.* 2011 Apr 12;29(17):3299-309. doi: 10.1016/j.vaccine.2011.02.019, PMID: PMC3130614.
60. Ardito M, Fueyo J, DaSilva K, Zhang S, Martin W, De Groot AS, Moss SF, Moise L. **An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design.** *2011.* *Immunome Res.* 2011 Nov 20;7(2):25. <http://immunome-research.net/journal/index.php/immunome>.
61. Messitt, T., Ardito, M, Moise, L, Gustafson, EA, Martin, WD, De Groot, AS. **A comparison of two methods for T cell epitope mapping: “cell free” in vitro versus Immunoinformatics.** *Immunome Research, Vol.7, No.2, 2011.* <http://immunome-research.net/journal/index.php/immunome>.
62. De Groot, AS, Ardito, M, Moise, L, Gustafson, EA, Spero, D, Tejada, Martin, WD. **Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine.** *2011.* *Immunome Research, Vol 7, No 2 (2011).* <http://immunome-research.net/>
63. Khan S, Velazquez V, O'Connor C, Simon RE, De Groot AS. **Health care access, utilization, and needs in a predominantly Latino immigrant community in Providence, Rhode Island.** *Med Health R I.* 2011 Oct;94(10):284-7. **2011**
64. Bicki, A., Rogers R., Velasquez, V., De Groot AS. **Clínica Esperanza/Hope Clinic Clinical Outcomes Review: February–July 2011,** *Journal of Medicine and Health, RI, October, Med Health R I.* **2011** Oct;94(10):288-9.
65. Leonard Moise, Chang Song, William D. Martin, Ryan Tassone, Anne S. De Groot and David W. Scott. **HLA DR epitope de-immunization of FVIII in vitro and in vivo.** *Clin Immunol.* **2012** Mar;142(3):320-31.
66. Anne S. De Groot, Lauren Levitz, Matthew T. Ardito, Gail Skowron, Kenneth H. Mayer, Soren Buus, Christine M. Boyle<sup>1</sup>, William D. Martin. **Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA Vaccine epitopes.** *Hum Vaccin Immunother.* 2012 Jul 1;8(7).
67. Andres H. Gutierrez, Leonard Moise, Frances Terry, Kristen Dasilva, Chris Bailey-Kellogg, William Martin, Anne S. De Groot. **Immunoinformatic Analysis of Chinese Hamster Ovary (CHO) Protein Contaminants in Therapeutic Protein Formulations,** *BCB '12 Proceedings of the ACM Conference on Bioinformatics, Computational Biology and Biomedicine.* Pages 637-642. ACM New York, NY, USA ©2012. Doi 10.1145/2382936.2383049
68. van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, Meijer SL, van Deventer SJ, Petry H, Hommes DW, Ferreira V. 1. **Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.** *World J Gastroenterol.* 2012 Aug 28;18(32):4288-99. doi: 10.3748/wjg.v18.i32.4288.
69. Elfaki ME, Khalil EA, Degroot AS, Musa AM, Gutiérrez Núñez A, Younis BM, Salih KA, El-Hassan AM. **Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.** *Hum Vaccin Immunother.* **2012** Aug 24;8(12).
70. Levitz, L., Koita O.A., Sangare K., Ardito MA, Boyle CM, Rozehnal J, Tounkara K., Dao SM, Koné Y, Koty Z., Buus, S., Moise L., Martin, WD, De Groot AS. **Conservation of HIV-1 T cell epitopes across time and clades: Validation of HLA-A2 epitopes selected for the GAIA HIV vaccine.** *Vaccine.* **2012** Oct 23. <http://www.sciencedirect.com/science/article/pii/S0264410X12014880>

71. Wei R, Yang C, Zeng M, Terry F, Zhu K, Yang C, Altmeyer R, Martin W, De Groot AS, Leng Q A **Dominant EV71-Specific CD4+ T Cell Epitope Is Highly Conserved among Human Enteroviruses.** PLoS One. 2012;7(12):e51957. doi: 10.1371/journal.pone.0051957. Epub 2012 Dec 14
72. Ahmed Eldakrourey, Ericka Olivera, Rebecca Martin, Anne S. De Groot. **Adherence to American Diabetes Association Guidelines in a Volunteer-run Free Clinic for the Uninsured in Providence, Rhode Island: Comparison with Standards Achieved by Clinics for Insured Patients.** Journal of Medicine and Health, Rhode Island. Rhode Island Medical Journal. 2013 Jan;96(1):25-9
73. Poole DN, Tracy JK, Levitz L, Rochas M, Sangare K, Yekta S, Tounkara K, Aboubacar B, Koita O, Lurie M, De Groot AS. **HPV vaccine acceptability and willingness to vaccinate in Bamako, Mali.** 1. PLoS One. 2013;8(2):e56402. doi: 10.1371/journal.pone.0056402. Epub 2013 Feb 19. PubMed PMID: 23431375; PubMed Central PMCID: PMC3576405.
74. Inaba H, Moise L, Martin W, De Groot AS, Desrosiers J, Tassone R, Buchman G, Akamizu T, De Groot LJ. **Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein or Peptides.** Endocrinology. 2013 Jun;154(6):2234-43. doi:10.1210/en.2013-1033. Epub 2013 Apr 16. PubMed PMID: 23592747.
75. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, Verberkmoes N, Szein MB, Losikoff P, Martin WD, Rothman A, De Groot AS. **The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix.** Hum Vaccin Immunother. 2013 Apr 12;9(7). PubMed PMID:23584251.
76. Leslie P. Cousens, Yan Su, Elizabeth McClaine, Xin Li, Frances Terry, Robert Smith, Jinhee Leed, William Martin, David W. Scott., Anne S. De Groot. **Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes.** Experimental Diabetes Research. J Diabetes Res. 2013:621693. doi: 10.1155/2013/621693. Epub 2013 Apr 23. <http://bit.ly/TregT1D>
77. Yan Su, Robert Rossi, Anne S. De Groot, and David W. Scott. **Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.** J. Leukocyte Biology. J Leukoc Biol. 2013 May 31. [http://bit.ly/Tregitopes\\_Per\\_Se](http://bit.ly/Tregitopes_Per_Se).
78. De Groot AS, Ardito M., Terry, F. Levitz L., Ross T., Moise L., Martin B. **Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design.** Hum Vaccin Immunother. Volume 9, Issue 5 May 2013:950–956 <http://dx.doi.org/10.4161/hv.24939> [http://bit.ly/H7N9\\_2013](http://bit.ly/H7N9_2013). [http://bit.ly/H7N9\\_HVandI](http://bit.ly/H7N9_HVandI).
79. Moise L., Terry F., Ardito M., Tassone R., Latimer H., Boyle C., Martin WD., De Groot AS. **Universal H1N1 Influenza Vaccine Development: Identification of Consensus Class II Hemagglutinin and Neuraminidase Epitopes Derived from Strains Circulating between 1980 and 2011,** Hum Vaccin Immunother. 2013 Apr 12;9(7).
80. Hui, DJ, Basner-Tschakarjan E., Chen Y., Davidson RJ, Buchlis G, Yazicioglu M, Pien, GC Finn JD Haurigot V, Tai A, Scott DW, Cousens LP, Zhou S, De Groot AD, Mingozzi F. **Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes.** Blood. Mol Ther. 2013 Jul 16. doi:10.1038/mt.2013.166. [http://bit.ly/CD8\\_Contact\\_AgSpecificity](http://bit.ly/CD8_Contact_AgSpecificity)
81. Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q. **Elevated antigen-specific Th2 type response is associated with the poor prognosis**

- of hand, foot and mouth disease.** *Virus Res.* 2013 Jul 22. doi:pii: S0168-1702(13)00231-1. 10.1016/j.virusres.2013.07.009.
82. Leonard Moise, Ryan Tassone, Howard Latimer, Frances Terry, Lauren Levitz, John P. Haran, Ted M. Ross, Christine Boyle, William D. Martin, Anne S. De Groot. **Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice.** *Hum Vaccin Immunother.* 2013 Sep 17;9(10).
  83. Bicki A, Silva A, Joseph V, Handoko R, Rico SV, Burns J, Simonelli A, Harrop J, Nedow J, De Groot AS. **A Nurse-Run Walk-In Clinic: Cost-Effective Alternative to Non-urgent Emergency Department Use by the Uninsured.** *J Community Health.* 2013 Jun 18. [Epub ahead of print] DOI 10.1007/s10900-013-9712-y. [http://bit.ly/Nurse\\_Run\\_cehc](http://bit.ly/Nurse_Run_cehc).
  84. Kibria F., Peters, J. L., Shulman, C., Joseph, V., & De Groot, A. S. **Assessment of Hypertension Guidelines Adherence at a Free Clinic Serving a Predominantly Latino Population in Providence, RI.** *Rhode Island J. Medicine,* 01 March, 2014. [http://bit.ly/CEHC\\_AHA\\_HTN](http://bit.ly/CEHC_AHA_HTN). 2014.
  85. Chau J, Kibria F, Landi M, Reilly M, Medeiros T, Johnson H, Yekta S, De Groot AS. **HPV Knowledge and Vaccine Acceptedness in a Low-income Hispanic Population.** *R I Med J* (2013). 2014 May; 97(4):35-39.
  86. Zhang S, Desrosiers J, Aponte-Pieras JR, Dasilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF. **Human Immune Responses to H. pylori HLA Class II Epitopes Identified by Immunoinformatic Methods,** *PLoS One.* 2014 Apr 16;9(4):e94974. doi: 10.1371/journal.pone.0094974. eCollection 2014. PMID: 24740005 [PubMed - in process].
  87. Lu He, Anne S De Groot, Andres H Gutierrez, William D Martin, Lenny Moise and Chris Bailey-Kellogg. **Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage.** *BMC Bioinformatics* 2014, 15(Suppl 4):S1 doi:10.1186/1471-2105-15-S4-S1. [http://bit.ly/Viral\\_Camouflage\\_2014](http://bit.ly/Viral_Camouflage_2014). 2014.
  88. Mishra S, Losikoff PT, Self AA, Terry F, Ardito MT, Tassone R, Martin WD, De Groot AS, Gregory SH. **Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells.** *Vaccine.* 2014 May 30;32(26):3285-92. doi: 10.1016/j.vaccine.2014.03.083. Epub 2014 Apr 8. PMID: 24721533 [PubMed - in process]
  89. Karim M. Abdel-Hady, Andres H. Gutierrez, Frances Terry, Joe Desrosiers, Anne S. De Groot, Hassan M. E. Azzazy. **Identification and Retrospective Validation of T-cell Epitopes in the Hepatitis C Virus Genotype 4 Proteome: An Accelerated Approach towards Epitope-Driven Vaccine Development.** *Human Vaccines and Immunotherapy.* Accepted for publication. 2014.
  90. Gutiérrez AH, Bailey-Kellogg C, DaSilva K, Terry F, Ardito M, Moise L, Martin W, De Groot AS. **CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production.** Accepted for publication. *Biotechnology and Bioengineering.* 2014.
  91. Buckley, J, Yekta, S., Joseph, V, Johnson, H.A., Oliverio, S, De Groot AS. **Vida Sana: A Lifestyle Intervention for Uninsured, Predominantly Spanish-Speaking Immigrants Improves Metabolic Syndrome Indicators.** *J. Comm Health,* Accepted for publication, June 2014.
  92. Sasmita Mishra, Bianca Lavelle, Joe Desrosiers, Matt Ardito, Frances Terry, William Martin Anne De Groot, Stephen Gregory. **Dendritic Cell-mediated, DNA-based Vaccination against Hepatitis C Induces the Multiepitope- specific Response of Humanized, HLA Transgenic Mice.** *PLoS One.* Accepted for publication, June 2014

**Chapters and Review Publications**

1. Chapter. Raybourne, RB. Hermann, E, Kellner, H, De Groot, A.S., Huang, F, Williams, K.M., Roth, G., Yu, D.T.Y. **The role of peptides in the recognition of HLA-B27 by cytotoxic T cells and by antibodies, with special emphasis on arthritis patients**, Chapter 11 in *HLA-B27 in the Development of Spondyloarthropathies*. Carlos Lopez Larrea. R. G. Landes Bioscience, Austin Texas USA.1997.
2. Proceedings. Flanigan TP, Vigilante K, Burzinsky J, Bubly G, Kim J, Cu-Uvin S, DeCiantis ML, Normandy L, Snead M, A.S. De Groot, DeBuono BA, **Medical Care of HIV-Infected Prisoners: The Rhode Island Experience**, in *AIDS Clinical Research and Care: Meeting the Challenges of an Epidemic in Flux*, PRIM&R Conference Proceedings Oct 29-30, 1992.
3. Report. Flanigan TP, Bury-Maynard D, Vigilante K, Burzinsky J, Bubly G, Kim J, Rich JD, Zierler S, DeCiantis DL, Normandy L, Snead M, A.S. De Groot, Loberti P, DeBuono BA, **The Rhode Island Prison Release Program**, in *Progress and Challenges in Linking Incarcerated Individuals with HIV/AIDS to Community Services*, Health Resources and Services Administration Bureau of Health Resources Development Office of Science and Epidemiology, June 1995.
4. Article. A.S. De Groot, Meister GE, Roberts CGP, Edelson BT, Ramirez B, Berzofsky JA, **Algorithms for Mycobacterial Vaccine Development**, Proceedings of the International symposium on Bovine TB in Animals and Human Beings, USDA/NIAID, NIH, 1995.
5. Chapter. A.S. De Groot, Meister GE, Cornette JL, Margalit H, DeLisi C, and Berzofsky JA; **Computer Prediction of T Cell Epitopes**, in *New Generation Vaccines*, 2nd edition, Myron M. Levine, Graeme C. Woodrow, James B. Kaper, Gary S. Cobon, eds., Marcel Dekker Inc. NYC, NY, 1996.
6. Review. A.S. De Groot, Hammett TM, Scheib RG, **Barriers to Care of HIV-Infected inmates: a public health concern**, *AIDS Reader*, 1996, May / June, pp. 78-87.
7. Review. A.S. De Groot, **HIV infection among incarcerated women: Epidemic behind bars**. *AIDS Reader*, 2000; 10:287-295.
8. Review of Proceedings. A.S. De Groot, Leibel SR, **Reports from the New England Regional Symposium on HIV Infection among incarcerated women**. *J. Correctional Health Care*, 1998, Vol. 5, Issue 2, pp. 125-127.
9. Chapter. A.S. De Groot and Debi Cuccinelli, **Put her in a cage: Childhood sexual abuse, incarceration, and HIV infection**, chapter in *The Gender Politics of HIV in Women: Perspectives on the Pandemic in the United States* J. Manlowe and N. Goldstein, ed., New York University Press, 1997.
10. Chapter. A.S. De Groot, Jesdale BM, Berzofsky JA, **Prediction and determination of MHC ligands and T Cell Epitopes**, Chapter 3, Immunology Methods, SHE Kaufmann, ed, Methods in Microbiology, Vol 25, p 79-106, Academic Press, NY 1998.
11. Review. A.S. De Groot, Leibel SR, **The need for Compassionate Care: HIV Infection Among Incarcerated Women**, *Medicine and Health*, RI, Vol 81. No. 6, p 209-211, 1998.
12. Review. A.S. De Groot, Stevens J, Pratt L, Leibel SR, Zierler S, **Setting the Standard for Care: HIV Risk Exposures and Clinical Manifestations of HIV in Incarcerated Massachusetts Women**, *New England Journal of Criminal and Civil Confinement*, Vol 24, pp 353-378, July 1998.

13. Book Review. De Groot, A. **Legacy of light for women living with HIV in prison** (review of *Breaking the Walls of Silence* by members of the ACE Program of Bedford Hills). *Lancet*, March 27 1999. 353. pp 1107, March 1999.
14. Editorial. A.S. De Groot and Rothman FG, **In Silico Predictions; in Vivo Veritas** (News and Views), *Nature Biotechnology* Vol 17, No. 6, pp. 533-34, June 1999.
15. Editorial. De Groot AS. **Shedding light on correctional HIV care.** *AIDS Reader* 2000; 10:285-286.
16. Review. A.S. De Groot, Jackson, EH, Stubblefield, S. **Clinical Trials in Correctional Settings: Proceedings of a conference held in Providence, RI**, Oct 14-15 1999. *Rhode Island Journal of Medicine*, 83; (12) December 2000, pp 376-379.
17. Commentary. A.S. De Groot, **Women Prisoners with HIV: An Open Letter from a Prison Doctor** (1996). In *Correctional Perspectives: Views from Academics, Practitioners, and Prisoners* edited by Paul Cromwell and Leanne Fiftal Alarid, Roxbury Publishing Company. 2001.
18. Report. Scientific Working Group on Tuberculosis. **Recommendations.** UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) 9-11 February 2000, Geneva, Switzerland <http://www.who.int/tdr/publications/publications/pdf/tb-swg.pdf>
19. Commentary. De Groot AS. **Women incest survivors in prison.** An open letter from a prison doctor to those who care for women living with HIV. *Posit Aware*. 2001 Jul-Aug; 12(4):27-9.
20. Review. De Groot AS. **Alarming statistics about incarcerated women.** *Posit Aware*. 2001 Jul-Aug; 12(4):19-21.
21. Editorial: **Learning From the Past, Planning for the Future—DOT for HIV Infection.** *The AIDS Reader*. 2002 Jul; 12(7):314-5.
22. Chapter. A.S. De Groot, S. Liebel. **Women in Prison. A Standard of HIV Care.** In *Reaching in, Reaching out. Treating HIV/AIDS in the Correctional Community*. Edited by Frederick Altice, P. Selywn, R. Watson ed. Published by the National Commission on Correctional Health Care. Chicago Illinois, 2002.
23. DeGroot AS. Bamako, not Timbuktu. *Posit Aware*. 2003 Mar-Apr;14(2):29.
24. PMID: 12693370 Chapter. A.S. De Groot, H. Sbai, Bill Martin, and Jay A. Berzofsky. **Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to vaccine design.** *Methods in Microbiology: Immunology of Infection*, 2nd Edition. (Volume 32 in the *Methods in Microbiology* series). Edited by Stefan Kaufmann and Dieter Kabelitz, 2002.
25. Chapter. H. Sbai, De Groot A.S., J. Sidney, A. Sette and Jay A. Berzofsky. **High throughput informatics and in vitro assays for T cell epitope determination: Application to the design of epitope-driven vaccines.** *New Generation Vaccines*, 3rd edition, Myron M. Levine, B. Kaper, Rino Rappuoli, Margaret Liu, Michael Good, eds., Marcel Dekker Inc. NYC, NY. (2004).
26. Commentary. De Groot, A.S. **How the SARS vaccine effort can learn from HIV—speeding towards the future, learning from the past.** *Vaccine* 21 (2003) 4095–4104 (Available on line; see <http://www.sciencedirect.com/science/journal/0264410X>)
27. Chapter. De Groot A.S. and Rachel Maddow, **Hepatitis B and hepatitis C among offenders within prisons**, in *Managing Special Populations in Jails and Prisons*, Civic Research Group, publisher; Stan Stojkovic Associate Dean and Professor, University of Wisconsin-Milwaukee. Civic Research Institute. 2005.
28. Chapter. Maddow, R. and A.S. De Groot. **HIV Infection in Incarcerated Women.** Chapter in



- Health Issues of Incarcerated Women*. Editors: Ronald L. Braithwaite, Kimberly Jacob Arriola, Cassandra Newkirk. Rutgers University Press, 2005.
29. Commentary. De Groot, AS. **Smallpox vaccination – Time for a Novel Approach?** Vaccine and Technology Development News, Vol 2 (8). November /December 2003.
  30. Proceedings. A.S. De Groot and W. Martin. **From immunome to vaccine: epitope mapping and vaccine design tools**. Novartis Foundation Symposium No.254. 2004.
  31. Review. De Groot AS, Rappuoli R. **Genome-derived vaccines**. Expert Rev Vaccines. 2004. Feb; 3(1):59-76.
  32. Editorial. De Groot A.S., **Immunome Derived Vaccines**. Expert Opin Biol Ther. Jun; 4(6):767-772, 2004.
  33. Editorial. De Groot A.S., J. A. Berzofsky, **From Genome to Vaccine – New Immunoinformatics tools for vaccine design**. In: Bioinformatics for Vaccine Design. Volume 34, Issue 4, December 2004, Pages 425-428.
  34. Chapter. De Groot AS, and McMurry JA. **TB Vaccine Development: Opportunity and Imperative**. In *Frontiers in the Development of New Vaccines*, Philippe Moingeon, editor. Horizon Scientific Press Ltd. 2005.
  35. Proceedings. De Groot A.S., Martin B., Marcon L., Knopf PI, Rodriguez-Annon, C., Rivera D., Klutzer M., Boren C., Weiner, DW. **Beyond Epitope Mapping: Making Vaccines and Modifying Therapeutics**. CBI 2005 Proceedings, Akihiko Konagaya, Editor. August 2005. Chem-Bio Informatics Sociaety (CBI), Tokyo, Japan.
  36. Commentary. L. Moise, De Groot A.S. News and Reviews. **Putting immunoinformatics to the test**. Nature Biotechnology, 2006; 24(7): 791-92.<http://www.bioinf.uni-sb.de/RB/groot06.pdf>
  37. Position paper. (Multiple authors) **Living up to Our Commitments: An assessment of the United States response to its domestic HIV/AIDS epidemic**. Open Society Institute Public Health Watch HIV/AIDS Project. May 2006.
  38. Position paper. A.S. De Groot, M. DiLorenzo, M. Sylla, J. Bick. **Challenges and Opportunities for HIV Care in Jails and Prisons in the United States**. International Journal of Prisoner Health, September 2006; 2(3): 173-191.
  39. Chapter. De Groot AS. Practitioner Perspective: Women Prisoners With HIV: **A Letter From a Prison Doctor, In Correctional Perspectives. Views from Academics, Practitioners, and Prisoners**. Edited by Leanne Fital Alarid and Paul F. Cromwell. Oxford University Press. Apr 2007.
  39. Commentary. De Groot A.S.. **Immunomics: discovering new targets for vaccines and therapeutics**. Drug Discovery Today. 2006 Mar;11 (5-6):203-9.
  40. Editorial. De Groot A.S., L. Moise **New tools, new approaches and new ideas for vaccine development**. Expert Rev Vaccines. 2007 Apr; 6 (2):125-7.
  41. Chapter. De Groot A.S., P. M. Knopf, D. Rivera and W. Martin. **Immunoinformatics applied to modifying and improving biological therapeutics**. Kluwer publications *Immunoinformatics*. Series: Immunomics Reviews: Vol. 1. Schönbach, Christian; Ranganathan, Shoba; Brusica, Vladimir (Eds.) 2007, ISBN: 978-0-387-72967-1. Available: September 21, 2007.
  42. Review. De Groot A.S. and L. Moise. **Prediction of immunogenicity for therapeutic proteins: State of the art**. Current Opinions in Drug Development and Discovery. May 2007. 10(3):332-40.
  43. Review. De Groot A.S. and D. Scott. **Immunogenicity of Protein Therapeutics**. Trends in

- Immunology. Invited Review. Trends Immunol. 2007 Nov;28(11):482-90.
44. Editorial. De Groot A.S. and L. Moise. **A Vaccine Renaissance – From Basic Research to Implementation.** Medicine and Health, Rhode Island. October 2007. Oct, 90(10):300.
  45. Proceedings. J.A. McMurry, D. S. Rivera, E. J. Carter, J. Lee, H. Kornfeld, MD, William D. Martin, and De Groot A.S.. **Progress Towards a Genome-derived, Epitope-driven Vaccine for Latent TB Infection.** Leonard Moise, PhD, Medicine and Health, Rhode Island. October 2007. Oct, 90(10):301-303.
  46. Proceedings. J. A. McMurry, Leonard Moise, PhD, Stephen H. Gregory, and De Groot A.S., **Tularemia Vaccines – An Overview.** Medicine and Health, Rhode Island. October 2007. Oct, 90(10):311-317.
  47. Editorial comment. De Groot AS, Closson E, Devore C. **HIV testing in prisons and jails--providing the carrot with the stick.** AIDS Read. 2007 Sep;17(9):463.
  48. Review. McMurry JA, Johansson BE, **De Groot AS. A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A.** Hum Vaccin. **2008** Mar-Apr;4(2):148-57.
  49. Chapter. **Mycobacterium Tuberculosis Vaccines.** Vaccines for Biodefense and Emerging and Neglected Diseases, edited by Alan D.T. Barrett and Lawrence R. Stanberry. Elsevier (Accepted December 2007. Published December, **2008**).
  50. Chapter. Hai S, McMurry JA, Knopf P, Martin W, De Groot AS. **Immunogenicity screening using in silico methods: Correlation between T-cell epitope content and clinical immunogenicity of monoclonal antibodies.** In An Z and Strohl WR, editors. Therapeutic Antibodies: from Theory to Practice. New York, New York: John Wiley and Sons; October 2009.
  51. Commentary. De Groot A.S., F. Bougadougo, S. Bamba. **The measles campaign in West and Central Africa: Remembering the future.** Vaccine Vol 26/31 pp 3783-3786, **2008**. DOI: 10.1016/j.vaccine.2008.04.088.
  52. Proceedings. Beltz, G. and De Groot, A.S., Meeting Report: **The Sir Mark Oliphant conferences: International frontiers of science and technology.** Belz GT, De Groot A. Hum Vaccin. **2008** Jul-Aug;4(4):260-1.
  53. Review. Gerber R, Charpentier M, Tecun S, Massi M, Diaz J, De Groot AS. **A place to be healthy: blueprint for a new free clinic for the medically uninsured of Rhode Island.** Med Health R I. **2008** Apr;91(4):105-8.
  54. Review. Anne S. De Groot, Julie McMurry and Lenny Moise, **Prediction of Immunogenicity: In Silico Paradigms, Ex Vivo and In Vivo Correlates,** Curr Opin Pharmacol. **2008** Oct;8(5):620-6.
  55. Chapter. **Anne S. De Groot, Julie McMurry, Lenny Moise, Bill Martin. Epitope-based Immunome-derived Vaccines: A Strategy for Improved Design and Safety.** Springer Immunomics Series. Falus, Andras (Ed.) 2009. Clinical Applications of Immunomics. Pages 39-69.
  56. Review. Anne S. De Groot and Bill Martin. **Reducing Risk, Improving Outcomes: Bioengineering less immunogenic protein therapeutics.** (Andy Saxon, Ed.). Clin Immunol. **2009** May;131(2):189-201. <http://tinyurl.com/ASDeGroot-Clin-Immunol-2009>
  57. Review. David W. Scott, Anne S. De Groot. **Can we prevent the immunogenicity of Protein Drugs.** Annals of Rheumatology. Ann Rheum Dis. 2010 Jan;69 Suppl 1:i72-76.
  58. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. **T cell epitope: Friend or Foe? Immunogenicity of biologics in context.** In Series "Optimizing the Future for Biotechnology

- Therapies, the Key Role of Protein Engineering”, *Advanced Drug Delivery Reviews*. Volume 61 (11), **2009**; 965-976. <http://dx.doi.org/10.1016/j.addr.2009.07.001>. <http://bit.ly/T-friend-or-foe>.
59. Chapter. Cohen T, Moise L, Martin W, DeGroot AS. **Immunoinformatics: The next step in vaccine design**. In: Sintchenko V, editor. *Infectious Disease Informatics*. New York: Springer; **2010**. p. 223-244.
  60. Proceedings. Lorna D. McLeod, Anne S. De Groot, Bill Martin. **Biotherapeutics**. *BioProcess International*, Vol. 7, No. S5, May 2009, pp. 28–33
  61. Proceedings. Moise L, Ardito M., DesRosiers J., Schriewer, J. Buller, M., Frey, S., Gregory SF, Moss, SF, Lee J, Kornfeld, H, Martin W, De Groot A.S., **Immunome-derived Epitope-driven Vaccines (ID-EDV), Protect against Viral or Bacterial Challenge in Humanized Mice**. July 2009. *Procedia in Vaccinology* Volume 1, Issue 1, 2009, Pages 15-22. 2nd Global Congress on Vaccines, December 7-9, **2008**, Boston, MA, USA.
  62. Portrait. Anne S. De Groot. **Exploring the Immunome: A Brave New World for Human Vaccine Development. Human Vaccines**. *Human Vaccines* 5:12, 1-4; December **2009**.
  63. Book Review. Anne S. De Groot. Darren Flower. **Bioinformatics for Vaccinology**. *Human Vaccines*. *Human Vaccines* Volume 6 Issue 5. **2010**.
  64. News and Reviews. Anne S. De Groot, Elizabeth McClaine, Lenny Moise, and William Martin; **Time for T? Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines**. *Human Vaccines*, *Human Vaccines* **2010** Feb 19;6(2)
  65. News and Reviews. Anne S. De Groot, Matthew Baker and Tobias Cohen. **Species neutral correlates of immunogenicity for vaccines and protein therapeutics: Fact or Science Fiction**. *Human vaccines*, **2010** May;6(5):371-2
  66. Chapter. De Groot AS, Cohen T, Ardito M, Moise L, Martin B, Berzofsky JA. **Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design**. In: Kaufmann S and Kabelitz D, editors. *Methods in Microbiology: Immunology<sup>y</sup> of Infection*. 3<sup>rd</sup> edition. Edited by Stefan Kaufmann and Dieter Kabelitz. **2010**.
  67. Proceedings. Matthew Ardito, Songhua Zhang, William Martin, Steven F. Moss, Anne S. De Groot. **Immunoinformatic-driven H. pylori Vaccine Design**. *Immunoinformatics and Computational Immunology Workshop*. August 2, **2010**, Niagara Falls, New York, U.S.A.
  68. Proceedings. Anne S. De Groot Leonard Moise, Tobias Cohen, Matthew Ardito, William Martin. **Putting immunoinformatics to work to develop better vaccines and protein therapeutics**. *Immunoinformatics and Computational Immunology Workshop*. August **2010**, Niagara Falls, New York, U.S.A.
  69. Editorial. He YO, Rappuoli R, De Groot AS, Chen RT. **Vaccine informatics**. *J Biomed Biotechnol*. **2010**:765762. Epub 2011 Jun 22.
  70. Review. He Y, Rappuoli R, De Groot AS, Chen RT. **Emerging vaccine informatics**. *J Biomed Biotechnol*. **2010**; 218590. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134832/?tool=pubmed>
  71. Review. Moise L, Cousens L, Fueyo J, De Groot AS. **Harnessing the power of genomics and immunoinformatics to produce improved vaccines**. *Expert Opin. Drug Disc*. **2011**;6:9-15. (doi:10.1517/17460441.2011.534454)
  72. Chapter. De Groot AS, Ardito MA, Tassone, R, Knopf, P., Moise L. , and Martin W. Tools for Vaccine Design: **Prediction and Validation of Highly Immunogenic and Conserved Class II**

- Epitopes and Development of Epitope-driven Vaccines.** For book entitled, Development of Vaccines: From Discovery to Clinical Testing. Editors Indrish Srivastava and Manmohan Singh (John Wiley and Sons). **2011** Google ebook at: <http://tinyurl.com/Dvt-of-Vaccines-Chapt-3>.
73. Review. Wassim Elyaman, Samia J. Khoury, David. W. Scott, and Anne S. De Groot. **Potential Application of Tregitopes as Immunomodulating Agents In Multiple Sclerosis.** Neurology Research International. Volume **2011**, Article ID 256460, 6 pages. doi:10.1155/2011/256460.
  74. Proceedings. De Groot A.S., Cohen TC, Moise, L, Martin WD. **Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction.** Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June 7-10, 2009 . ESACT Proceedings, **2012**, Volume 5, Part 6, 525-534, DOI: 10.1007/978-94-007-0884-6\_90 <http://www.springerlink.com/content/w086t8065l666g74/> Published on line in 2012.
  75. Review. Gutiérrez AH, Spero D, Gay C, Zimic M, De Groot AS. **New vaccines needed for pathogens infecting animals and humans: One Health.** Hum Vaccin Immunother. **2012** Jul 1;8(7).
  76. Review. Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS. **In Vitro and In Vivo Studies of IgG-Derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity.** J Clin Immunol. 2013. January; 33(1): 43–49. PMID:22941509. <http://bit.ly/TregInVivo12>.
  77. Review. Cousens LP, Mingozzi F, van der Marel S, Su Y, Garman R, Ferreira V, Martin W, Scott DW, **De Groot AS.** Teaching Tolerance: **New Approaches to Enzyme Replacement Therapy for Pompe Disease.** Hum Vaccin Immunother. 2012 Oct 1;8(10). [Epub ahead of print. PMID: 23095864
  78. Review. Leonard Moise, Steven F. Moss and Anne S. De Groot. **Moving H. pylori Vaccine Development Forward with Bioinformatics and Immunomics.** Invited Editorial for *Expert Review of Vaccines*. **Expert Rev Vaccines. 2012 Sep;11(9):1031-3.** doi: **10.1586/erv.12.80.**
  79. Opinion. Andres H. Gutiérrez, Leonard Moise, Anne S. De Groot, **Of [Hamsters] and Men: A New Perspective on Host Cell Proteins.** Hum Vaccin Immunother. 2012 Sep 1;8(9):1172-4. doi: 10.4161/hv.22378. PMID: 23124469
  80. Review. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. **Tregitope update: mechanism of action parallels IVIg.** Autoimmun Rev. 2013 Jan;12(3):436-43. doi: 10.1016/j.autrev. 2012.08.017. Epub 2012 Aug 28. PubMed PMID: 22944299. [http://bit.ly/Tregitope\\_IVIG](http://bit.ly/Tregitope_IVIG).
  81. Chapter. Vibha Jawa; Leslie Cousens and Anne S. De Groot. **Immunogenicity of Therapeutic Fusion proteins: Contributory Factors and Clinical Experience.** Chapter in: Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges, John Wiley and Sons, Inc. 2013. [http://bit.ly/Amgen\\_Pro prospective\\_Tregitope\\_Data](http://bit.ly/Amgen_Pro prospective_Tregitope_Data).
  82. Editorial. De Groot AS. **Fifth Vaccine Renaissance introduction.** Hum Vaccin Immunother. 2012 Jul;8(7):960. doi: 10.4161/hv.21442. Epub 2012 Jul 1.
  83. Proceedings. Spero D, Petrovsky N, De Groot AS. **Report from the field: Fifth Vaccine Renaissance in Providence RI.** Hum Vaccin Immunother. 2012 Jul;8(7):1006-9. doi: 10.4161/hv.19779. Epub 2012 Jul 1.

84. Review. Missa P, Sanou, Anne S. De Groot, Michael Murphey-Corb, Jay A. Levy, and Janet K. Yamamoto **HIV-1 Vaccine Trials: Evolving Concepts and Designs**. Open AIDS J. 2012;6:274-88. doi: 10.2174/1874613601206010274. Epub 2012 Nov 30. PMID 23289052.
85. Proceedings. Yongqun He, Zhiwei Cao, Anne S. De Groot, Vladimir Brusic, Christian Schönbach, Nikolai Petrovsky **Computational Vaccinology and the ICoVax 2012 Workshop**. *BMC Bioinformatics* 2013, **14**(Suppl 4):I1 doi:10.1186/1471-2105-14-S4-I1: <http://www.biomedcentral.com/1471-2105/14/S4/I1> Accepted for publication.
86. Review. Moise L., Marcello, A, Tassone, R., Cousens, L., Martin, W., De Groot, A.S., **Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company**. Rhode Island Medical Journal, February 2013. [rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf](http://rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf)
87. Proceedings. He Y, Cao Z, De Groot AS, Brusic V, Schönbach C, Petrovsky N. **Computational vaccinology and the ICoVax 2012 workshop**. *BMC Bioinformatics*. 2013;14 Suppl 4:I1.doi: 10.1186/1471-2105-14-S4-I1. Epub 2013 Mar 8. PubMed PMID: 23514034; PubMed Central PMCID: PMC3599086.
88. Review. **De Groot AS**, Einck L., Moise L, Chambers M., Ballantyne J., Malone RW, Ardito M, Martin W. Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense? *Human Vaccines and Immunotherapy*. Accepted for publication June 27, 2013.
89. Chapter. Vibha Jawa; Leslie Cousens and **De Groot AS, Immunogenicity of Therapeutic Fusion proteins: Contributory Factors and Clinical Experience**. Chapter in: *Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges*. Stefan R. Schmidt (Editor). John Wiley and Sons, Inc. March 2013. [http://bit.ly/Amgen\\_Prospective\\_Tregitope\\_Data](http://bit.ly/Amgen_Prospective_Tregitope_Data).
90. Review. Leslie Cousens, Vibha Jawa; Michel Awwad; Eric Wakshull; Harald Kropshofer; **De Groot AS. T-cell dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation**. Accepted to *Clinical Immunology*, August 14, 2013. [http://bit.ly/The\\_TCWP](http://bit.ly/The_TCWP)
91. Commentary. **De Groot AS**, Frances Terry, Leslie Cousens and William Martin. **Beyond Humanization and De-immunization: Tolerization as a Method for Reducing the Immunogenicity of Biologics**. *Expert Rev Clin Pharmacol*. 2013 Nov;6(6):651-62. doi: 10.1586/17512433.2013.835698. <http://bit.ly/Tolerization>.
92. Proceedings. Spero D, Levitz L, De Groot AS. **Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference**. *Hum Vaccin Immunother*. 2013 Jul;9(7):1555-7. doi: 10.4161/hv.24833. Epub 2013 May 31.
93. Opinion. De Groot AS, Cousens L, Mingozi F, Martin W. **Tregitope Peptides: The Active Pharmaceutical Ingredient (API) of IVIG?** Invited Article (Darren Flower, Pedro Reche, Editors): Special Topic: Peptide Immuno-therapeutics and Vaccines, *Clinical and Developmental Immunology*, December 2013. <http://www.hindawi.com/journals/jir/2013/493138/abs/>. [http://bit.ly/Tregitope\\_API](http://bit.ly/Tregitope_API)
94. Editorial. De Groot AS. **Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?** *Expert Review of Clinical Immunology*, December 2013, Vol. 9, No. 12, Pages 1155-1157(doi: 10.1586/1744666X.2013.858602)
95. Opinion. De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. **Cross-conservation of T-cell epitopes: Now even more relevant to [H7N9] influenza vaccine design**. *Hum Vaccin Immunother*. 2014. Feb 13;10(2). [Epub ahead of print] PMID: 24525618.

### Publications in Preparation

1. Jack Wands et al. **Aspartate- $\beta$ -hydroxylase Induces Epitope-specific T Cell Responses in Hepatocellular Carcinoma,** The Journal of Immunology. Submitted, May 23 2014.
2. Ahmed Eldakrouy, Lisa DiMaria, Ericka Olivera, Valerie Joseph, Rebecca F. Martin, Susan Oliverio, Anne S. De Groot. **A Push-Pull Electronic-Medical Record-based Intervention Improves Diabetes Compliance at a Free Clinic for the Uninsured.** Submitted. Diabetes Care. 2014.
3. Losikoff, PT, Mishra S, Terry F, Gutierrez-Nunez A, Fast L, Nevola M, Martin WD, Bailey-Kellogg, CJ, De Groot AS and Gregory SH. **HCV Epitope, Homologous to Multiple Human Protein Sequences, Induces a Regulatory T Cell Response in Infected Patients.** In preparation. 2014.
4. Rui Liu, Lenny Moise, Kotou Sangare, Andres H. Gutierrez, Matthew A. Ardito, Frances Terry, William D. Martin, Chris Bailey Kellogg, Anne S. De Groot. **Immunogenicity of T effector and Treg epitopes from H7N9 Avian-Origin Influenza: Impact of Cross-Reactivity with the Human Genome.** In preparation. 2014.
5. Anne S. De Groot, Frances Terry, Ryan Tassone, Matt Ardito, Bill Martin. **In silico modeling of T cell epitopes restricted by HLA-DP and -DQ does not improve HLA-DR based immunogenicity prediction for biologic products.** In preparation. 2014.
6. Marsia Gustiananda, Tedjo Sasmono, Andres Gutierrez Nunez, Benediktus Yohan, Leonard Moise, Aryati, Puspa Wardhani, Anne S. De Groot, William Martin. **Analysis of ChimeriVax Dengue virus envelope for T-cell epitopes and comparison to circulating viral strains in Indonesia** In preparation 2012.

### Publications Featuring EpiMatrix Toolkit Developed by De Groot and Martin

- Caturegli P, Vidalain PO, Vali M, Aguilera-Galaviz LA, Rose NR. **Cloning and characterization of murine thyroglobulin cDNA.** Clin Immunol Immunopathol. 1997 Nov;85(2):221-6.
- Mutsunori Shirai, Tatsumi Arichi, Ming Chen, Mikio Nishioka, Kazumasa Ikeda, Hidemi Takahashi, Nobuyuki Enomoto, Takafumi Saito, Marian E. Major, Teruko Nakazawa, Toshitaka Akatsuka, Stephen M. Feinstone and Jay A. Berzofsky. **T Cell Recognition of Hypervariable Region-1 from Hepatitis C Virus Envelope Protein with Multiple Class II MHC Molecules in Mice and Humans: Preferential Help for Induction of Antibodies to the Hypervariable Region.** The Journal of Immunology, 1999, 162: 568-576. [EpiMer technology used to map epitopes; contribution acknowledged].
- Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, Oftung F, Olobo J, von Reyn F, Andersen P. **Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis.** J Infect Dis. 1999 Mar; 179 (3):637-45. [EpiMer technology used to map epitopes; contribution acknowledged].
- Hazel M. Dockrell, Shweta Brahmhatt, Brian D. Robertson, Sven Britton, Uli Fruth, Negussie Gebre, Mesfin Hunegnaw, Rabia Hussain, Rakesh Manandhar, Luis Murillo, Maria Cristina V. Pessolani, Paul Roche, Jorge L. Salgado, Elizabeth Sampaio, Firdaus Shahid, Jelle E., R. Thole, and Douglas B. Youn. **A Postgenomic Approach to Identification of Mycobacterium leprae-Specific Peptides as T-Cell Reagents.** Infection and Immunity, October 2000, p. 5846-5855, Vol. 68, No. 10. [EpiMer technology used to map epitopes; contribution acknowledged].

- Murtaza Vali, Noel R. Rose, and Patrizio Caturegli. **Thyroglobulin as Autoantigen: Structure–Function Relationships**. Reviews in Endocrine & Metabolic Disorders. Kluwer Academic, NY. Volume 1, Numbers 1-2, February 2000, Pages: 69 – 77. [EpiMer technology used to map epitopes; contribution acknowledged].
- Michèl R. Klein, Abdulrahman S. Hammond, Steve M. Smith, Assan Jaye, Pauline T. Lukey, and Keith P. W. J. McAdam. **HLA-B\*35-Restricted CD8+-T-Cell Epitope in Mycobacterium tuberculosis Rv2903c**. Infection and Immunity, February 2002, p. 981-984, Vol. 70, No. 2. [EpiMatrix technology used to map epitopes; contribution acknowledged].
- Smith DJ, King WF, Barnes LA, Peacock Z, Taubman MA. **Immunogenicity and protective immunity induced by synthetic peptides associated with putative immunodominant regions of Streptococcus mutans glucan-binding protein B**. Infect Immun. 2003 Mar; 71 (3):1179-84.
- Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, NJ Gibson, M Armstrong, ME Lagerström-Ferme´r1, A Dellse´n1, EM Brown, M Thornton, C Dukes, SC Jenkins, MA Firth, GO Harrod, TH Pinel, SME Billing-Clason1, LR Cardon4 and RE March. **Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis**. The Pharmacogenomics Journal, 15 May 2007; doi:10.1038/sj.tpj.6500458. [EpiMatrix technology used to map epitopes; contribution acknowledged]
- Culshaw S, Larosa K, Tolani H, Han X, Eastcott JW, Smith DJ, Taubman MA **Immunogenic and protective potential of mutans streptococcal glucosyltransferase peptide constructs selected by major histocompatibility complex class II allele binding**. Infect Immun. 2007 Feb;75(2):915-23. Epub 2006 Nov 6. [EpiMatrix technology used to map epitopes; contribution acknowledged]
- Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. **Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminial infusion**. J Clin Immunol. 2007 Nov;27(6):620-7. Epub 2007 Jul 14. [EpiMatrix technology used to map epitopes; contribution acknowledged].
- Gámez A, Wang L, Sarkissian CN, Wendt D, Fitzpatrick P, Lemontt JF, Scriver CR, Stevens RC. **Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria**. Mol Genet Metab. 2007 Aug;91(4):325-34. Epub 2007 Jun 8. [EpiMatrix technology used to map epitopes; contribution acknowledged].
- Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ. **Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection**. PLoS Pathog. 2009 Dec;5(12):e1000707. Epub 2009 Dec 24. [Extensive analysis of Treg epitopes for HCV acknowledged as an addendum to the published article].
- Seeliger, D. Development of Scoring Functions for Antibody Sequence Assessment and Optimization. PLOS One. Published: Oct 21, 2013DOI: 10.1371/journal.pone.0076909. [http://bit.ly/PlosOne\\_ISPRI](http://bit.ly/PlosOne_ISPRI)

**Journalism (News and Reviews for HEPP, IDCR, Medscape, and AIDSscience) (Not Updated 2014)**

1. A.S. De Groot, **Update from the 6th Conference on Retroviruses and Opportunistic Infections** Chicago, Illinois, Jan 31-Feb 3 1999. *HEPP News*, April 1999, 1 (4) pp. 1-4.

2. A.S. De Groot, **Update from the 6th Conference on Retroviruses and Opportunistic Infections (Part One)**. Jan 31-Feb 3 1999 (**Part Two**). *HEPP News*, May 1999, 1 (5) pp.1-5.
3. A.S. De Groot, K. Anastos, S.R. Leibel, E. Stubblefield, **Women in Prison: The Impact of HIV**. *HEPP News*, June 1999 1 (6) pp.1-7.
4. A.S. De Groot, J. Bick, F. L. Altice, **HIV Management Guidelines: News and Trends**. *HEPP News*, February 2000, 2 (2) pp.1-3.
5. A.S. De Groot, **HIV Infection among Incarcerated Women: an Epidemic behind the Walls**. *HEPP News*, April 2000; 3(4) pp.1-4.
6. A. S. De Groot, Joseph Bick. **The Correctional Doctor's Dilemma: Hepatitis C Treatment**. *HEPP News*, June 2000, 3 (6) pp. 1-5.
7. A. S. De Groot, **Corrections on the National Conference Agenda: Update from the 24<sup>th</sup> NCCHC** *HEPP News*, October 2000, 3 (9) pp. 1-5.
8. **A. S. De Groot, Treatment Update for Correctional HIV providers: News from Chicago** *HEPP News*, February 2001, 1 (2) pp. 1-5.
9. **A. S. De Groot, E. Stubblefield, The new HAART: What it means for Prisoners**. *Medscape Infectious Diseases (Prison Series)*. (Posted March 2001).
  - a. <http://www.medscape.com/medscape/ID/journal/2001/v03.n02/mid0306.degr/mid0306.degr.html>.
10. A.S. De Groot, **HCV: The Correctional Conundrum**. *HEPP News*, April 2001, 4 (4) pp. 1-5.
11. A.S. De Groot, MD, Elizabeth Stubblefield, Joe Bick, **Infections Behind Bars: Hepatitis C: A Correctional-Public Health Opportunity**. *Medscape Infectious Diseases (Prison Series)*.
  - a. <http://www.medscape.com/medscape/ID/journal/2001/v03.n03/mid0614.groo/mid0614.groo-01.html> (Posted June 2001)
12. A. S. De Groot. **Open Letter from a Prison Doctor**. *Positively Aware Magazine* (story on HIV infected incarcerated women). July/August 2001.
13. M. Nicodemus, H. Sbai, and A.S. De Groot. **Urgency and optimism at the AIDS Vaccine 2001 conference**. *AIDScience* Vol. 1, No. 11, October 2001.  
<http://www.aidsscience.com/Articles/aidsscience009.asp> (Posted October 2001).
14. A.S. De Groot, **Immunotherapy of HIV: On the Horizon?** *HEPP News* October 2001, 4 (11) 1-5.
15. A.S. De Groot **Women incest survivors in prison. An open letter from a prison doctor to those who care for women living with HIV**. *Positively Aware*. 2001 Jul-Aug;12(4):27-9.
16. A.S. De Groot **Alarming statistics about incarcerated women**. *Positively Aware*. 2001 Jul-Aug;12(4):19-21.
17. A.S. De Groot and Thomas, D. **Preparing for Bioterrorist Threats in Corrections**. *HEPP News* February 2002 Vol. 5, Issue 2.
18. R. Nerenberg, M. Wong, De Groot A.S. **HCV in Corrections: Frontline or Backwater?** *HEPP News* April 2002, Vol. 5, Issue 4.
19. S. De Groot and Rick Altice. **HIV Treatment Update for Correctional Providers, 2002**. *HEPP News* May 2002, Vol. 5, Issue 5.
20. A. S. De Groot, and Roland C. Merchant. **Hepatitis B, C, and HIV Post-exposure Prophylaxis in Correctional Settings**. *HEPP Report*, October 2003, Vol 6, issue 9.



21. A. S. De Groot, S. Cu Uvin. **HIV Infection in incarcerated Women.** *IDCR (formerly HEPP Report)*, May 2005,
22. Kathleen Bernard, Courtney Colton, Joe Paris, Anne S. De Groot. **HIV Care in Correctional Settings, How do we Measure Up?** *IDCR (formerly HEPP Report)*, March 2006.
23. De Groot A.S., R. Ridzon. **TB in Corrections: Constant Companion and Future Scourge.** *IDCR (formerly HEPP Report)*, May/June 2007.
24. Perkins, M, De Groot AS, **Using half-life extension to move a pioneering treatment for autoimmune diseases towards clinical trials.** *ONdrugDelivery Issue No 43*, July 2013.

#### **Online Essays and Blogs** (Not Updated 2014)

1995: Sexual Abuse and HIV Risk Behavior: "Open Letter from a Prison Doctor"

<http://www.thebody.com/content/art1195.html>

also at [http://www.tpan.com/publications/positively\\_aware/jul\\_aug\\_01/womenincestsurvivors.html](http://www.tpan.com/publications/positively_aware/jul_aug_01/womenincestsurvivors.html)

2001: Incarceration: "A trip to Chowchilla" on "The Other side of the Wall" 2001 (links no longer active)

2002- present: Writings from West Africa: GAIA Vaccine Foundation Website <http://blog.gaiavaccine.org/>

2010-present: Thinking Out Loud (Blog on Immunogenicity, Biotherapeutics and Vaccines). <http://www.epivax.com/blog/>

#### **Abstracts/poster presentations** (Updated 2014)

1. A.S. De Groot, Clerici M, Hosmalin A., Barnd D, Hughes S, Hendrix JA, Houghten R, Shearer GM, Berzofsky JA, **Identification of a T-Helper cell epitope in HIV reverse transcriptase which is also recognized by CTL**, poster and abstract, New Approaches to Vaccines, Cold Spring Harbor Laboratory 09/91.
2. Gozansky W, A.S. De Groot, Noble J, Scheib RJ, Griffiths JK, Wong JB, **Prophylactic therapy for Toxoplasma Infection in HIV-1 Seropositive Subjects: Decision Analysis**, poster and abstract, IX International conference on AIDS, Berlin, 06/93.
3. Gozansky W, Schmid CP, Moody S, Cheeseman S, McGowan K, A.S. De Groot, **A Prospective Study of the Incidence of Reactivation of Latent Toxoplasma Infection in HIV-1-Seropositive Subjects in Massachusetts**, poster and abstract, IX International Conference on AIDS, Berlin, 06/93.
4. A.S. De Groot, Woo D, Meister GE, Berzofsky JA, **Identification of antigenic regions of Mycobacterium tuberculosis proteins using Natural Peptide and Amphi algorithms**, poster and abstract, Conference on MultiDrug Resistant TB, Bethesda, MD 09/93.
5. A.S. De Groot, Shinde SR, Roberts CGP, Haskal R, Meister GE, Lieberman J, **A comparison of Cell-mediated responses to Mycobacterium tuberculosis (Mtb) antigens in Mtb-immune subjects and HIV-seronegative and HIV-seropositive Mtb-susceptible subjects**, poster and abstract, New Approaches to Vaccines including AIDS, Cold Spring Harbor Laboratory 09/93.
6. A.S. De Groot, Meister GE, Roberts CGP, Edelson BT, De Groot LJ, Berzofsky JA, **Two novel algorithms for the identification of T cell epitopes that are based on MHC binding motifs**

- poster and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory, 10/94.
7. Meister GE, Roberts CPG, Berzofsky JA, A.S. De Groot. ***Mycobacterium tuberculosis* peptide epitopes predicted by two novel epitope identification algorithms** presentation and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory, Long Island, New York, 10/94.
  8. Roberts CGP, Meister GE, Berzofsky JA, A.S. De Groot, **Peptide epitopes for five HIV-1 proteins predicted by a novel T cell epitope prediction algorithm**, poster and abstract, NCDVG conference, Washington DC, 10/94.
  9. A.S. De Groot, Meister GE, Roberts CGP, Edelson BT, De Groot LJ, Berzofsky JA, **Two novel algorithms for the identification of T cell epitopes that are based on MHC binding motifs**, poster and abstract, Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory, 10/94.
  10. Meister GE, Roberts CGP, Berzofsky JA, A.S. De Groot. ***Mycobacterium tuberculosis* peptide epitopes predicted by two novel epitope identification algorithms**, poster and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory, Long Island, New York, 10/94.
  11. Stevens J, Zierler S, Cram V, Dean D, Mayer KH, A.S. De Groot, **The Prevalence of HIV, Risks for HIV Infection, and Gynecological Comorbidity in Women Incarcerated in Massachusetts**, poster and abstract, Conference on Women's Health, Washington DC, 06/94.
  12. A.S. De Groot, Kimberly Fisher, Caroline G.P. Roberts, Gabriel E. Meister, Brian T. Edelson, Katherine McGowan, John Phair, Ken Mayer, **T cell response to Tuberculosis in HIV seropositive subjects; longitudinal and cross-sectional analysis**, poster and abstract, Keystone Symposium on the Molecular Mechanisms of Tuberculosis, 02/95. J. Biol. Chem., suppl 19B: abstract B3 402, 1995.
  13. A.S. De Groot, Fisher K, Roberts CGP, Meister GE, Edelson BT, McGowan K, Phair J, Mayer K, **T cell response to Tuberculosis in HIV seropositive subjects; longitudinal and cross-sectional analysis**, Poster and abstract, Keystone Symposium on the Molecular Mechanisms of Tuberculosis, 02/95. J. Biol. Chem., 1995, suppl 19B: abstract B3 402.
  14. A.S. De Groot, Stevens J, Cram V, Chalfen B, Mayer K, Zierler K, **Childhood sexual abuse increases vulnerability to HIV exposure among incarcerated women**, 1st National Congress on HIV in Women, poster and abstract, Washington DC 02/95.
  15. A.S. De Groot, Stevens J, Chalfen B, Cram V, Dean D, Mayer K, Zierler S, **HIV and gynecological comorbidity among women incarcerated in Massachusetts**, poster and abstract, 1st National Congress on HIV in Women, Washington DC, 02/95
  16. Pratt L, Stevens J, Andujar E, Manlowe J, Flanigan T, Zierler S, A.S. De Groot; **Discharge planning needs of incarcerated women living with HIV**, poster and abstract ,1st National Congress on HIV in Women, Washington DC 02/95.
  17. Gampper, SNR, Nacar E, O'Connell J, Stein M, Fisher AE, Jesdale W, Carter J, Mayer K, A.S. De Groot, **Co-infection with M. tuberculosis and HIV-1 in Providence**, poster and abstract, American Thoracic Society Meeting, Seattle WA, 05/95.
  18. Renaud T, Carter J, Jesdale BM, A.S. De Groot, **Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls including UVG Irradiation and HEPA filtration**, poster and abstract, Lancet Tuberculosis Conference, 09/95,

Washington DC.

19. A.S. De Groot, Wong S, O'Connell J, Nacar L, Meister GE, Jesdale BM, Carter J, **Use of pediatric tuberculosis infection as a marker of tuberculosis transmission in communities in Providence, Rhode Island**, poster and abstract, Lancet Tuberculosis Conference, 09/95, Washington DC.
20. A.S. De Groot, Stevens J, Dean D, Cram V, Andujar E, George JA, Goodman AK, Poutsiaka DD, Scheib RG, Cohen JL, **Health services for HIV seropositive incarcerated women: The Framingham model**, poster and oral presentation at the National Commission on Correctional Health Care 19th conference, 11/95.
21. Renaud R, Carter J, Jesdale BM, A.S. De Groot, **Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls: A cost benefit analysis**, poster and oral presentation at the National Commission on Correctional Health Care 19th conference, 11/95.
22. Nguyen KB, George JA, Dong KL, Corah T, Whittle H, Jesdale BM, A.S. De Groot, **Designing a subunit vaccine for M. tuberculosis using a novel epitope prediction algorithm: Gambian responses to population weighted vs. unweighted peptides**, poster and abstract, Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory, 09/96.
23. A.S. De Groot, Zierler, S, Stevens, J, Dean, D, Ferdinand MM, Jesdale, BM, George, JA, Scheib RG, **HIV risk behaviors and HIV related morbidity in a cohort of incarcerated women in Massachusetts**, poster and abstract, International AIDS Conference, Vancouver, 1996.
24. Schafer JR, Gotch F, Mayer K, Ho D, Koup R, A.S. De Groot. **The predicted utility of several phase III HIV-1 vaccines for selected world populations**, poster and abstract, Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory, 09/96.
25. Santiago MLO, Hafalla JCR, Jesdale BM, Ramirez BDLL, A.S. De Groot, **Identification of Phylogenetically conserved clusters of published and predicted HIV 1 CD8+ CTL epitopes in geographically diverse populations**, poster and abstract, presentation #98.009. International Infectious Disease society meeting, Hong Kong, 06/96.
26. Natividad M, Cajimat B, Santiago MLO, Hafalla JCR, Libranda-Ramirez BDL, Jesdale BM, A.S. De Groot, **Clusters of published HIV-1 CD8+ CTL epitopes: peptide diversity and HLA-dependent population coverage**, poster and abstract, Annual Convention of the Philippine Society for Biochemistry and Molecular Biology, 12/96.
27. Jesdale BM, Schafer JR, Santiago MLO, Granek JA, Roberts CGP, Koup RA, A.S. De Groot **Population-dependent prediction of CTL epitopes for HIV clades using a computer-driven algorithm**, poster and abstract, International AIDS conference, Vancouver, 07/96.
28. Jin X, Nixon DF, Roberts CGP, Safrin J, Zhang LQ, Huang YX, Jesdale BM, A.S. De Groot, Koup RA, **Prediction and validation of HLA-B7 restricted CTL epitopes based on upon autologous HIV-1 sequences**, poster and abstract, Keystone HIV/AIDS Pathogenesis meeting, Keystone, Colorado, 1997.
29. Bond K, Pau CP, Malegam JY, De Groot A.S., Szu E, Hodge TW, Mastro TD, Stephens H, McNicholl JM, **HLA-A11 Cytotoxic T Lymphocyte Epitopes in HIV-1 env Subtype E**, poster and abstract, Keystone HIV/AIDS Pathogenesis meeting, 1997.
30. A.S. De Groot, Jesdale BM, Szu E, Mullen L, Deocampo D, **Matrix-based definition of MHC ligands from primary HIV-1 and HIV-2 protein sequences: the EpiMatrix/HIV Web Site**, poster and abstract, Keystone HIV/AIDS Pathogenesis meeting, 1997.

31. Barnea JD, Bollinger RC, George JA, Jesdale BM, A.S. De Groot, **Towards Developing an HIV-1 Vaccine for India: Computer-Driven Prediction and Analysis of Cytotoxic T-Lymphocyte (CTL) Epitopes**, poster and abstract, First Annual Vaccine meeting (ASM, NIAID), Washington DC 1998.
32. Brichkov I, George JA, Whalen RJ, A.S. De Groot, **Construction of a DNA vaccine for TB containing promiscuous T cell epitopes**, poster and abstract, First Annual Vaccine meeting (ASM, NIAID, NFID), Washington DC 1998.
33. Froebel KS; Aldhous MC; De Groot A; Alonso A; Leigh Brown AJ; Mok J; **Cytotoxic T cell activity against HIV-tat in HIV infected children**. HIV Pathog Treat Conf. 03/98; 88 (abstract no. 4030). Unique Identifier : AIDSLINE AIDS/98930453.
34. Santiago ML; Hafalla JC; Santiago EG; Manalo MA; Martin C; Cajimat MN; De Groot AS; **V3 loop immunoreactivity and diversity among HIV-1 isolates from the Philippines**. Int Conf AIDS. 1998;12:16-7 (abstract no. 11172). Unique Identifier : AIDSLINE ICA12/98385185
35. Bond KB, Pau CP, Malegam JY, A.S. De Groot, Jesdale, BM, Hodge TW, Mastro TD, McNicholl SH, **HLA-A11 Cytotoxic T Lymphocyte Epitopes in HIV-1 env Subtype E**, poster and oral presentation at the International AIDS Conference, Geneva, June 1998.
36. A.S. De Groot, Jesdale BM, Fleischmann RD, **Matrix based prediction of MHC binding peptides: the TIGR/EpiMatrix website, reagent for TB research**, poster and abstract, Conference on TB: Molecular mechanisms and Immunopathogenesis, Keystone, Colorado, 04/98.
37. A.S. De Groot, Schafer JR, Barnea JD, George JA, Jesdale BM, **Evaluation of HIV sequences for MHC binding patterns by computer driven algorithm**, poster and abstract, HIV Evolution Meeting, Santa Fe, NM, 04/98.
38. A.S. De Groot, George JA, Gonzalez M, Chinai N, **Genome to T Cell: Epitope-Driven Vaccine Design**, Abstract and oral presentation, Microbial Genomes Conference, Chantilly, VA, 01/99.
39. A.S. De Groot, George J, Gonzalez M, Jin X, Bond K, Koup R, McNicholl J, **Prospective Identification of MHC Ligands and CTL Epitopes from HIV Proteins using Bioinformatics**, Abstract number 43, Poster and oral presentation at the 6th conference on Retroviruses and Opportunistic Infections, Chicago, IL, 01/99.
40. A.S. De Groot, Gonzalez M, Chinai N, Barnea JD, **From Genome to T Cell: Searching for Agretopes**, poster and abstract, Second Annual Vaccine meeting (ASM, NIAID, NFID), Washington DC 1999.
41. A. Breu, M. Gonzalez, I. Brichkov, R. Whalen, H. Sbai, A.S. De Groot. **Use of the plasmid pRc/CMV-HBs(S) as a vector for an epitope-based DNA vaccine against Mycobacterium tuberculosis**. Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory, 12/99. Poster presentation.
42. N. Chinai, Assan Jaye, A. Bosma, Hilton Whittle, A.S. De Groot. **Successful identification of novel HIV-2 epitopes and a single "cross-reactive" HIV-1/HIV-2 CTL epitope using a bioinformatics approach**. Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory, 12/99. Poster presentation.
43. M. Gonzalez, J. Frost, A. Bosma, J. R. Schafer, R. Whalen, H. Sbai, G.A. Skowron, A.S. De Groot **Developing a "World Clade" HIV Vaccine using a Bioinformatics Approach**. Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory, 12/99. Oral and Poster presentation.

44. De Groot A.S., M. Gonzalez, J. Frost, A. Bosma, J. R. Schafer, G. Skowron, W. Martin. **Designing and Assessing HIV Vaccines for Cross-Clade Immunogenicity using Bio-informatics** Abstract number 589, Poster at the 6th conference on Retroviruses and Opportunistic Infections, Chicago, IL, 01/99.
45. N. M. Chinai, Michael B. Gonzalez, A. Bosma, J. A. George, R. C. Bollinger, A.S. De Groot. **Towards developing an HIV 1 vaccine for India: Computer driven prediction and analysis of CTL epitopes.** Molecular approaches to Vaccine Design. Cold Spring Harbor Laboratory, Cold Spring Harbor New York. 12/99.
46. A. Breu, M. Gonzalez, Igor Brichkov, J. George, R. Whalen, H. Sbai, Anne S. De Groot. **Use of the plasmid prc/CMV-HBS(S) as a vector for an epitope-based vaccine against Mycobacterium tuberculosis.** Molecular approaches to Vaccine Design. Cold Spring Harbor Laboratory, Cold Spring Harbor New York. 12/99.
47. A.S. De Groot, J. George, M. Gonzalez, X Jin, K Bond, R Koup, J McNicholl. **Prospective Identification of MHC Ligands and CTL Epitopes from HIV Proteins using Bioinformatics 7<sup>h</sup>** Conference on Retroviruses and Opportunistic infections, San Francisco, 01/00, Poster.
48. S. Demaria, X Sun, BM Jesdale, A.S. De Groot, C Steinzig, WN Rom, and Y Bushkin, **HLA A2 Restricted, CD8 Dependent Cytotoxic T cell response to mycobacterial superoxide dismutase.** Microbial Pathogenesis and Host Response, Cold Spring Harbor, NY, 2000.
49. A.S. De Groot, J. McMurry, H. Sbai, and W. Martin. **From Genome to T Cell: Epitope-Driven TB Vaccine Design.** Molecular and Cellular Aspects of Tuberculosis Research in the Post-Genome Era. (Keystone Symposia) 01/01 (Abstract 262)
50. A.S. De Groot, J. Frost<sup>1</sup>, M. Gonzalez, C. Saint-Aubin, H. Sbai, G. Skowron, and W. Martin. **"World Clade" Vaccine Design: Selection and Confirmation of Conserved HIV-1 CTL Epitopes Using a Bioinformatics Approach.** 8<sup>th</sup> Conference on Retroviruses and Opportunistic infections, Chicago, 02/01, Poster 195
51. P. Hansasuta, S. Buranapraditkul, J. Sanruk, T. Rostron, P. Phanuphak, K. Ruxrungtham, J. McNicholl, Kyle Bond, De Groot A.S., and S. Rowland-Jones. **Cross-Clade CTL in Thai HIV-Infected Subjects.** 8<sup>th</sup> Conference on Retroviruses and Opportunistic infections, Chicago, 02/01, Poster 164
52. Neel K. Shah, Michael J.B. Gonzalez, A. Bosma, Kenneth H. Mayer, A.S. De Groot. **Cross-Clade Conservation of HIV-1 CTL Epitopes in the Aidsvax<sup>®</sup> and Aventis CP205<sup>™</sup> Vaccines.** NFID Fourth Annual Conference on Vaccines, Arlington VA 2001. Oral presentation S17.
53. De Groot A.S., Caitlin Saint-Aubin, J. Rayner, W. Martin **Rapid Determination of candidate HLA B\*07- restricted CTL epitopes from the West Nile Virus NY99 genome.** NFID Fourth Annual Conference on Vaccines, Arlington VA 2001. Oral presentation Poster presentation P17.
54. N. Chinai, Assan Jaye, A. Bosma, Hilton Whittle, A.S. De Groot. **Defining novel immunogenic HIV-2 peptides using a bioinformatics approach.** Keystone meeting HIV Vaccines. 04/01.
55. H. Sbai, J.A. McMurry, Bill Martin, J. Rayner, J. Frost, Anne DeGroot. **Computational methods for mapping T cell epitopes: A streamlined approach to vaccine design.** FOCIS Annual Meeting, Boston, 05/01.
56. H. Sbai, N. Chinai, J. Frost, A. Bosma, G.A. Skowron, W. Martin, De Groot A.S.. **Designing an HIV world clade vaccine using bioinformatics-based approach,** Second International Conference on Vaccine Development and Immunotherapy in HIV, San Juan, 05/01.

57. H. Sbai, J. Frost, C. Saint-Aubin, J.A. McMurry, A. Girvin, Bill Martin, A. Bosma, J. Rayner, Anne DeGroot. **Computational methods for mapping T cell epitopes in the TB proteome: A streamlined approach to vaccine design.** U.S.-Japan Joint Tuberculosis/Leprosy Conference, New Orleans, 07/01.
58. A.S. De Groot, R.G. Scheib, K. McGowan, D. Doughty, A. Bosma, W. Martin. **Building Vaccines from Immunogenic Consensus Sequences.** Oral Presentation S29: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, 05/02, Baltimore, Maryland
59. A.S. De Groot, A. Bosma, C. Saint Aubin, H. Sbai, W. Martin **New Uses for Licensed Vaccines: Evaluation of the Japanese Encephalitis Virus Vaccine and the NY99 West Nile Virus Genomes for Cross-reactive T Cell Epitopes.** Oral presentation S35: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, 05/02, Baltimore, Maryland
60. Z. Peacock, W.F. King, L. Barnes, W. Martin, **A S. De Groot**, M.A. Taubman, and D.J. Smith, Immunogenicity of Peptides Derived from *S. mutans* GBP-B. International Association of Dental Researchers (IADR) /2002, SanDiego abstract\_219. June 2002.
61. A.S. DeGroot, H. Sbai, A McMurry, ML Gennaro, EJ Carter, W. Martin. **Analyzing Mycobacterium Tuberculosis Proteomes for Candidate TB Vaccine Epitopes.** Oral presentation S36: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, Baltimore, Maryland 05/02.
62. J. I. Franco, L. Marcon, H. Sbai, S. Foti, D. Rivera, A. Bosma, B. Martin, De Groot A.S. **Prototype Multi-Epitope DNA Vaccine Design for HIV.** Poster: The National Foundation for Infectious Diseases: Sixth Annual Conference on Vaccine Research, 05/03.
63. De Groot A.S. J. A. McMurry, W. Martin. **Analyzing Mycobacterium tuberculosis proteomes for candidate TB vaccine epitopes.** The National Foundation for Infectious Diseases: Sixth Annual Conference on Vaccine Research, 05/03.
64. X. D. Guo, W. Martin; A. D. Groot, M. L. Gennaro<sup>1</sup> **Use of Bioinformatics and Molecular Biology for Mycobacterium tuberculosis Antigen.** Keystone Symposium. 01/03.
65. De Groot A.S., H. Sbai, J. A. McMurry, M. L. Gennaro, E. J. Carter, W. Martin. **Analyzing the Mycobacterium tuberculosis proteomes for candidate TB vaccine epitopes.** 4th World TB Congress, Marriot Hotel, 06/02. Washington DC.
66. A.S. De Groot, H. Sbai, E. A. Bishop, S. Foti, J. Franco, M. Lally, D. B. Weiner, K. H. Mayer, C. C. J. Carpenter, W. Martin. **Developing an Immunogenic Consensus Sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine** ( Poster 15 ) Sixth Annual Conference on Vaccine Research/NFID National Foundation for Infectious Diseases, 05/03 Arlington, Virginia.
67. R. Doctors, H. Sbai, B. Martin, A.S. De Groot. **Using Computational methods and in vitro testing to identify novel epitopes in Epstein Barr Virus.** Cold Spring Harbor Laboratory Microbial Pathogenesis & Host Response, 09/03.
68. J.I. Franco, H. Sbai, B. Khan, B. Martin, M. Stellar, A.S. De Groot. **Towards Developing an Epitope-Based HPV Vaccine.**” Poster Presentation. Microbial Pathogenesis and Host Response. Cold Spring Harbor, 09/03.
69. De Groot A.S., J. A. McMurry, H. Sbai, M. L. Gennaro, E. J. Carter, W. Martin, David Sherman. **Epitope-Driven TB DNA Vaccines: An Immunoinformatics Approach** TB Vaccine 2003. Montreal, Canada. 09/03.

70. Judith Franco HIV Epitope Delivery: **Prototype Multi-epitope DNA Vaccine Design**. Oral Presentation Undergraduate International Research Conference on Global Public Health. CDC. 05/03 <http://www.sit.edu/publichealth/>
71. Sangeeta Tripathi **Knowledge, Attitudes, Practice survey of an HIV Vaccine in Bamako Mali**. Oral Presentation. Undergraduate International Research Conference on Global Public Health. CDC. 05/03. <http://www.sit.edu/publichealth/>
72. S. Foti, De Groot A.S., W. B. Martin, J. E. Crowe, M. T. Rock. **Prediction and Confirmation of Novel Smallpox Ligands Based on Conserved T cell Epitopes from the Vaccinia and Variola Genomes**. The National Foundation for Infectious Diseases: Eighth Annual Conference on Vaccine Research, 05/04.
73. A.S. De Groot, H. Sbai, E.A. Bishop, S. Foti, J. Franco, M. Lally<sup>3</sup>, D. B. Weiner, K.H. Mayer, C.C.J. Carpenter, W. Martin. **Developing an Immunogenic Consensus Sequence T cell Epitopes for the Cross-Clade HIV Vaccine**. The National Foundation for Infectious Diseases: Eight Annual Conference on Vaccine Research, 05/04.
74. A Tounkara, S Dao, H Guiteye, C Noumsi, D Dabitaio, E A Bishop, W Martin, A S De Groot **Bamako, Mali: confirmation of immunogenic consensus sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine** Abstract no. ThPeA6996 The XV International AIDS Conference, 2004.
75. A S DeGroot, EA Bishop, S Foti, J Franco, W Martin, M Lally, C C J Carpenter, K H Mayer **Providence, USA: Confirmation of immunogenic consensus sequence T cell Epitopes for the GAIA cross-clade HIV vaccine** Abstract no. ThPeA6995 The XV International AIDS Conference, 2004.
76. S. Foti, W. Martin, L. Marcon A.S. De Groot **In silico and in vitro evaluation of cross-conserved T cell epitopes for Japanese encephalitis virus and West Nile virus**. Accepted, (Poster P4) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
77. S. Foti, W. Martin, L. Marcon A.S. De Groot **T-cell epitopes conserved between variola and vaccinia: Prediction and confirmation**. (Poster P5) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
78. R. Doctors, S. Foti S. Kimball<sup>1</sup>, B. Martin A.S. De Groot. **Computational methods and in vitro testing to identify novel epitopes for a therapeutic EBV vaccine**. (Poster P6) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
79. Martin W, Marcon L, Rivera D, Kutzler M, Bishop EA, O.A. Koita, Weiner DB, De Groot A.S. **T-helper Multiepitope HIV-1 Vaccine Constructs Engineered by Computer-Assisted Selection and Design elicit broad T cell responses in vivo in the presence of IL-15**; Poster Abstract AIDS Vaccine 2005, 09/05, Montreal, Canada.
80. D Rivera, C Boren, E.A. Bishop, W. Martin, M. Lally, KA Mayer, A.S. De Groot, **Mapping and confirming highly conserved HLA B7-restricted epitopes for the GAIA vaccine**. Poster Abstract AIDS Vaccine 2005; 09/05, Montreal, Canada
81. J.A. McMurry, O.A. Koita, D. Dabitaio, I. Mahamadou, M. Tall, A.S. Dao, A. Tounkara, W. Martin, A.S. De Groot. **Confirmation of Immunogenic Consensus Sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine In Bamako, Mali**. Poster Abstract AIDS Vaccine 2005, 09/05, Montreal, Canada.
82. E.A. Bishop, L. Marcon, W. Martin, OA Koita, M. Lally, KA Mayer, A.S. De Groot. **Cross-**

- presentation of Confirmed A3 supertype T cell Epitopes selected for the GAIA Cross-Clade HIV Vaccine.** Poster Abstract AIDS Vaccine 2005, 09/05, Montreal, Canada.
83. Marcon L, Martin W, Bishop EA, Rivera D, Lally, M, Kutzler M, Weiner DB, Mayer, KH, De Groot A.S. **Expanded T cell response repertoire achieved by a HLA A2 multi-epitope cross-clade HIV vaccine in the presence of IL-15.** Poster Abstract. AIDS Vaccine 2005. 09/05, Montreal, Canada.
  84. De Groot, AS, Kone, M, Koita, OA, Marcon, L, Martin, W, McMurry, JA, Rivera, D, Bishop, E, Lally, M, Mayer, KA, Kutzler, M, Weiner DB. **GAIA HIV Vaccine Development: Optimization of the Immunogens in Pre Clinical Studies.** Oral Abstract, AIDS Vaccine 2005 (poster). 09/05, Montreal, Canada
  85. J Beckerman, N Vu, N Keita, M Koné, A De Groot, M Lally, K Mayer. **Potential Barriers to an HIV Vaccine Trial in Bamako Mali.** Poster Abstract, AIDS Vaccine 2005. 09/05, Montreal, Canada.
  86. Paul Mark Knopf, Sarah Kimball, William Martin, Anne DeGroot. **Class II HLA-binding peptides in C3d: possible role as co-signal 2 in B-cell help.** American Association of Immunologists, Boston 2006
  87. C Cohen, M Kone, A LaFaunce, N Vu, M Lally, K Mayer, N Keita, A De Groot. **Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials.** Paper Number: 231.00. AIDS Vaccine 2006, Amsterdam, 08/06.
  88. AS De Groot, M. Goldberg, D Rivera, JA McMurry, L Moise, M Kone, OA Koita, L Marcon, M Kutzler, M Lally, KH Mayer, DB Weiner, WD Martin. **2006 progress update on the GAIA HIV Vaccine: Broad coverage by HLA alleles and Geographic Location, Optimization of HIV Immunogens in Pre Clinical Studies.** Paper Number: 438.00. AIDS Vaccine 2006, Amsterdam, 08/06.
  89. L Marcon, L Moise, D Rivera, M Lally, M Kutzler, JA McMurry, WD Martin, DB Weiner, AS De Groot. **Elicitation of robust T cell responses in HLA DRB1\*0101 transgenic mice by MHC class II compartment-targeted and untargeted HIV T helper multiepitope molecular constructs.** Paper Number: 441.00. AIDS Vaccine 2006, Amsterdam, 08/06.
  90. Sueker J.J, Bernard K, Colton E., Paris J., Wohl D., De Groot A.S. **Provider perspectives about the standard of HIV care in correctional settings and comparison to the community standard of care: How do we measure up?** World AIDS Conference. Toronto, 2006.
  91. C Cohen, M Koné, A LaFaunce, N Vu, M Lally, K Mayer, N Keita, AS De Groot. **Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials.** World AIDS Conference. Toronto, 2006.
  92. AS De Groot, M. Goldberg, D Rivera, JA McMurry, L Moise, M Kone, OA Koita, L Marcon, M Kutzler, M Lally, KH Mayer, DB Weiner, WD Martin. **2006 progress update on the GAIA HIV Vaccine: Broad coverage by HLA alleles and Geographic Location, Optimization of HIV Immunogens in Pre Clinical Studies.** Paper Number: 438.00. AIDS Vaccine 2006, Amsterdam, August 2
  93. Marcon L, L Moise, D Rivera, M Lally, M Kutzler, JA McMurry, WD Martin, DB Weiner, AS De Groot. **Elicitation of robust T cell responses in HLA DRB1\*0101 transgenic mice by MHC class II compartment-targeted and untargeted HIV T helper multiepitope molecular constructs.** Paper Number: 441.00. AIDS Vaccine 2006, Amsterdam.
  94. Sueker J.J, Bernard K, Colton E., Paris J., Wohl D., De Groot A.S. **Provider perspectives about the standard of HIV care in correctional settings and comparison to the community**



- standard of care: How do we measure up?** World AIDS Conference. Toronto, 2006.
95. C Cohen, M Koné, A LaFaunce, N Vu , M Lally, K Mayer, N Keita, AS De Groot. **Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials.** World AIDS Conference. Toronto, 2006.
  96. Daniel Rivera, Christine Malboeuf, Julie McMurry, Leonard Moise, Bill Martin, Annie De Groot. **High Throughput validation of predicted T-cell epitopes conserved between Variola and Vaccinia: Development of a novel immunome based Smallpox vaccine.** Abstract Number: 241561. Poster presentation at the 6th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2006), June 1-5 in San Francisco, Calif.
  97. Kimball SL, Rivera DS, Rodriguez C, McMurry JA, Martin W, and De Groot AS. **High Throughput validation of predicted T-cell epitopes in F. Tularensis: The development of a novel T-cell epitope based Tularemia vaccine.** Abstract Number: 241551. Poster presentation at the 6th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2006), June 1-5 in San Francisco, Calif.
  98. Rivera DS, Kimball SL, McMurry JA, Moise L, Martin W, Marcon L, and De Groot AS. **High Throughput validation of predicted T-cell epitopes conserved between Variola and Vaccinia: Development of a novel immunome based Smallpox vaccine,** 9th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases.
  99. Wright C, Malboeuf CM, Rodriguez C, Rivera DS, Finucane D, Lee J, McMurry JA, Moise L, Gregory S, Martin W, and De Groot AS. **High Throughput Validation of Predicted T-cell Epitopes in F. Tularensis: The Development of a Novel T-cell Epitope Based Tularemia Vaccine;** Poster Abstract, 32nd Annual New England Immunology Conference, October 2006, Woods Hole, MA, USA.
  100. Moise L., Rivera DS, J.A. McMurry, W. Kim, D. Lee, J. Pappo, E. Sordillo, S. Moss, W.D. Martin, and A.S. De Groot. **Targeted PCR confirmation of vaccine components conserved between human and mouse-adapted strains of H. pylori.** American Gastro Association meeting, May 2007 Washington DC. L.Moise presented poster/oral abstract.
  101. Moise L, Rivera DS, McMurry JA, Kim W, Lee D, Pappo J, Sordillo E, Moss S, Martin W, and De Groot AS. **Potential immunogenicity of predicted epitopes conserved between human and mouse-adapted strains of H. pylori.** 10<sup>th</sup> Annual Conference on Vaccine Research, NFID, 2007 Baltimore, MD.
  102. Moise L, Rivera DS, Malboeuf CM, Rodriguez C, McMurry JA, Goldberg M, Martin W, Frey S, Buller M, and De Groot AS. **Further progress on the immunome-based DNA prime / Peptide boost smallpox vaccine: Results from in vivo immunogenicity assays.** L.Moise presented poster/oral abstract. 10<sup>th</sup> Annual Conference on Vaccine Research, NFID, 2007. Baltimore, MD.
  103. Rivera DS, Malboeuf CM, Rodríguez C, Lee J, McMurry JA, Moise L, Gregory S, Martin W and De Groot AS. **Protective effect of an epitope driven vaccine against F. tularensis: Survival of aerosol-challenged mice. Oral presentation.** 10<sup>th</sup> Annual Conference on Vaccine Research, NFID, 2007. Baltimore, MD. L.Moise presented poster/oral abstract.
  104. Coulibaly K, Koita OA, Rivera DS, Moise L, Martin WD, De Groot AS. **Updated results from ongoing work on the GAIA HIV Vaccine: Recognition of class I and II-restricted epitopes in Bamako, Mali and Providence, USA.** CROI meeting, January 2008, Boston MA.
  105. De Groot A.S. **IgG Tregitopes and AITD-ASATI: Antigen Specific Tolerance Induction in Autoimmune Thyroid Disease,** Poster presentation Tregs and Th17 Cells in Autoimmunity

- March 25-26, **2008**. Washington, DC. LJ De Groot presented poster at the meeting.
106. De Groot A.S. **Updated results from ongoing work on the GAIA HIV Vaccine: Broad Recognition of class I and II-restricted epitopes and in vivo studies**, Poster presentation, Eleventh Annual Conference on Vaccine Research, National Foundation for Infectious Diseases. Baltimore, May, **2008**.
  107. De Groot A.S. **Positive Prediction of Immunogenic Vaccine Candidate Epitopes and Progress on the Development of an IDV Vaccine for H. pylori**, Oral presentation and abstract, , Eleventh Annual Conference on Vaccine Research, National Foundation for Infectious Diseases, Baltimore, May **2008**. L. Moise presented oral report and poster at the meeting.
  108. Moise L, McMurry JA, W, Lee J, Buller M, Frey S Martin W, and De Groot AS. **Immunogenicity in vivo: Proof-of-concept study of an immunome-derived smallpox vaccine**. NFID Eleventh Annual Meeting on Vaccine Research. National Foundation for Infectious Diseases, **2008** Baltimore, MD.
  109. TOUNKARA Karamoko, KONE Youssouf, KOTY Zoumana, ABOUBACAR Ben, Bicki, Alexandra, WERWIE Timothy, DE GROOT Anne S. **Patient adherence to HIV treatment and prevention in the Centre de Santé Communautaire de Sikoro, Bamako, Mali**. IAPAC, Miami, Florida May 2008.
  110. Yattasaye R, Tounkara K, Kone Y, Closson E, Perez Reyes A, De Groot A.S., **Hand of Hope (Here Bolo): A Peer Education Tool for Low Literacy Settings**. GAIA Mali, ASACOMSI, Millennium Villages Project, University of Bamako, GAIA Vaccine Foundation (USA). Poster and Abstract A-072-0179-00876 International AIDS Conference, Mexico City, **2008**.
  111. Tounkara, K., Aboubacar, B. Kone Y, Closson E, Perez Reyes A, De Groot A.S. **Increased HIV and STI testing in Bamako, Mali using a push/pull intervention**. Poster CDC0368 accepted to the CD-ROM of the XVII International AIDS Conference, Mexico City, 3-8 August 2008.
  112. McMurry JA, Moise L, Rivera DS, Martin WD, Gregory SH, De Groot AS. **Development of a novel epitope-based vaccine that protects against lethal F tularensis LVS challenge**. Vaccine Technology, Portugal, **2008**.
  113. J.A. McMurry, L. Moise, W.D. Martin, S.H. Gregory, A.S. De Groot, **High Throughput validation of predicted T-cell epitopes in F. Tularensis: The development of a novel T-cell epitope-based Tularemia vaccine** Rhode Island Research Alliance Symposium on June 3, **2008** at the RI Convention Center.
  114. De Groot A.S., L Moise, J McMurry, B Wu, J Desrosiers, C Eil, W Martin, LJ De Groot. **IgG Tregitopes and AITD-ASATI: Antigen specific tolerance induction in Autoimmune Thyroid Disease**. Rhode Island Research Alliance Symposium on June 3, **2008** at the RI Convention Center.
  115. Daniel S Rivera, William Martin<sup>1</sup>, Erik Wambre, Laurence Van Overvelt, David W Scott, Paul M Knopf, Philippe Moingeon<sup>3</sup>and Anne S De Groot, **A Novel Model of IVIG Immunosuppression: Activation of Natural Regulatory T cells by IgG-Derived Peptides**. FASEB. The FASEB Journal. 2008;22:848.18.
  116. Cohen TSD, Ardito M, Trehan S, Martin W, De Groot AS. **Does Epstein-Barr virus activate natural regulatory T cells?** Poster session presented at: Vaccine Development 2008; 2008 Sep 28-30; Pittsburgh, PA.
  117. J. McMurry, L. Moise, W. Martin, De Groot A.S.. **A call to humoral and cellular arms: A case for enlisting cognate T cell help to develop broad-spectrum vaccines against influenza**. Sixth

- World Congress on Vaccines, Immunisation and Immunotherapy, 23-25 September **2008**: Milan, Italy.
118. Anne S. De Groot, M.D, Leonard Moise, Yan Su, Julie A McMurry, William D Martin and David W. Scott. **IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo**. Oral Presentation 677, 50th annual Meeting of the American Society for Hematology. December 6-10, **2008**. San Francisco, California.
  119. Leonard Moise, Ph.D, Jonathan Skupsky, Ryan Tassone, Julie A McMurry, William D Martin, Anne S. De Groot, and David W. Scott. **De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain**. Poster 1030, 50th annual Meeting of the American Society for Hematology. December 6-10, **2008**. San Francisco, California.
  120. Shuo Li, Stefan Floess, Gaudieri Silvana, Andrew Lucas, Alf Hamann, Matt Ardito, Anne S. De Groot, William Martin, and Eric J. Gowans. **Role of Tregs: Insights for the design of improved Hepatitis C vaccine**. Poster 128. 2<sup>nd</sup> Global Vaccine Congress, Boston Massachusetts, Dec 7-9 **2008**.
  121. J. McMurry, K. Coulibaly, L. Moise, J. Desrosiers, R. Tassone, O. A. Koita, W. Martin, De Groot A.S.. **The GAIA HIV vaccine progress report: broad recognition of class I and II-restricted epitopes and in vivo studies**. Poster 127. 2<sup>nd</sup> Global Vaccine Congress, Boston Massachusetts, Dec 7-9 **2008**.
  122. L. Moise, W.D. Martin, J. Desrosiers, R. Tassone, J.A. McMurry, S.H. Gregory, De Groot A.S.. **Rapid development and validation of a T-cell epitope-based Tularemia vaccine for F. Tularensis**. Poster 125. 2<sup>nd</sup> Global Vaccine Congress, Boston Massachusetts, Dec 7-9 **2008**.
  123. L. Moise, JA. McMurry, J. Lee, J. Desrosiers, R. Tassone, M. Buller, S. Frey, W. Martin, De Groot A.S.. **A Venn vaccine: selection and validation of vaccinia-variola-conserved epitopes**. Poster 126. 2nd Global Vaccine Congress, Boston Massachusetts, Dec 7-9 2008.
  124. M. Ardito, De Groot A.S., J.A. McMurry, L. Moise, W. Yang<sup>1</sup>, W.D. Martin. **EpiMatrix: Tool for Accelerated Epitope Selection and Vaccine Design**. Poster 133. 2nd Global Vaccine Congress, Boston Massachusetts, Dec 7-9 2008. (**Award winning poster**).
  125. L Moise; H Veelken; W Yang; C Weber; J McMurry; W Martin; A De Groot **De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery**. HIV Immunobiology: From Infection to Immune Control (X4) March 22 - March 27, 2009 Keystone Resort, Keystone, Colorado. Poster Number: 2095.
  126. De Groot A.S., W. Yang, L. Moise, J. A. McMurry, J. Desrosiers, W. Martin; **A Novel Compound for the Treatment of Allergy and Autoimmune Disease**. Oral Presentation, AAAI, March 13-17, Washington, DC. 2009. Journal of Allergy and Clinical Immunology, Volume 123, Issue 2, Pages S139-S139
  127. Leonard Moise, Ph.D., Jill M. Schriewer, William Martin, Jinhee Lee, Ph.D., R. Mark L. Buller, Ph.D., Sharon Frey, M.D., and Anne S. De Groot, M.D. **T-cell Epitope Vaccine Protects HLA Transgenic Mice Against Lethal Vaccinia Challenge**. NFID, Baltimore, MD, March 2009.
  128. L. Moise, W.D. Martin, J. Desrosiers, R. Tassone, J.A. McMurry, S.H. Gregory, De Groot A.S.. **Rapid development and validation of a T-cell epitope-based Tularemia vaccine for F. Tularensis**. Poster Presentation. NFID, Baltimore, MD, March 2009.
  129. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin WD, De Groot AS. **HelicoVax - a genome-derived vaccine candidate developed from T cell epitopes conserved between human and mouse-adapted strains of H. pylori**. Oral Presentation. NFID, Baltimore, MD, March

- 2009.
130. Hui D.J., Pien G.C., Basner-Tschakarjan E., Mingozi F., Finn J.D., Martin W., De Groot A.S., High K.A. Antigen-Specific Modulation of CTL Responses Triggered by AAV-Capsid Epitope Presentation on Transduced Hepatocytes. American Society of Gene and Cell Therapy, 13th Annual Meeting, San Diego, CA, May 2009.
  131. Leonard Moise, Wen Yang, Yan Su, Daniel J. Hui, Federico Mingozi, William D Martin, David W. Scott, Katherine A. High, Francesca D'Addio, N Najafian, Mo H Sayegh, Anne S. De Groot. **T cell epitopes (Tregitopes) contained in IgG Constant Domains activate natural Tregs: Relevance for autoimmune disease, gene therapy, and less immunogenic biologics.** Oral Presentation, **WSD18/**. 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
  132. Joseph Desrosiers II, Leonard Moise Jonathan Skupsky, Ryan Tassone, , Julie A. McMurry, William D. Martin, David W. Scott, Anne S. De Groot. **De-immunization” of Human Factor VIII: Identification of Epitopes in the C2 Domain.** Oral presentation. WSD14/1. 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
  133. Anne S. De Groot, Leonard Moise, Xin Li, Yan Su, Wen Yang1, Joseph Desrosiers, Ryan Tassone, Preema Mehta, William D. Martin, David W. Scott. **Effect of Tregitopes on T1D Immune response in vitro and on diabetes in NOD mice. oral presentation.** WSC11/3. 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
  134. Tounkara Karamoko, Kone Youssouf, Koty Zoumana, Aboubacar Ben, Wirwie Timothy, De Groot Anne S. **Patient adherence to HIV treatment and prevention in the Centre de Santé Communautaire de Sikoro, Bamako, Mali.** Poster and Abstract 0294. 4th International Conference on HIV Treatment Adherence, Miami FLA, April 2009.
  135. Karamoko Tounkara, Yssouf Kone, Ben Aboubacar, Ousmane Koita, Sankare Moussa, Dolo Ibrahima, Siby Fanta, and Anne S. De Groot. **Knowledge, Attitudes, Practices and Willingness to Participate in HIV Vaccine trials among urban residents of Bamako, Mali, in West Africa.** Prevention of HIV/AIDS (X3) Dates: March 22 - March 27, 2009 Keystone Resort, Keystone, Colorado, **Poster.**
  136. L Moise; H Veelken; W Yang; C Weber; J McMurry; W Martin; A De Groot **De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery.** HIV Immunobiology: From Infection to Immune Control (X4) March 22 - March 27, 2009 Keystone Resort, Keystone, Colorado. **Poster Number:** 2095.
  137. L Moise; J Desrosiers; W Martin; A De Groot; J McMurry; C **Weber Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine:** Advances in vaccine design based on current preclinical success Prevention of HIV/AIDS (X3) Dates: March 22 - March 27, 2009 Keystone Resort, Keystone, Colorado, **Poster Number:** 2036.
  138. De Groot A.S., W. Yang, L. Moise, J. A. McMurry, J. Desrosiers, W. Martin; **A Novel Compound for the Treatment of Allergy and Autoimmune Disease.** Oral Presentation, AAAI, March 13-17, Washington, DC. 2009. Journal of Allergy and Clinical Immunology, Volume 123, Issue 2, Pages S139-S139.
  139. Daniel J. Hui, Gary Pien, Etiena Basner-Tschakarjan, Federico Mingozi, Jonathan D. Finn, Bill Martin, Anne S. De Groot, Katherine A. High. **Antigen-specific modulation of CTL responses triggered by AAV-capsid epitope presentation on transduced hepatocytes.** American Society of Gene Therapy.
  140. F. D'Addio, O. Boenisch, T. Wattanabe, A De Groot, M.H. Sayegh and N. Najafian. **Immuno-**

- modulatory functions of a novel IgG Fc-derived Peptides, Tregitopes, in alloimmunity.** Oral presentation. **Young Investigator Award** (D'Addio) American Transplant Conference (ATC) June, 2009.
141. Yan Su, Leonard Moise, Xin Li, Robert Rossi, Jonathan Skupsky, William D Martin, Anne S. De Groot, and David W. Scott. **T cell epitopes (Tregitopes) contained in IgG Constant Domains activate Natural Tregs.** 1<sup>st</sup> International Conference on Tolerance, Boston MA. Sept 2009. Elsevier.
  142. De Groot AS, Moise L, Li X, Su Y, Yang W, Desrosiers J, Tassone R, Mehta P, Cohen T, Martin W, Scott DW. **Effect of "Tregitopes" on T1D immune response in vitro and diabetes in NOD mice.** Oral Presentation 0085. 1st International Conference on Immune Tolerance, Boston MA 25 - 27th October 2009.
  143. Constanze A. Weber, Leonard Moise, Ph.D., William D. Martin, Hendrik Veelken, M.D. and Anne S. De Groot, M.D. **De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery.** 1st International Conference on Immune Tolerance, Boston MA 25 - 27th October 2009.
  144. Francesca D'Addio<sup>1</sup>, Olaf Boenisch<sup>1</sup>, Toshiko Watanabe<sup>1</sup>, Leonard Moise<sup>2,3</sup>, William D Martin<sup>3</sup>, Anne S. De Groot<sup>2,3,4</sup>, Mohamed Sayegh<sup>1</sup>, Nader Najafian<sup>1</sup>. **Regulatory T cell epitope IgG Fc derived peptide (Tregitope) modulates tolerance/immunogenicity balance in murine and human allo-antigen stimulation models.** 1st International Conference on Immune Tolerance, Boston MA 25 - 27th October 2009.
  145. Leonard Moise, Ph.D., Jill M. Schriewer, William Martin, Jinhee Lee, Ph.D., R. Mark L. Buller, Ph.D., Sharon Frey, M.D., and Anne S. De Groot, M.D. **T-cell Epitope Vaccine Protects HLA Transgenic Mice Against Lethal Vaccinia Challenge Without B Cell Priming.** Poster # 131452, Cold Spring Harbor Laboratory. Meeting, "Harnessing immunity to prevent and treat disease". October 11-14, 2009.
  146. Leonard Moise, Ph.D., Ryan Tassone, Tobias Cohen, Rachel DuPont, William Martin, Jinhee Lee, Ph.D., Hardy Kornfeld, M.D. and Anne S. De Groot, M.D. **Immunoinformatic-discovered mycobacterium tuberculosis T-cell epitopes are immunogenic in HLA transgenic mice.** Poster # 131449, Cold Spring Harbor Laboratory. Meeting, "Harnessing immunity to prevent and treat disease". October 11-14, 2009.
  147. Tobias Cohen, Matthew Ardito, Joe Desrosiers, William Martin, Anne S. De Groot, M.D. Individualized T cell epitope measure (item): **A new tool for vaccine design and personal therapeutics.** Poster # 131448, Cold Spring Harbor Laboratory. Meeting, "Harnessing immunity to prevent and treat disease". October 11-14, 2009.
  148. Constanze A. Weber, Leonard Moise, Ph.D., William D. Martin, Hendrik Veelken, M.D. and Anne S. De Groot, M.D. **De-tolerization of anti-dec-205 for HIV subunit vaccine delivery.** Poster # 131453, Cold Spring Harbor Laboratory. Meeting, "Harnessing immunity to prevent and treat disease". October 11-14, 2009.
  149. Tounkara Karamoko, Kone Youssouf, Koty, Zoumana, Aboubacar Ben, Dilorenzo, Madeline, De Groot Anne S. **Longitudinal study of pregnant women's acceptance of and adherence to HIV treatment in the Centre de Santé Communautaire de Sikoro, Bamako, Mali.** Poster Presentation, IAPAC 09. November 29 - December 1, 2009, New Orleans. (Maddie DiLorenzo Presented Poster).
  150. AS De Groot, L Moise, J Desrosiers, C Weber and W Martin. **Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current**

- preclinical success. P17-26.** AIDS Vaccine 2009. Paris, France. 19–22 October 2009.
151. K Tounkara, B Aboubacar, O Koita, A Traore, S Dao, S Moussa, D Ibrahima, S Fanta, F Bougoudogo, R Gerber and AS De Groot. **Knowledge, attitudes, practices and willingness to participate in HIV vaccine trials among urban residents of Bamako, Mali, in West Africa, 2005–2009. P15-07.** AIDS Vaccine 2009. Paris, France. 19–22 October 2009. Retrovirology, Volume 6 Suppl 3.
  152. C Weber, L Moise, H Veelken and W Martin. **Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform. P19-43.** AIDS Vaccine 2009. Paris, France. 19–22 October 2009. Retrovirology, Volume 6 Suppl 3.
  153. Scott D.W., Su Y., Skupsky J., Li X., Martin W.D., and De Groot, A.S. Activation of Regulatory T cells by T-cell epitopes (Tregitopes) contained in IgG Constant Domains. International Forum on Immunoglobulin Research (IFIR), 2009.
  154. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. **A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: iTEM (individualized T Cell Epitope Measure).** 13th annual conference on vaccine research. Hosted by the National Foundation for Infectious Diseases; 2010 Apr 26-28; North Bethesda, MD
  155. Hui, Daniel J, Pien, Gary C, Basner-Tschakarjan, Etiena, Mingozzi, Federico, Finn, Jonathan D, Zhou, Shangzhen, Martin, William, Groot, Anne S. De, High, Katherine A. Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells. **American Society of Hematology**, Annual Meeting Abstracts 2009 114: 377 (Oral presentation) <http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/377>
  156. Pischel L., Caplow J., Chokshi B., Tounkara K., Berthé M., Aboubacar B., Bougoudogo F., De Groot A.S. **Tuberculosis Knowledge, Attitudes and Practices in Sikoro, Mali.** IUALTb North America, Oral and Poster presentation, 14th Annual North American International Union Against Tuberculosis and Lung Disease (IUATLD NA), Orlando Florida, March 11-13 2010.
  157. Hui, D.J., Pien, G., Basner-Tschakarjan, E., Mingozzi, F., Finn, J.D., Zhou, S., Martin, W., De Groot, A.S., and High, K.A. **Induction of Regulatory T Cells As An Approach To Modulate CTL Responses Against AAV Capsid Epitopes.** Oral Presentation. American Society of Gene and Cell Therapy 13th Annual Meeting, Washington, D.C., May 19-22, 2010.
  158. Constanze A. Weber, Leonard Moise, Janet E. Buhlmann, William D. Martin, Hendrik Veelken and Anne S. De Groot, **De-Tolerization of Anti-DEC205 for HIV Subunit Vaccine Delivery**, abstract, Vaccine Technology III, Nuevo Vallarta, 06/10.
  159. Anne S. De Groot, Robert Malone, Toby Cohen, Liz McLaine, Matt Ardito, Bill Martin, **Universal Flu Vaccines: Now more than Ever**, abstract, Vaccine Technology III, Nuevo Vallarta, 06/10.
  160. Leonard Moise, Jill Schriewer, William Martin, Jinhee Lee, Mark Buller, Sharon Frey and Anne S. De Groot **T-cell Epitope Vaccine Provides Complete Protection Against Lethal Vaccinia Infection In HLA Transgenic Mouse Model**, abstract, Vaccine Technology III, Nuevo Vallarta, 06/10.
  161. Tobias Cohen, Matthew Ardito, William Martin, Anne S. De Groot, **Personalizing Immune Responses to Vaccines, Autoantigens, and Protein Therapeutics: The iTEM (individualized T Cell Epitope Measure) Tool**, Vaccine Technology III, Nuevo Vallarta, 06/10.
  162. Anne S. De Groot, Mark Buller, Sharon Frey, Steven Gregory, Steven Moss, Hardy Kornfeld, Jinhee Lee, Leonard Moise, William Martin. **T cell-driven Vaccines: Now more than Ever.** Oral Presentation Accepted to Vaccine Technology III, Nuevo Vallarta, 06/10.

163. EpiMatrix: Tool for Accelerated Epitope Selection and Vaccine Design. **Ardito, M., Cohen T., Martin B. De Groot AS.** Poster Presentation Accepted to Vaccine Technology III, Nuevo Vallarta, 06/10.
164. J.E. Buhlmann, N. Najafian, D. J. Hui, F. D'Addio, F. Mingozzi, L. Moise, L. J. De Groot, A. Keegan, K. A. High, M. H. Sayegh, D. W. Scott, A. S. De Groot. **Preclinical Design of Less Immunogenic Biologics: Tregitopes and Tolerance.** Poster Presentation. AAI, Baltimore, MD May 2010.
165. Su Y ,Moise L., Li X., Rossi R., Skupsky J., Martin W.D., De Groot A.S., and Scott D.W. T cell epitopes (Tregitopes) Suppress Immune Responses in vivo by Activating Natural Tregs. Poster Presentation. AAI, Baltimore, MD May 2010. J Immunol 2010 184:49.24 (Abstr)
166. Chang (Jerry) Song, Leonard Moise, R. Tassone, William D. Martin, Anne S. De Groot, and David W. Scott. **Deimmunization of HLA-DR Epitopes in the C2 Domain of Human FVIII.** Poster Presentation. AAI, Baltimore, MD May 2010.
167. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. **A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: iTEM (individualized T Cell Epitope Measure).** Poster session presented at: The 13<sup>th</sup> annual conference on vaccine research. Hosted by the National Foundation for Infectious Diseases; 2010 Apr 26-28; North Bethesda, MD.
168. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. **A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: iTEM (individualized T Cell Epitope Measure).** Poster session presented at: Vaccine Technology III. Hosted by Engineering Conferences International; 2010 Jun 6-11; Nuevo Vallarta, Nayarit, Mexico.
169. Tounkara, K., Aboubacar, B., Diallo, FS, Bougoudogo, F, Traore, Y., Dao, S, Traore, S, Kone, Y, Koita, OA, Rochas, M, De Groot, AS. **Development of an HIV Vaccine trial site in collaboration with regional DOH, HIV experts, and community based organizations in Mali, West Africa.** Submitted, AIDS Vaccine Conference, September 2010.
170. De Groot A.S., N. Najafian, D. J. Hui, F. D'Addio, F. Mingozzi, L. Moise, J.E. Buhlmann, L. J. De Groot, A. Keegan, K. A. High, M. H. Sayegh, D. W. Scott. **Preclinical Design of Less Immunogenic Biologics: Tregitopes and Tolerance, \*AAPS Innovation Award 2010\* Oral and poster presentation** AAPS 2010 National Biotechnology Conference. May 16-19 in San Francisco, California.
171. De Groot A.S., Epitope-Based Immunome-Derived Vaccines: **A Strategy for Improved Design and Safety.** Oral Presentation accepted at 5<sup>th</sup> Annual Novel Vaccines, Design and Development, Cambridge, MA. August 2010. [This abstract was withdrawn by CHI]
172. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. **A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: iTEM (individualized T Cell Epitope Measure).** Poster session presented at: Immunoinformatics and computational immunology workshop. In conjunction with ACM International Conference on Bioinformatics and Computational Biology; 2010 Aug 2-4; Niagara Falls, NY.
173. Buhlmann JE, Najafian, N, Hui, DJ, D'Addio, F, Mingozzi, F, Moise, L, De Groot, LJ, Keegan, A, K. High, KA, Sayegh, MH, Scott, DW, De Groot AS. **Preclinical Design of Less Immunogenic Biologics: Tregitopes and Tolerance.** Poster Presentation. **AAI**, Baltimore, MD May 2010.
174. D'Addio F., Boenisch O., Wattanabe T., De Groot A.S., Sayegh M.H. and Najafian N. **Immuno-modulatory functions of a novel IgG Fc-derived Peptides, Tregitopes, in alloimmunity.** Oral presentation. Young Investigator Award (D'Addio) American Transplant Conference (ATC) June, 2009.

175. Hui, DJ, Basner-Tschakarjan E, Pien GC, Martin WD, De Groot AS, High KA, and F Mingozi, **Peptide-Induced Antigen-Specific CD4+CD25+FoxP3+ T Cells Suppress Cytotoxicity T Cell Responses Directed Against the AAV Capsid.** *American Society of Hematology. Blood (ASH Annual Meeting Abstracts)*, Nov 2010; 116: 3769. <http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/3769>
176. Cousens, L. P., C. A. Weber, L. Moise, W. D. Martin, H. Veelken and A. S. De Groot. **Development of De-tolerized Anti-DEC-205 for Delivery of an HIV Subunit Vaccine (Abstract).** *Immunological Mechanisms of Vaccination*, Seattle, Washington. 2010.
177. Cousens, L. P., C. A. Weber, A. Reslow, J. E. Buhlmann, W. D. Martin, L. Moise and A. S. De Groot. **Importance of Regulatory T-Cells Epitopes in Vaccine Delivery Design (Abstract).** *Vaccine and ISV 4th Annual Vaccine Congress*, Vienna, Austria. 2010.
178. D'Addio, F., O. Boenish, T. Watanbe, W. Martin, A. DeGroot and N. Najafian. **Ex Vivo Expansion of Human Antigen-Specific Natural Tregs Using IgG Fc Derived Peptides ("Tregitopes")** (Abstract). *American Journal of Transplantation*. 10(Suppl.4):188. April 2010.
179. De Groot, A., J. Bulmann, C. Weber, A. Reslow, B. Martin, W. Martin and L. Moise. **De-Tolerization of Anti-DEC-205 for HIV Vaccine** (Abstract). *AIDS Research and Human Retroviruses*. 26(10):A135-A136. October 2010.
180. De Groot, A. S., N. Najafian, D. J. Hui, F. S'Addio, F. Mingozi, J. Buhlmann, L. Moise. L. J. De Groot, A. Keegan, K. A. High, M. H. Sayegh and D. W. Scott. **Clinical Design of Less Immunogenic Biologies: Tregitopes and Tolerance.** *Inflammation Research*. 59(S3):S288-S289. September 2010. (Poster award).
181. Inaba, Hidefumi, William Martini, Matt Ardito, Anne Searls De Groot and Leslie J. De Groot. **The Role of Glutamic or Aspartic Acid in Position Four of Epitope Binding Motif of TSH-R-ECD Epitope Selection in Graves Disease** (Poster Presentation Abstract). *Endocrine Journal*. 57(S2):S475-S476. March 2010. Oral Presentation 851146 at ENDO 2010: The 92nd Annual Meeting & Expo, June 19-22 2010 in San Diego.
182. Moise, L., J. A. McMurry, J. Desrosiers, C. Weber, W. D. Martin and A. S. De Groot. **Effectively Designing T-Cell Driven Vaccines With Immunoinformatics Tools.** *Journal of Medical Primatology*. 39(4):285. August 2010.
183. Sangare, K., O. Koita, K. Tounkara, Z. Koty, L. Moise, M. Ardito, T. Cohen, J. Desrosiers, R. DuPont, M. Riochas, W. Martin and A. DeGroot. **Tracking Highly Conserved and Immunogenic Cross-Clade HIV CTL Epitopes Included the GAIA HIV Vaccine Over Time** (Abstract). *AIDS Research and Human Retroviruses*. 26(10): A136. October 2010.
184. Zhang, Songhua; Moise, Leonard; Tassone, Ryan; Fast, Loren; Maraj, Bharat; Ardito, Matthew T.; Martin, William; DeGroot, Anne S.; Moss, Steven F. **Bioimmunoinformatic approach to mine H. pylori genomes for targeted vaccine development.** DDW 2011 Abstract # 1028775
185. Moise L, Gustafson E, Ardito M, McGowan M, Martin W, De Groot AS. Cousens LP, Weber CA, Moise L, Martin WD, Veelken H, De Groot AS. Development of de-tolerized anti-DEC-205 for delivery of an HIV subunit vaccine. *Immunological Mechanisms of Vaccination*. October, 2010. Seattle Washington.
186. Moise L, Ardito M, Martin WD, De Groot AS, J Desrosiers; K DaSilva, Zhang S, Moss SF. **Immunoinformatic identification of H. pylori core genome vaccine candidates.** *Keystone Immunological Mechanisms of Vaccination*. October 2010, Seattle, WA.
187. Ardito M, Fueyo J, DaSilva K, Zhang S, Martin W, De Groot AS, Moss SF, Moise L. **Immunoinformatic-driven H. pylori vaccine design.** *First Immunogenicity: Determinants and Correlates (IDC) Conference*. Poster presentation. Providence, RI, USA. 2011 May 10-12.



188. Cousens LP, Dupont R, Levitz L, Martin WD, De Groot AS. **Development of in vitro methods for monitoring Tregitope efficiency.** First Immunogenicity: Determinants and Correlates (IDC) Conference. Poster presentation. Providence, RI, USA. 2011 May 10-12.
189. Cousens LP, Levitz L, DuPont R, Martin WD, De Groot AS. **Tregitope mechanism of action at the immunological synapse.** First Immunogenicity: Determinants and Correlates (IDC) Conference. Poster presentation. Providence, RI, USA. 2011 May 10-12.
190. Cousens L, Martin B, Reslow A, Aguirre D, Weber CA, Martin WD, Moise L, De Groot AS. **Removal of tolerogenic signals in dendritic cell targeting antibodies for improved vaccine delivery.** First Immunogenicity: Determinants and Correlates (IDC) Conference. Poster presentation. Providence, RI, USA. 2011 May 10-12.
191. Cousens LP, Moise L, Martin WD, DuPont R, Martin BA, De Groot AS. **Designing the optimal delivery vehicle for Regulatory T Cell Epitopes, "Tregitopes".** First Immunogenicity: Determinants and Correlates (IDC) Conference. Poster presentation. Providence, RI, USA. 2011 May 10-12.
192. Tassone R, Moise L, Ardito M, Desrosiers J 3rd, Scott DW, Martin W, De Groot AS. **In vitro and in vivo validation of FVIII deimmunization by T cell epitope modification.** First Immunogenicity: Determinants and Correlates (IDC) Conference. Poster presentation. Providence, RI, USA. 2011 May 10-12.
193. Ardito M, Martin W, Gregory S, Losikoff P, De Groot A. **Epitope Selection for a Dendritic Cell-Based Vaccine against Hepatitis C.** Keystone Symposia: Immunological Mechanisms of Vaccination; Seattle, WA; October 2010.
194. Gustafson E, Moise L, Ardito M, Tejada G, Desrosiers J, Martin W, De Groot AS. **Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine.** Accepted poster presentation. 2011. NFID Fourteenth Annual Conference on Vaccine Research. Baltimore, MD.
195. Zhang S, Moise L, Tassone R, Levitz L, Fast L, Desrosiers J, DaSilva K, Meraj B, Ardito M, Martin B, De Groot A, Moss SF. **Bioimmunoinformatic approach to mine H. pylori genomes for targeted vaccine development.** American Gastroenterology Association annual meeting, May 2011, Chicago, IL
196. Cousens L, De Groot A. **Regulating immune response to biologics with Tregitopes, a paradigm-shifting solution?** 2011 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). Invited oral presentation. Session 191 Immune Tolerance Induction. San Francisco, CA, USA. 2011 May 16-18.
197. Ardito M, Terry F, Kurczyk G, Martin W, De Groot AS. **Interactive Protein Screening and Reengineering Interface (ISPRI).** 2011 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). Poster presentation. San Francisco, CA, USA. 2011 May 16-18.
198. Ardito M, Fueyo J, DaSilva K, Zhang S, Martin W, De Groot AS, Moss SF, Moise L. **An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design.** 2011 NFID Fourteenth Annual Conference on Vaccine Research. Baltimore, MD.
199. Reslow A, Aguirre D, Cousens L, Martin B, Weber CA, Martin WD, De Groot AS, Moise L. **Improved vaccine delivery by removal of tolerogenic signals in dendritic cell targeting antibodies.** 2011. NFID Fourteenth Annual Conference on Vaccine Research. Baltimore, MD.
200. Kotou Sangare, Ousmane Koita, Karamoko Tounkara, Zoumana Koty, Lenny Moise, Matt Ardito, Toby Cohen, Joe Desrosiers, Rachel Dupont, Mali Rochas, Bill Martin, Anne S. De Groot. **'Conservation across time and sequence: Validation of immunogenic HLA-A2 'Achilles' heel' epitopes for the GAIA HIV vaccine'.** Poster **218130**. AIDS Vaccine 2011, Bangkok Convention Centre. Monday, 12 September- Wednesday, 14 September 2011

201. Leonard Moise, Ousmane Koita, Kotou Sangare, Lauren Levitz, John Rozehnal, Zoumana Koty, Karamoko Tounkara, Matthew Ardito, Mali Rochas, William Martin, Anne S. De Groot; **GAIA HIV Vaccine progress report: Further validation of broadly conserved class I epitopes in West Africa'**; Poster Abstract 218180. AIDS Vaccine 2011, Bangkok Convention Centre. Monday, 12 September- Wednesday, 14 September **2011**
202. KOTY Zoumana, SANGARE Kotou, TOUNKARA Karamoko, DIALLO Fanta Siby, TRAORE Sylvestre, KONE Yssouf,, KOITA Ousmane , ROZEHNAL John, LEVITZ Lauren, ROCHAS Mali, DE GROOT Anne S. **Providing care and education prior to engaging in an HIV vaccine trial, Bamako Mali, West Africa..** Poster Abstract 217875. AIDS Vaccine 2011, Bangkok Convention Centre. Monday, 12 September- Wednesday, 14 September **2011**.
203. De Groot AS, Cousens LP, Mazer B, Najafian N, Mingozi F, Elyaman W, Hui DJ, Levitz L, DuPont R, Messitt T, Khoury S, Su Y, Scott DW. **Tregitope mechanism of action and applications to autoimmunity.** Second International Forum on Immunoglobulin Research (IFIR 2011). Invited Oral Presentation. Barcelona, Spain. 2011 Sep 14-17.
204. Mazer B, Massoud AH, Ablona A, Langelier AB, Cousens L, De Groot AS. Tregitopes recapitulate action of IVIg by abrogating **OVA-induced allergic airways** disease via induction of T regulatory cells (Treg). Second International Forum on Immunoglobulin Research (IFIR 2011). Invited Oral Presentation, Barcelona, Spain. 2011 Sep 14-17.
205. Scott DW, Mingozi F, Su Y, Zhang A, De Groot A. **Effect of Regulatory T cell-epitopes (Tregitopes) on CD4, CD8 and B-cell Responses.** 2<sup>nd</sup> International Conference on Immune Tolerance. Oral presentation. Abstract #O12. Amsterdam, The Netherlands. 2011 Oct 23-25.
206. Cousens LP, Levitz L, DuPont R, Tassone R, Martin WD, De Groot AS. **Tregitope mechanism of action at the immunological synapse.** 2<sup>nd</sup> International Conference on Immune Tolerance. Poster presentation. Abstract #35. Amsterdam, The Netherlands. 2011 Oct 23-25.
207. De Groot AS, Cousens LP, Najafian N, Mingozi F, Elyaman W, McClaine EM. **Tregitope mechanism of action and applications for tolerance induction.** 2<sup>nd</sup> International Conference on Immune Tolerance. Poster presentation. Abstract #36. Amsterdam, The Netherlands. 2011 Oct 23-25.
208. Elyaman W, Bassil R, De Groot AS, McClaine EM, Cousens LP, Scott DW. **Tregitopes expand regulatory T cells and ameliorate experimental autoimmune encephalomyelitis.** 2<sup>nd</sup> International Conference on Immune Tolerance. Poster presentation. Abstract #37. Amsterdam, The Netherlands. 2011 Oct 23-25.
209. Levitz L, Messitt T, McClaine E, Tassone R, Ardito M, Buhlmann JE, Moise L, Knopf PM, Martin W, De Groot AS. **Adjuvant Effects of C3d Are Mediated Through the Activation of C3d-specific Autoreactive T-cells.** Poster Presentation and Oral Presentation by Lauren Levitz. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
210. Moss SF, Zhang S, Ardito M, Terry F, Fueyo J, DaSilva K, Martin W, De Groot AS, and Moise L. **Bioinformatic-Driven H. pylori Vaccine Design.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
211. Ardito M, Terry F, Kurczy G, Gregory SH, Losikoff PT, Spero D, Martin W, **De Groot AS. Personalizing Immune Responses to Vaccines, Autoantigens, and Protein Therapeutics: The iTEM (individualized T cell Epitope Measure) Tool.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
212. Terry F, Ardito M, Mather TN, Coy W, Ribeiro JMC, Martin W, **De Groot AS. Epitope Selection for a Transmission-Blocking Vaccine Against Tick-Borne Diseases.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.

213. Moise L, Ardito M, Martin W, **De Groot AS. Immunoinformatic Discovery of Potential Cross-reactive T Cell epitopes in the Measles Genome.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
214. **De Groot AS,** Ardito M, Moise L, Tassone R, Martin W. **An Integrated Genomic and Immunoinformatic Approach to Pan-Burkholderia Biodefense Vaccine Development.** Poster Presentation, NERCE/BEI Annual Retreat. Newport, Rhode Island, USA. November **2011**.
215. Ardito M, Terry F, Kurczy G, Gregory SH, Losikoff PT, Spero D, Martin W, **De Groot AS. iVAX Web-based Vaccine Design: Application to a Hepatitis C Virus Vaccine.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
216. Terry F, Ardito M, Mather TN, Coy W, Ribeiro JMC, Martin W, **De Groot AS. Epitope Selection for a Transmission-Blocking Vaccine Against Tick-Borne Diseases.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
217. Moise L, Ardito M, Martin W, **De Groot AS. Immunoinformatic Discovery of Potential Cross-reactive T Cell epitopes in the Measles Genome.** Poster Presentation. 5th Vaccine and ISV Annual Congress. Seattle, Washington, USA. October **2011**.
218. **De Groot AS,** Moise L, Ardito M, McClaine E, DuPont R, Tassone R, Haran J, Suner S, Martin WD. **Evidence from H1N1 Supporting Development of Broad-Spectrum Vaccines Against Influenza.** Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Poster presentation. Abstract #W14-021. Las Vegas, NV, USA. 2011 Nov 14-18.
219. De Groot A. **iVax: Extremely rapid online immunoinformatics tool for vaccine design.** 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Oral presentation. Abstract #1107. Las Vegas, NV, USA. 2011 Nov 14-18.
220. Terry F, Ardito M, Cohen T, Moise L, Martin W, **De Groot AS.** A method for individualizing the prediction of immunogenicity for vaccines and protein therapeutics: **iTEM (Individualized T cell Epitope Measure).** 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Poster presentation. Abstract #W20-006. Las Vegas, NV, USA. 2011 Nov 14-18.
221. Moise L, Schriewer J, Martin W, Lee JH, Buller M, Frey S, **De Groot AS. T-cell Epitopes Are Sufficient for Protective Vaccination Against Lethal Vaccinia Infection In HLA Transgenic Mouse Model.** Poster Presentation, Chemical and Biological Defense Science and Technology Conference, Las Vegas, Nevada, USA. November **2011**.
222. Dupuy LC, Mitchell D, Richards MJ, Bounds C, Ardito M, McClaine E, Moise L, Martin W, De Groot AS, Schmaljohn CS. **Immunogenicity and protective efficacy of a multi-epitope vaccine composed of Ebola Virus and Venezuelan Equine Encephalitis Virus** HLA class II T cell epitopes in HLA transgenic mice. 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Poster presentation. Abstract #W14-014. Las Vegas, NV, USA. 2011 Nov 14-18. **\*\*Winner of Outstanding Poster Presentation Award\*\***
223. De Groot AS, Moise L, Messitt T, McClaine E, Einck L, Del Pozzo J, Martin W. **FastVax: Accelerated Vaccine Design, Production and Delivery.** Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Poster presentation. Abstract #W14-020. Las Vegas, NV, USA. 2011 Nov 14-18.
224. Losikoff PT, Fast LD, Nevola MM, Mishra S, Desrosiers J, Martin W, Ardito M, De Groot AS, Gregory SH. **Human peptide homologues encoded by hepatitis C virus promote a regulatory T cell response in chronically infected patients.** Annual NERCE Conference, Newport, RI; November **2011**.
225. DIARRA Abdoulaye Lassana,, PISCHEL Lauren, CAPLOW Julie, DIARRA Guide, CHOKSHI Binny, TOUNKARA Karamoko, ABOUBACAR Ben, **Bicki, Alexandra,** ROCHAS Mali, BOUGOUDOUGO Flabou, DE GROOT, Anne S., **TB Bolo: A five-finger mnemonic and**

- motivational method used for promoting tuberculosis testing in Bamako Mali, West Africa.** Abstract submitted to IAS World AIDS Conference, Washington DC, 2012.
226. De Groot AS, Cousens LP, Najafian N, Mingozzi F, Elyaman W, McClaine EM, Mazer B, Hui DJ, Khoury S, Su Y, Scott DW, Martin W. **Tregitope applications to tolerance induction in autoimmune diseases.** The American Association of Immunologists (AAI) Immunology 2012. Oral presentation. Abstract #1337905. Poster presentation #P1565. Boston, MA, USA. 2012 May 4-8. J Immunol. 2012 May;188 (Meeting Abstract Supplement):116.10.
227. Cousens LP, Moise L, Ardito MA, McClaine EM, Terry F, Martin W, De Groot AS. **Regulating immune responses to biologics: epitope prediction and applications.** The American Association of Immunologists (AAI) Immunology 2012. Oral presentation and abstract #13384505. Poster presentation. Abstract #P1153. Boston, MA, USA. 2012 May 4-8. J Immunol. 2012 May;188(Meeting Abstract Supplement):58.23.
228. De Groot AS, Cousens LP, Najafian N, Mingozzi F, Hui DJ, Mazer B, McClaine E, Elyaman W, Khoury S, Levitz L, Tassone R, Messitt T, Su Y, Scott DW, Martin W. **Tregitope applications to tolerance induction in autoimmune diseases.** 8th International Congress on Autoimmunity. Invited Plenary IV and poster presentation. Granada, Spain. 2012 May 9-13.
229. Cousens LP, McClaine EM, Levitz L, Tassone R, Messitt T, Martin W, De Groot AS. **Tregitope mechanism of action and applications for tolerance induction.** 8th International Congress on Autoimmunity. Oral and poster presentation. Abstract #816. Granada, Spain. 2012 May 9-13.
230. Su Y, Rossi R, De Groot AS, Scott DW. **IgG-derived T cell epitopes (Tregitopes) suppress immune responses by activating nTregs.** 8th International Congress on Autoimmunity. Oral presentation. Abstract #852. Granada, Spain. 2012 May 9-13.
231. Sander van der Marel, Anna Majowicz, Karin Kwikkers, Richard van Logtenstein, Anje A. te Velde, Anne S. De Groot, Sybren L. Meijer, Sander van Deventer, Harald Petry, Daniel W. Hommes, and Valerie Ferreira. **AAV5 mediated delivery of Regulatory T-cell epitope 167 ameliorates acute experimental colitis and prevents a type 1 hypersensitivity reaction in a TNBS model of Crohn's disease.** Digestive Diseases Week, San Diego CA, May 2012.
232. De Groot AS, Sangare K, Koita O, Ardito M, Boyle CM, Levitz L, Rozehnal J, Tounkara K, Dao S, Kone Y, Koty Z, Moise L, Martin W. **Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.** AIDS Vaccine 2012. Poster presentation. Abstract #P12.05. Boston, MA, USA. 2012 Sep 9-12. Retrovirology. 2012;9(Suppl 2):P294.
233. Moise L, Koita O, Sangare K, Levitz L, Rozehnal J, Koty Z, Tounkara K, Ardito M, Boyle CM, Rochas M, Martin W, De Groot AS. **Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV Vaccine.** Poster presentation. Abstract #P12.06. AIDS Vaccine 2012. Boston, MA, USA. 2012 Sep 9-12. Retrovirology. 2012;9(Suppl 2):P295.
234. De Groot AS, TOUNKARA Karamoko, ABOUBACAR Ben, DIALLO Fanta Siby, BOUGOUDOGO, Flabou, KOITA Ousmane A, DAO Sounkalo, DIALLO Souleymane, TRAORE Youssef, DIARRA, Lassina, DIARRA Guide, KONE Yssouf, ROCHAS Mali, LUTTERBECK Steven, **A Decade of Partnering to Stop HIV in West Africa: GAIA VF Prevention, Education, Access to Care and Vaccine Trial Site Development in Bamako Mali.** AIDS Vaccine Conference, Boston MA 2012.
235. Yssouf Kone., Ben Aboubacar, Lauren Levitz, Christina Gomez Mira, Julia Toffoli, Natasha Ryback, Emily Kossow, Tonhu Huang, **Ali Bicki**, Karamoko Tounkara, Youssef Traore, Fanta Siby Diallo, Mali Rochas, Annie S. De Groot. **HIV-Free children born to Seropositive Mothers in Bamako Mali: A six-year perspective on providing MTCTP at the front line of AIDS.** AIDS Vaccine Conference, Boston MA 2012.

236. Zoumana Koty: **Evaluating short-term patient outcomes after HIV care interventions in a low resource setting: Preparing for an HIV vaccine trial site in Bamako, Mali.** AIDS Vaccine Conference, Boston MA. September 2012.
237. Tounkara Karamoko. **Pediatric HIV infection due to maternal transmission: A solvable problem in a peri-urban setting in Bamako, Mali'** AIDS Vaccine Conference, Boston MA. September 2012.
238. Danielle Poole, Kathleen Tracy, Lauren Levitz, Shahla Yekta, Emily Kossow, Tonhu Huang, Mali Rochas, Kotou Sangare, Karamoko Tounkara, Ben Aboubacar, Ousmane Koita, Siby Fanta, Samba Sow, Ibrahima Tégouété, Amadou Dolo, Flabou Bougoudogo, Anne S. De Groot, **Knowledge, attitudes, practices of HPV and cervical cancer and willingness to participate in a vaccine trial in preparation for HIV and HPV vaccine clinical trials in Mali, West Africa.** AIDS Vaccine Conference, Boston MA. September 2012.
239. Z. Koty, A. Bicki, N. Platt, Y. Koné, L. Diarra, K. Tounkara, Fanta Siby Diallo. Lauren Levitz, B. Aboubacar, M. Rochas, S. Dao A.S. De Groot. HIV Care in a Low Resource Setting in Mékin-Sikoro, Commune I, Bamako, Mali: **Does Providing Universal Access Improve Short Term Outcomes?** Abstract submitted to IAS World AIDS Conference, Washington DC, 2012.
240. De Groot A.S., Najafian N., Hui D.J., Mingozi F., Cousens L.P., Moise L., Khoury S.J., Elyaman W., Martin W., and Scott D.W. **Tregitopes and tolerance: Harnessing regulatory T cells to suppress inflammation. Oral presentation.** 10th World Congress on Inflammation. Paris, France. 2011 June 25-29. *Inflamm. Res.* 2011; 60(Suppl 1): S1-S321.
241. De Groot A.S., Najafian N., Hui D.J., Mingozi F., Cousens L.P., Moise L., Scott D.W., Khoury S., Elyaman W., and Martin W. **Making Better Biologics by Harnessing Tolerance and Immunogenicity.** AAPS National Biotechnology Conference 2011 Meeting. Oral presentation. San Francisco, CA. 2011 May 16-18. *AAPS Journal.* 2011;13(S1).
242. Cousens L.P., De Groot A.S., Najafian N., Mingozi F., Elyaman W., McClaine E.M., Mazer B., Hui D.J., Khoury S., Su Y., Scott D.W., and Martin W.D. **Tregitope applications to tolerance induction in autoimmune diseases.** Oral and poster presentation. AAI "Immunology 2012" Meeting. Boston, MA. 2012 May 4-8. *J. Immunol.* 2012;188:116.10.
243. De Groot A.S., Cousens L.P., Najafian N., Mingozi F., Elyaman W., McClaine E.M., Mazer B., Hui D.J., Khoury S., Su Y., Scott D.W., and Martin W.D. **Tregitope Applications to Tolerance Induction in Autoimmune Diseases.** Poster presentation. American Association of Pharmaceutical Sciences (AAPS) National Biotechnology Conference 2012 Meeting. San Diego, CA. 2012 May 21-23. *AAPS Journal.* 2012;14(S1).
244. Gutiérrez AH, Bailey-Kellogg C, DaSilva K, Terry F, Ardito M, Moise L, Martin W, De Groot AS. **Cross-reactivity analysis of the Chinese Hamster Ovary genome.** The 17th International Inflammation Research Association (IRA) Conference. Poster presentation. Abstract #A112. Bolton Landing, NY, USA. 2012 Sep 9-13. *Inflammation Res.* 2012 Sep;61(S):S15.
245. Welsh, RA, De Groot AS, Williams S. From "Gene to Vaccine" for Brugia malayi: Applying Immunoinformatics tools to Neglected Tropical Diseases. Third Immunoinformatics and Computational Immunology Workshop (ICIW 2012). Held in conjunction with the ACM Conference on Bioinformatics, Computational Biology and Biomedicine 2012. Orlando, FL, USA. 2012 Oct 10.
246. Terry F, Ardito M, De Groot AS, Martin W. **iVax: Interactive Vaccine Design Toolkit.** Third Immunoinformatics and Computational Immunology Workshop (ICIW 2012). Held in conjunction with the ACM Conference on Bioinformatics, Computational Biology and Biomedicine 2012. Workshop tutorial. Orlando, FL, USA. 2012 Oct 7-10.
247. Losikoff PT, Fast LD, Nevola MM, Mishra S, Desrosiers J, Martin W, Ardito M, Terry F, De Groot AS, Gregory SH. **Human peptide homologues encoded by hepatitis C virus promote the**

- response of regulatory T cells in chronically infected patients.** Third Immunoinformatics and Computational Immunology Workshop (ICIW 2012). Held in conjunction with the ACM Conference on Bioinformatics, Computational Biology and Biomedicine 2012. Oral and poster presentation. Orlando, FL, USA. 2012 Oct 7-10.
248. Loli S, Gutiérrez AH, Zimic M, De Groot AS. **Immunogenicity scores across the Leishmania major proteome.** Third Immunoinformatics and Computational Immunology Workshop (ICIW 2012). Held in conjunction with the ACM Conference on Bioinformatics, Computational Biology and Biomedicine 2012. Oral and poster presentation. Orlando, FL, USA. 2012 Oct 7-10.
249. Gutiérrez AH, Bailey-Kellogg C, DaSilva K, Terry F, Ardito M, Moise L, Martin W, De Groot AS. **Immunogenicity analysis of HCP derived from CHO genome.** 17th International IRA Conference September 9 - 13, 2012, Lake George Bolton Landing, NY.
250. Gutiérrez AH, Loving C., Garmendia A, Verardi P, Golde W, Martin W, De Groot AS. **'PigMatrix' - Development of T cell epitope prediction tools.** Summer School on Computational Immunology, University of Rochester, June 10-14, 2012, Rochester, NY.
251. Gutiérrez AH, De Groot AS, Zimic M, Ardito M, Terry F, DesRosiers J, Spero D, Martin W. **'PigMatrix' and the Design of a Genome-derived Epitope-driven Taenia solium Vaccine: Conservation of Pig-Human T helper Epitopes.** Second Immunoinformatics and Computational Immunology Workshop, August 2011, Chicago, IL.
252. Gustiananda M, Sasmono T, Gutiérrez Nunez A, Yohan B, Moise L, Aryati, Wardhani P, De Groot AS, Martin W. **Analysis of ChimeriVax Dengue virus envelope for T-cell epitopes and comparison to circulating viral strains in Indonesia.** The Second International Society of Vaccines (ISV) Pre-conference Computational Vaccinology Workshop (ICoVax 2012). Poster presentation. Shanghai, China. 2012 Oct 13.
253. Moise L. Heterologous DNA-prime/peptide-boost vaccination with cross-conserved **H1N1 influenza** CD4<sup>+</sup> T-cell epitopes reduces viral load in HLA transgenic mice. The International Society of DNA Vaccines 20<sup>th</sup> Anniversary Meeting DNA Vaccines 2012. Oral presentation. San Diego, CA, USA. 2012 Dec 4-7.
254. Elyaman W, Bassil R, Messitt T, McClaine E, Cousens L, De Groot A, Khoury S. **Tregitope peptides enhance regulatory T cell development and attenuate the autoimmune responses in a murine model of multiple sclerosis.** International Society of Neuroimmunology 11th International Congress of Neuroimmunology. Poster presentation. Abstract #440. Boston, MA, USA. 2012 Nov 4-8. J Neuroimmunol. 2012 Dec 15;253(1):168.
255. Liu R, Martin BA, Desrosiers J, Moise L, De Groot AS. **Immunogenicity assessment of in silico-selected T cell epitopes for a Burkholderia biodefense vaccine.** American Society for Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting. Oral and poster presentation. Washington, DC, USA. **2013** Feb 25-27.
256. Dupuy LC, Mitchell D, Richards MJ, Bounds C, Ardito M, McClaine E, Moise L, Martin W, De Groot AS, Schmaljohn CS. Immunogenicity and protective efficacy of a multi-epitope vaccine composed of **Ebola virus and Venezuelan Equine Encephalitis Virus** HLA class II T-cell epitopes in HLA transgenic mice. National Foundation for Infectious Disease (NFID) 16<sup>th</sup> Annual Conference on Vaccine Research. Baltimore, MD, USA. **2013** Apr 22-24.
257. Liu R, Desrosiers J, Martin BA, Moise L, De Groot AS. **Immunogenicity assessment of in silico-selected T cell epitopes for a Burkholderia biodefense vaccine.** National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research. Abstract #164. Baltimore, MD, USA. **2013** Apr 22-24.
258. Moise L, Boyle C, Latimer H, Tassone R, Ardito M, Terry F, Martin WD, De Groot AS. **CD4+ T Cell Responses to Cross-Reactive Influenza H1N1 T-cell Epitopes Identified by Immunoinformatic Methods.** National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research. Abstract #184. Baltimore, MD, USA. **2013** Apr 22-24.

259. Zhang S, Moise L, Terry F, Desrosiers J, Aponte J, Fast L, Martin W, De Groot AS, Moss S. **H. pylori vaccine development by reverse vaccinology**. National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research. Abstract #164. Baltimore, MD, USA. **2013** Apr 22-24.
260. De Groot AS, Tassone R, Cousens LP, Terry F, Martin R, Ardito M, Martin W. **In silico prediction of HLA-DP and -DQ epitope content is poorly correlated with clinical immunogenicity of therapeutic proteins**. 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). San Diego, CA, USA. **2013** May 20-22.
261. Cousens LP, Moise L, Martin W, De Groot AS. **Tregitopes: The active ingredient in IVIG-mediated tolerance induction?** 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). San Diego, CA, USA. **2013** May 20-22.
262. De Groot AS, Cousens LP, Moise L, Najafian N, Mingozi F, Elyaman W, Mazer B, Khoury S, Su Y, Scott DW, Martin W. **Antigen-specific tolerance induction by Tregitopes in vivo**. 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). San Diego, CA, USA. **2013** May 20-22.
263. Cousens LP, Moise L, Terry F, Martin W, De Groot AS. **Immunogenic biologics: Validation of screening, deimmunization and tolerization approaches**. 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). San Diego, CA, USA. **2013** May 20-22.
264. Gutiérrez A, Bailey-Kellogg C, Moise L, Terry FE, Abdel Hady K, Leng Q, Losikoff P, Verberkmoes N, Martin WD, Rothman A, De Groot AS. **The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix**. 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). Submitted for presentation. San Diego, CA, USA. **2013** May 20-22.
265. Zhang S, Moise L, Terry F, Desrosiers J, Aponte J, Fast L, Martin W, De Groot AS, Moss S. **Selection, identification and validation of a panel of immunogenic H. pylori peptides**. Digestive Diseases Week (DDW) 2013. Accepted for poster presentation. Abstract #1598639. Orlando, FL, USA. **2013** May 18-21.
266. De Groot A, Boyle C, Ardito M, Terry F, Latimer H, Tassone R, Cote M, Moise L, Martin W. **Cross-reactive influenza H1N1 T-cell epitopes identified by immunoinformatic methods stimulate CD4+ T cell responses**. The American Association of Immunologists (AAI) Immunology 2013. Abstract #1644033. Honolulu, Hawaii, USA. **2013** May 3-7.
267. Cousens LP, Terry F, Ardito M, Martin W, De Groot AS. **In silico high throughput pre-clinical determination of monoclonal antibody immunogenicity**. The American Association of Immunologists (AAI) Immunology 2013. Abstract #1644702. Honolulu, Hawaii, USA. **2013** May 3-7.
268. Cousens LP, Moise L, Martin W, De Groot AS. **Tregitopes: The active ingredient in IVIG-mediated tolerance induction?** The American Association of Immunologists (AAI) Immunology 2013. Also accepted for oral presentation. Abstract #1641263. Honolulu, Hawaii, USA. **2013** May 3-7.
269. De Groot AS, Cousens LP, Moise L, Najafian N, Mingozi F, Elyaman W, Mazer B, Khoury S, Su Y, Scott DW, Martin W. **Antigen-specific tolerance induction by Tregitopes in vivo**. The American Association of Immunologists (AAI) Immunology 2013. Also accepted for oral and poster presentation. Abstract #1644276. Honolulu, Hawaii, USA. **2013** May 3-7.
270. Cousens LP, Moise L, Terry F, Martin W, De Groot AS. **Immunogenic biologics: Validation of screening, deimmunization and tolerization approaches**. The American Association of Immunologists (AAI) Immunology 2013. Honolulu, Hawaii, USA. Abstract #1641519. **2013** May 3-7.
271. De Groot AS, Bertino P, Hoffman P, Carbone M, Siccardi AG, Terry F, Cousens LP, Moise L, Martin W. **Highly immunogenic vaccine for prevention and therapy of malignant**

- mesothelioma.** The American Association of Immunologists (AAI) Immunology 2013. Abstract #1644630. Honolulu, Hawaii, USA. **2013** May 3-7.
272. De Groot AS, Terry F, Spero D, Moise L, Martin W. **iVax: A sophisticated suite of online vaccine design tools.** The American Association of Immunologists (AAI) Immunology 2013. Abstract #1644599. Honolulu, Hawaii, USA. **2013** May 3-7.
273. Gutiérrez A, Bailey-Kellogg C, Moise L, Terry FE, Abdel Hady K, Leng Q, Losikoff P, Verberkmoes N, Martin WD, Rothman A, De Groot AS. **The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix.** The American Association of Immunologists (AAI) Immunology 2013. Abstract #1672581. Honolulu, Hawaii, USA. **2013** May 3-7.
274. Su Y, Cousens L, De Groot A, Scott DW. **Regulatory T cell epitopes in IgG (Tregitopes) suppress immune responses without skewing toward TH2.** 15th Annual International Congress of Immunology. Milan, Italy. **2013** Aug 22-27.
275. Gutiérrez AH, Moise L, Terry F, Bailey-Kellogg C, Martin W, De Groot AS. **Immunogenicity analysis of Chinese Hamster Ovary (CHO) host cell protein contaminants in therapeutic protein formulations.** 2013 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC). San Diego, CA, USA. **2013** May 20-22.
276. Curtin A, Martins DC, Schwartz-Barcott D, Yekta S, Tovar A, Di Maria L, De Groot A. **Development of a community-academic partnership in patient-centered outcomes research.** American Public Health Association (APHA) 141st Annual Meeting and Exposition. Abstract 289854: Oral Presentation. Boston, MA, USA. **2013** Nov 2-6.
277. **Identifying risk factors for vertical HIV transmission from a prevention of mother-to-child transmission (PMTCT) program evaluation in Bamako, Mali.** American Public Health Association (APHA) 141st Annual Meeting and Exposition. Abstract 289854: Oral Presentation. Boston, MA, USA. 2013 Nov 2-6. Abstract 289047: Session 3301.0: Global perspectives in HIV prevention Monday, November 4, **2013**: 2:30 PM-3:30 PM.
278. **Cheer project: Financial and QALY impact of emergency room diversion achieved by walk-in non-urgent care at a nurse-run clinic for the uninsured.** American Public Health Association (APHA) 141st Annual Meeting and Exposition. Boston, MA, USA. 2013 Nov 2-6. Abstract 286349: Poster presentation. Session 3401.0: Impacting Underserved Populations. Monday, November 4, **2013**: 4:30 PM - 5:30 PM
279. **Knowledge, attitudes, and practices relating to HPV, cervical cancer, and vaccination against HPV in a low-income, uninsured, urban population (Olneyville, RI).** American Public Health Association (APHA) 141st Annual Meeting and Exposition. Boston, MA, USA. 2013 Nov 2-6. Abstract 280517: Oral presentation. Session 5033.0: Strategies to improve immunization rates among vaccine-hesitant parents, individuals, and health care personnel. Wednesday, November 6, **2013**: 8:50-9:10 a.m.
280. L.P. Cousens, V. Jawa, M. Awwad, E. Wakshull, H. Kropshofer, W. Martin, A.S. De Groot. **T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation** AAPS. NBC-14-0563, National Biotechnology Conference, San Diego, May 2014
281. L.P. Cousens, M. Perkins, F. Antunes, M. Marshall, D. Shelly, W. Martin, A.S. De Groot. **Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease.** AAPS NBC-14-0548, National Biotechnology Conference, San Diego, May 2014.
282. L.P. Cousens<sup>1</sup>, A.S. De Groot<sup>1,2</sup>, F. Mingozzi<sup>3,4</sup>, D. Koeberl, W. Elyaman<sup>6</sup>, B. Mazer<sup>7</sup>, S. Khoury<sup>5</sup>, and W. Martin **Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity.** AAPS NBC-14-0549, National Biotechnology Conference, San Diego, May 2014.
283. L.P. Cousens, L. Moise, F. Terry, W. Martin, and A.S. De Groot. **Regulating Immune Responses to Biologics: Validation of Screening, Deimmunization and Tolerization Approaches.** AAPS NBC-14-0338, National Biotechnology Conference, San Diego, May 2014.
284. A.S. De Groot, A.J. Vincelli, F. E. Terry, L.P. Cousens, J.M. Tivin, R. F. Martin, and W. D. Martin,



**Tolerization as a Rational Design Approach for Reducing the Immunogenicity of Biologics.**  
AAPS NBC-14-0552, National Biotechnology Conference, San Diego, May 2014.

**Invited Presentations • Infectious Diseases, Immunopathogenesis, Vaccines**

1. **Tuberculosis: Epidemiology and Treatment in the 1990's**, Pulmonary Rounds, St. John's Hospital, Lowell MA, 12/91.
2. **T Cell Responses to Mycobacterium tuberculosis in the HIV-infected Host**, Modern Approaches to New Vaccines, Cold Spring Harbor Laboratory, 09/92.
3. **Tuberculosis: Multi Drug Resistant Tuberculosis and Drug Therapy**, Pulmonary Rounds, St. John's Hospital, Lowell MA, 12/92.
4. **Multi Drug Resistant Tuberculosis**, Massachusetts Association of Physician's Assistants Annual Meeting, Falmouth, MA, 10/92.
5. **Immunopathogenesis of an Epidemic: TB and HIV infection**, Invited Speaker. Grand Rounds, Lemuel Shattuck Hospital, Boston MA, 01/93.
6. **Two Novel Computer Driven T Cell Epitope Prediction Algorithms for Vaccine Development** Invited Speaker. Brown University Immunology Seminar, Brown University, Providence, RI, 09/94.
7. **Algorithms for mycobacterial vaccine development**, Invited Speaker. International symposium on Bovine TB in Animals and Human Beings, USDA/NIAID, NIH, 05/95.
8. **A novel algorithm for the efficient identification of T cell epitopes: prediction and testing of candidate TB vaccine peptides in genetically diverse populations**, Invited Speaker. Cold Spring Harbor meeting on Vaccines for Infectious Diseases, 09/95.
9. **Computer Algorithms for Vaccine Development**, Invited Speaker. Biology and Technology Seminar: Boston University (Dr. Charles Delisi, host), Boston MA, 09/95.
10. **Computer Algorithms for TB Vaccine Development**, Invited Speaker. Public Health Research Institute (Dr. Marilla Gennaro, host), New York, 10/95.
11. **Evolution of HIV Quasi Species: Response to Immune Pressure?** Invited Speaker. Aaron Diamond AIDS Research Center (Dr. Rick Koup, host), New York City, NY 11/95.
12. **EpiMatrix algorithm, reagent for HIV vaccine research**, Invited Speaker. Molecular Approaches to Vaccines for Infectious Diseases, Cold Spring Harbor Laboratory, New York 09/96.
13. **Comstock Conference on Epidemiology and Control of TB: Vaccines & TB Control**, Invited Participant, Baltimore Maryland; organized by Phil Hopewell, UCSF: 06/96.
14. **Matrix based prediction of MHC binding peptides**, Division of AIDS Spring workshop on HIV Variability and Cellular Immune Recognition, Bethesda, Maryland, 04/96.
15. **Epitope prediction for HIV vaccine development**, Harvard AIDS Institute, HIV Vaccines for Developing Countries: Antigen Design, Boston, Massachusetts, 04/96.
16. **CTL workshop: Computer driven epitope prediction for HIV vaccine development, NCDVG conference on HIV Vaccine development**, Invited Speaker. CTL workshop. (Jim Bradac, DAIDS Program Officer). Bethesda, Maryland, 02/96.
17. **Computer Algorithms for Cancer Vaccine Development**, Invited Speaker. Wistar Institute (Dorothee Herlyn, host), Philadelphia, Pennsylvania, 01/96.

18. **Computer Algorithms for TB and HIV Vaccine Development**, Invited Speaker. Department of Immunology (Dr. David McMurray, host), Texas A & M University, College Station Texas, 01/96.
19. **Computer Algorithms for HIV Vaccine Development**, Invited Speaker. HIV Research Unit, (Drs. Brigitte Autran, Anne Hosmalin, hosts) Hôpital Pitié-Salpêtrière, Paris, France, 06/96.
20. **Computer algorithms for TB vaccine design**, Invited Speaker. Pasteur Institute (Dr. Brigitte Gicquel, host), Paris, France 09/97.
21. **Computer-driven Design of new HLA-based vaccines for HIV**, Invited Speaker. Partners AIDS Research Center (Dr. Bruce Walker, host), Massachusetts General Hospital, 02/97.
22. **Symposium on Immunogenicity of Recombinant Human Proteins. EpiMatrix: Prediction of MHC ligands**, Invited Speaker. Genentech (Dr. Gene Koren, host), South San Francisco, 03/97.
23. **Epitope Predictions for TB vaccine development**, Invited Speaker. Global Tuberculosis Programme for Vaccines and Immunization/Vaccine Research and Development conference, "Definition of Strategies for an optimal use of Information resulting from Mycobacterial genome sequencing" at the World Health Organization Headquarters (Dr. John Foulds, organizer), Geneva 09/97.
24. **TB and HIV vaccine development**, Invited Speaker. Infectious Disease Conference (Dr. Jennifer Daly, Host) TB/HIV vaccine development, Worcester MA, 03/98.
25. **From Genome to T Cell: Searching for Agretopes**, Invited Speaker. Microbial Genomes conference, sponsored by the Institute for Genomic Research (TIGR) (Dr. Clare Fraser, host), Chantilly VA, 01/99.
26. **HIV Vaccine Development** (speaker on panel, presenting poster, Dr. Doug Nixon, panel chair) 6th conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 02/99.
27. **Epitope Predictions and Vaccine Testing**, Invited Speaker. EEC committee on the Ethical and Legal Applications of Vaccines (ELAV, (R. Whalen, host), Paris, France. 01/99.
28. **Bio informatics approaches to Vaccine Development for TB and HIV**. Invited Speaker. DASTLR, Center for Disease Control and Prevention, Immunology, (Dr. Janet McNicholl, host), Atlanta Georgia, 02/99.
29. **Bio informatics approaches to Vaccine Development for HIV**, Invited Speaker. Emory Center for Vaccine Research, (for the CFAR program, Dr. Mark Feinberg, host), Atlanta, Georgia, 02/99.
30. **Scientific Working Group on TB**, Participant. World Health Organization. (Dr. Paul Nunn, organizer), 02/00 Geneva, Switzerland
31. **From Genome to T cell: *In silico* predictions, *in vivo veritas***. Invited speaker. **Symposium on Genomics and Vaccinology**. National Foundation for Infectious Diseases annual Vaccine conference. 04-05/00. (Regina Rabinovich, M.D.)
32. **Informatics Approaches to Vaccine Design**. Invited Speaker. Vaccines and Immunotherapeutics in the Third Millennium CSIRO, Lorne Australia, 03/00
33. **From Genome to Vaccine: Bioinformatics and Vaccine Design**. Invited speaker, Emerging Technologies Seminar, Center for Biomedical Inventions and Department of Internal Medicine & Cardiology University of Texas-Southwestern Medical Center at Dallas, 10/00. (Dr. Irene Rombel and Stephen Johnston).
34. **Genomic Approaches for Identifying Vaccine Candidates – Bioinformatics and Predictive Algorithms**. Invited Speaker. Special meeting on Otitis Media: New Approaches for Analysis, Treatment and Prevention, 11/00 (Dr. Thomas M. Johnson, NIDCD and Dr. Lauren Bakeletz)

35. **Scanning the TB Genome for DNA Vaccine Epitopes.** Invited Speaker. Sequella TB Vaccine Conference, 11/00, at Brown University (Carol Nacy, Director, SGTBF)
36. **TB pathogenesis, Vaccination, and Treatment update.** Invited Speaker. Anesthesiology Rounds, Kent Hospital 11/00 (Steve St. Aubin, Nurse Anesthetist).
37. **Genomics and Vaccinomics.** Invited Speaker. (Dr. Brad Goodner). University of Richmond, VA, 12/00.
38. **Cross-Clade Conservation of HIV-1 CTL Epitopes in the Aidsvax® and Aventis CP205™ Vaccines** National Foundation for Infectious Diseases annual Vaccine conference. 04-05/01.
39. **Epitope-Driven Vaccines for TB and HIV infection,** Invited Speaker. (Dr. Kay McGowan) Grand Rounds, Lemuel Shattuck Hospital, Boston MA, 07/01.
40. **Epitope-Driven HIV Vaccine Development.** Invited Speaker (Jim Bradac, Senior Program Officer). Division of AIDS. 06/01.
41. **From Genome to T cell: Bioinformatics and Vaccine Design.** Invited Speaker (Dr. Marcelo Szein). Lecture at Center for Vaccine Development. ( Myron M. Levine, M.D., D.T.P.H. Director). University of Maryland School of Medicine. 06/01.
42. **Computational Algorithms to Predict T cell Immunogenicity,** Conference on Immunogenicity of Therapeutic Biological Products, Lister Hill Auditorium, NIH, Bethesda MD 10-11/01
43. **TB Genome to Vaccine (Bringing a Genome Derived TB Vaccine to Phase I Trials).** Sequella Foundation Vaccine 2001 Conference, Renaissance Conference Center, 11/01, Montreal, Canada.
44. **Developing an Epitope-Driven Cross-Clade HIV Vaccine using Bioinformatics** (Dr. Ray Dolan) Harvard HIV Vaccine Trial Unit, Harvard Medical School, 11/01.
45. Plenary Speaker: **From Genome to T Cell: Epitope-Driven Vaccine Design** Australian Society for Immunology Canberra Australia, 12/01.
46. De Groot A.S., R.G. Scheib, K. McGowan, D. Doughty, A. Bosma, W. Martin. **Building Vaccines from Immunogenic Consensus Sequences.** Oral Presentation S29: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, 05/02, Baltimore, Maryland.
47. De Groot A.S., A. Bosma, C. Saint Aubin, H. Sbai, W. Martin **New Uses for Licensed Vaccines: Evaluation of the Japanese Encephalitis Virus Vaccine and the NY99 West Nile Virus Genomes for Cross-reactive T Cell Epitopes.** Oral presentation S35: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, 05/02, Baltimore, Maryland.
48. A.S. DeGroot, H. Sbai, A McMurry, ML Gennaro, EJ Carter, W. Martin. **Analyzing Myobacterium Tuberculosis Proteomes for Candidate TB Vaccine Epitopes.** Oral presentation S36: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research, 05/02, Baltimore, Maryland.
49. **Epitope mapping and vaccine design tools.** Invited Speaker, Novartis Foundation Symposium No.254 Immuno-informatics: Bioinformatic strategies for better understanding of immune function. 10/02, London.
50. **Harnessing the 'Immunome',** Invited Speaker, Phacilitate Vaccine Forum. 11/ 2002, Swiss Hotel, Boston, MA.
51. **Medical Update on Opening Pandora's Box: Is there Hope after AIDS?** Invited lecturer (Marlene Cuititar), 2002 Rhode Island Medical Women's Association's Educational Session on

- 11/02.
52. **Adolescent STDs: The situation with HIV and update on the GAIA HIV Vaccine.** Pediatric Grand Rounds, Hasbro and Rhode Island Hospital. Pediatric Grand Rounds (Rosalind Vaz), 02/03.
  53. **From genome to vaccine: epitope mapping and vaccine design tools.** Invited Speaker, Computational Molecular Biology Series. Brown University [Franco Preparata]. 03/03.
  54. **TB Vaccines: How long do we need to wait?** Tuberculosis Education Day 2003, Miriam Hospital. 05/03.
  55. **In Silico Prediction of Immunogenicity.** Invited speaker (Tony Mire Suis). State of the art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability Natcher Building, National Institutes of Health Bethesda, Maryland. 06/03.
  56. **The GAIA HIV Vaccine: Vaccine for the World.** HIV Vaccines: Design, Potency and Delivery. The Knowledge Foundation. Conference on HIV Vaccines. Royal Sonesta Hotel. Cambridge, MA USA 06/03.
  57. **Rapid Vaccine Design for Emerging Infections; EpiVax-Brown University Collaborations on SARS, WNV, Smallpox, WNV, TB and HIV.** Rhode Island Department of Public Health (Grey Hayes, Ph.D) 09/03.
  58. **TB vaccine development: practical design and implementation.** Presentation of work by invitation. (Norren Meehan, host). World Vaccine Congress, Lyon, 09/03.
  59. **From TB Genome to Vaccine.** TB Vaccines for the World- TBV 2003, Montreal Marriott Chateau Champlain, Montreal, Canada. Presentation of work by invitation (TBVW, host). 09/03.
  60. **From Genome to Vaccine: Faster, Better Design of Vaccines and Therapeutic Products through Immunoinformatics** Fall Connecticut Nanotech Initiative Conference, University of Connecticut, Storrs. CT. 10/03.
  61. **Immunomodulation: In silico prediction and in vitro confirmation.** Immunogenicity testing for Protein-based therapeutics. Back Bay Hilton, Boston MA. 11/03.
  62. **From Genome to Vaccine, A story about Microsoft, Motifs, and Molecules.** Colloquium Series, Biology Department at Rhode Island College (Charles Owens, host). 11/03.
  63. **Accelerating Vaccine Design: new in silico epitope mapping methods.** Animal Research Service (ARS) Immunology Research Workshop Bethesda MD. (Cyril Gay, Host). 12/03.
  64. **From immunome to vaccine: the epitope-driven vaccine approach.** 1st International Immunoinformatics Symposium - Immunology meets Bioinformatics. RIKEN (The Institute of Physical and Chemical Research), Yokohama Institute, Genomic Sciences Center (GSC), Bioinformatics Group. Session on Computer-aided vaccine and adjuvant development. Yokohama, Japan (Scientific Advisory Committee). (Christian Shonbach, Host). 02/04.
  65. **From immunome to vaccine: the epitope-driven vaccine approach.** Singapore Immunoinformatics Symposium. From databases to vaccines. Institute for Infocomm Research, Singapore. (Vladimir Brusic, Host). 03/04.
  66. **The Economics of AIDS and HIV Vaccine Development.** International Affairs Committee, Providence Rhode Island. (Charles Andrews, Host). 03/04.
  67. **HIV Vaccine for all Clades.** (In French) Rencontre des Specialistes VIH/SIDA a Bamako. GAIA Vaccine Foundation / Fondation Merieux 01/04.

68. **Genome-derived Vaccines.** Southern Center for Vaccine Development. University of Texas Medical Branch, Galveston, Texas, 03/04.
69. **From Genome to Vaccine.** University of Rhode Island. BRIN seminar. (Joan Peckham, Host) 04/04.
70. **New Immunoinformatics Approaches to Emerging Infectious Diseases.** Boston University, Bioinformatics program. 04/04. (Charles DeLisi, Host).
71. **AIDS Vaccines and Prevention.** Provoking Hope, A Brown University AIDS Symposium. 04/04.
72. **The AIDS Pandemic** – with Ira Magaziner (chairman of the Clinton Foundation AIDS Initiative), Sandra Nusinoff Lehrman, M.D., (director of the Therapeutics Research Program Division of AIDS, National Institutes of Health). Brown University 135th Commencement Forum. Sayles Hall, The College Green, 05/04.
73. **Elicitation of de novo T-cell responses in mice immunized with an multi HIV-1 epitope cross-clade DNA vaccine** L. Marcon, W. Martin, J.I. Franco, E.A. Bishop, D. Rivera, M. Lally, M. Kutzler, D.B. Weiner, K.H. Mayer, De Groot A.S., Brown Medical School, EpiVax Inc., University of Padua, University of Pennsylvania (Providence, USA; Padua, IT; Philadelphia, USA); AIDS Vaccine 2004, Lausanne, 08-09/04.
74. De Groot A.S.. **Immunogenic consensus sequence T cell epitopes for a cross-clade HIV vaccine.** (Oral Presentation, Thursday, September 30, 15:45 S1-7) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
75. De Groot A.S.. From tuberculosis immunome to vaccine: **The epitope-driven vaccine approach.** (Invited presentation S2-4. Friday, October 1, 15:00) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
76. J. I. Franco, H. Sbai, S. Foti, J. McMurry, K. Forsythe, M. Steller, B. Martin, A. S. DeGroot. **Developing an Epitope-Based HPV Vaccine.** (Invited presentation W4-6, Saturday, October 2, 15:40), Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
77. Anne S. De Groot, Bill Martin, Luisa Marcon, Elizabeth Bishop, Shawn Foti, Judith Franco, Daniel Rivera, Gandhi Drak and Paul Knopf. **From Immunome to Vaccine: the Epitope-Driven Vaccine Approach,** [Invited Presentation S1-6]. Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan, 09-10/04.
78. **From Immunome to Vaccine.** Statistical and Applied Mathematical Sciences Institute, Opening Workshop of the SAMSI Program Genomes To Global Health: Computational Biology Of Infectious Disease. Invited presentation (Host Tom Kepler, Duke University Medical Center. 09/04.
79. **TB Vaccine Development Update.** 9th Annual Meeting of the North American Region of the International Union Against Tuberculosis and Lung Disease to be held in Vancouver, British Columbia, Canada on 02/05. Vancouver IUALTb. (Hosts Jane Carter, Lee Reichman) 02/05.
80. **T epitope Revelations: Antigen Discovery (Vaccines) and De-Immunization (Therapeutics)** Salk Institute, San Diego, 03/05. Hosts Tony Hunter and David Roth.
81. **What's New? From Genomics to Vaccine Design; From Immunome to Vaccine.2<sup>nd</sup>** International Immunomics Symposium. Boston University, 03/05.
82. **Deimmunization - the DeFT (T cell epitope mapping) approach.** FDA-CDER, HFD-122, 03/05 (Amy Rosenberg, Director, Division of Therapeutic Proteins, CDER, host).
83. **FDA Science Forum** (04/05). Interactive Round Table Discussion Immunology: "Host-Product

- Interactions and Immune Responses" Moderator: Amy Rosenberg, Director, Division of Therapeutic Proteins, CDER. Topic: **"What can Therapeutics learn from Vaccines"**
84. Cohen, B. Pelsue, A. Lafaunce, M. Koné, P. Symonds, M. Lally, K. Mayer, N. Keita, De Groot A.S., **Survey of Knowledge, attitudes and practices related to HIV and HIV Vaccines in Urban Markets, Bamako Mali**. Oral presentation at the 3ème Journées VIH/SIDA de Bamako, 2006, 01/07. Bamako Mali.
  85. J Beckerman, N Vu, N Keita, M. Koné, M. Lally, K. Mayer, A .S. De Groot, **Potential Barriers to an HIV Vaccine Trial in Bamako Mali**. Oral presentation at the 3ème Journées VIH/ SIDA de Bamako, 2006, 01/07. Bamako Mali.
  86. O. Koita,, S. Dao, A. Tounkara, M. Koné, W. Martin, K. Mayer, M. Lally, J. McMurry, L. Marcon, De Groot A.S., **Update on the GAIA HIV Vaccine 01/06**. Oral presentation at the 3ème Journées VIH/ SIDA de Bamako, 2006, 01/07. Bamako Mali.
  87. De Groot. CBER Brown Bag Seminar – **Update on De-immunization Studies (DeFT)**. FDA-CDER, HFD-122, 01/06. (Amy Rosenberg, Director, Division of Therapeutic Proteins, CDER, host).
  88. A. De Groot. **"Vaccine Development from Soup to Nuts - the GAIA HIV Vaccine Case Study,"** 04/06, Brown Medical School Infectious Disease Division Lecture Series.
  89. Plenary talk –**"Sugar or Splice: New approaches to solve the Immunogenicity Problem"** Cell Culture Engineering X – Whistler Resort, Vancouver CA. 04/06. Invited by Konstantin Konstantinov, Bayer Inc.
  90. **Cancer Grand Rounds "Immunoengineering of Cancer Vaccines and Therapeutics - Recent developments."** Alan Rosmarin, MD, Host. Rhode Island Hospital (Lifespan Hospitals, Brown University).
  91. De Groot AS, Martin W, Marcon L, Knopf P, Bishop B, McMurry J, Rivera D, Klutzer M, Boren C, Rodriguez-Annon C, Weiner D. **Beyond epitope mapping: Making vaccines and modifying therapeutics. Chem-Bio Informatics Society (CBI) 2005 Proceedings Chem-Bio Informatics in Post Genome Era**. Invited Oral presentation. Abstract #S7. Tokyo, Japan. 2005 Aug 24-26. *Proceedings Chem-Bio Informatics Society*. 2005;33(2005):S7.
  92. Invited Presentation. Annie De Groot, L. Moise, D. Rivera, J. McMurry, M. Goldberg, W. Martin. **Applied Epitope Mapping: Progress report on Epitope-driven BioDefense Vaccine Development for Smallpox and Tularemia**, International Immunomics Society Meeting, Budapest, 10/06.
  93. Invited Presentation to University of Rhode Island Department of Cellular and Molecular Biology January 22 2007; **Upregulating and Downregulating Immunity from the T cell Perspective**. Jan 22, 2007 (Dr. Jay Sperry, Chair of CMB, URI).
  94. Invited Presentation – Nature Biotechnology Winter Symposium, organized by the University of Miami, **Moving Computer Driven Vaccine Design in silico to in vivo**. Nature Biotechnology Miami January 28, 2007.
  95. Organizer and Panelist, **Cutting Edge: Screening and Reengineering Biological Therapeutics** Track: Drug Discovery and Development, Bio 2007. Boston, June, 2007.
  96. Invited Talk, **De-immunization of protein therapeutics**. Crossroad of Biotechnology 12th edition at the Biotechnology Research Institute of the National Research Council (NRC-BRI), June 13, 14 2007.
  97. **De Groot AS**. CBER Brown Bag Seminar - **Update on De-immunization Studies (DeFT)**.

- January 2006 and March 2007**; hosted by Amy Rosenberg, Director, Division of Therapeutic Proteins. CDER, FDA-CDER, HFD-122. Baltimore, MD.
98. **De Groot AS. De-Immunization of Protein Therapeutics.** Crossroad of Biotechnology, Montreal, Canada. June 13, 14, 2007. Hosted by Biotechnology Research Institute, NRC/CNRC, Canada.
  99. **De Groot AS. New Approaches to Immunogenicity: Screening, Reengineering and Modulation.** Antibodies Europe. 7-8 November 2007. Intercontinental Hotel, Vienna Austria.
  100. **De Groot AS.** Invited Speaker. **Moving Computer Driven Vaccine Design From In Silico to In Vivo.** January 30, 2008; Nature Biotechnology Winter Symposium. Miami, FL.
  101. De Groot, A.S. **A Novel Model of IVIG Immunosuppression: Activation of Natural Regulatory T cells by IgG-Derived Peptides,** Oral Presentation and poster, Keystone Symposium Tolerance in Transplantation and Autoimmunity (A8), Organizer(s): Jeffrey A. Bluestone, Abul K. Abbas, Laurence A. Turka and Diane J. Mathis, Keystone Resort, Keystone, Colorado, January 29 - February 3, 2008.
  102. De Groot, A.S. Voices from the Vanguard Lecture Series, 2008: **HIV Vaccines: Time for a New Vision,** University of Georgia Atlanta. Grady College, University of Georgia. Host Professor Patricia Thomas, Knight Chair in Health and Medical Journalism at UGA's Grady College of Journalism and Mass Communication. April 15, 2008.
  103. De Groot, A.S. **Rational design and regulatory issues of immunotherapeutic vaccines,** Vaccine and Immunotherapy Technologies, Sir Mark Oliphant Conference. Invited Presentation at the Australian Academy of Sciences, 4/8/08. Gus Nossal, Ian Fraser, Ian Ramshaw, Hosts. Canberra, Australia, April, 2008.
  104. De Groot A.S. **Epitope-based Immunome-derived Vaccines: A Strategy for Improved Design and Safety,** Invited oral Presentation Eleventh Annual Conference on Vaccine Research, National Foundation for Infectious Diseases. Baltimore May **2008.**
  105. De Groot A.S., **Epitope Driven GAIA HIV Vaccine Development,** Invited oral presentation, Vaccine Technology II. Barry Buckland, Host. Portugal, June, **2008.**
  106. De Groot, A.S. **Immunogenicity of Biologics.** Inflammation Research Association's 15th International Conference. 21-24 September, Chantilly, VA,
  107. De Groot A.S., **The GAIA Vaccine Progress Report: Broad Recognition of Class I and II-Restricted Epitopes and in vivo Studies.** Invited oral presentation at the Vaccine Development conference, 2008, Pittsburgh, PA, September, **2008.**
  108. De Groot A.S., **Computer-Driven Vaccine Design: From Concept to Reality.** Invited oral presentation, Vaccine Development 2008, Pittsburgh, PA, September, **2008.**
  109. De Groot A.S. **Designing Personalized Vaccines for the 21st Century.** Invited oral Presentation. Sixth World Congress On Vaccines, Immunization and Immunotherapy. Milan, September, 2008.
  110. De Groot A.S., **Relevance of T cell epitopes, effector T cells and regulatory T cells to the development of immunogenicity, and the accuracy of T cell epitope analysis for immunogenicity screening.** EpiVax, Inc. **Oral presentation to European Medicines Agency (EMA) London, UK October 29, 2008.** Invited Presentation. Christian Schneider (Host).
  111. Anne S. De Groot, M.D, Leonard Moise, Yan Su, Julie A McMurry, William D Martin and David W. Scott. **IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo.** Oral

- Presentation 677, selected from more than 10,000 abstracts, 50th annual Meeting of the American Society for Hematology. December 6-10, 2008. San Francisco, California.
112. Anne S. De Groot, M.D.. **Immunogenicity Problems: A Paradigm Shift?** 19<sup>th</sup> annual Antibody Engineering: Immunotherapeutics for the 21<sup>st</sup> Century. December 7-11, 2008 - Sheraton San Diego Hotel and Marina - San Diego, California. Invited Speaker.
  113. A.S. De Groot. **Immunoinformatics: How to design more effective vaccines and therapeutic proteins.** Host, Jeremy Kunkel, Ph. D. Regulatory Scientific Research Seminar Series, Centre for Biologics Research, Health Canada. January 18<sup>th</sup> 2009.
  114. Anne De Groot, M.D. NOVA Southeastern University, David Thomas M.D. J.D. Host. Protecting Our Next Generation. **Immunology of Vaccines. January 30<sup>th</sup>. 2009.** Ft. Lauderdale, FL.
  115. Anne De Groot, M.D. **Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction.** Invited talk in Emerging, "Disruptive" Technologies: Disruptive Science and Technology Session, **Accelerating Biopharmaceutical Development, San Diego, March 2009.** Invited Speaker. Host – Jim Swarz. Chairs: Gordon Moore (Centocor), Brian Kelley (Genentech) and Jim Swartz (Standford).
  116. Anne S. De Groot, Bill Martin. **Immunome-derived, Epitope-driven vaccine design.** Laboratory of Parasitic Disease, NIH. David Sacks, host. **May 6<sup>th</sup>, 2009.**
  117. Anne De Groot, Bill Martin. **Enhancing Safety by Reducing Immunogenicity through Tolerance Induction. Invited talk at the FDA,** Amy Rosenberg, Host. May 7, 2009.
  118. Anne S. De Groot, Invited Seminar at the National Institute of Health Sciences, Japan; **Enhancing Safety for Protein Therapeutics by (1) Reducing Immunogenicity and (2) Tolerance Induction.** June 3, 2009. Dr. Shingo Niimi, Division of Biological Chemistry and Biologicals, Host.
  119. Annie De Groot, EpiVax, **Reducing protein immunogenicity by Design: Deimmunization and tolerance induction,** 21st ESACT Meeting will be held in Dublin, Ireland from 7th to 10th June 2009, Invited Speaker, Nigel Jenkins, host.
  120. Annie De Groot — **VennVax: T cell mediated protection against aerosol challenge; Epitope Driven Vaccines;** 3rd Vaccine Congress, Singapore, October 2009. Oral presentation selected from abstracts.
  121. De Groot/ **New Vaccines for Old Diseases** / CMB Seminar, University of Rhode Island, Fall 2009
  122. Leonard Moise, Wen Yang, Constanze Weber<sup>3</sup>, Julie A. McMurry, William D. Martin, Hendrik Veelken and Anne S. De Groot. **De tolerization of anti-DEC 205 for HIV subunit vaccine delivery.** Poster. PD01/14. DEC205 ECI/Berlin September 2009.
  123. Leonard Moise, Wen Yang, Yan Su, Daniel J. Hui, Federico Mingozi, William D Martin, David W. Scott, Katherine A. High, Francesca D'Addio, N Najafian, Mo H Sayegh , Anne S. De Groot. **T cell epitopes (Tregitopes) contained in IgG Constant Domains activate natural Tregs:Relevance for autoimmune disease, gene therapy, and less immunogenic biologics.** Oral Presentation, **WSD18/.** 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
  124. Joseph Desrosiers II, Leonard Moise Jonathan Skupsky, Ryan Tassone, Julie A. McMurry, William D. Martin, David W. Scott, Anne S. De Groot. **De-immunization” of Human Factor VIII: Identification of Epitopes in the C2 Domain.** Oral presentation. WSD14/1. 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
  125. Anne S. De Groot, Leonard Moise, Xin Li, Yan Su, Wen Yang<sup>1</sup>, Joseph Desrosiers, Ryan Tassone, Preema Mehta, William D. Martin, David W. Scott **Effect of Tregitope on immune**



- response to T1D antigens in vitro and on diabetes in NOD mice.** Oral presentation. WSC11/3. 2nd European Congress of Immunology, September 13 - 16, 2009 in Berlin, Germany.
126. Anne S. De Groot. **Oral presentation to European Medicines Agency (EMA) on H1N1 Epitopes to EMA** – November 2009.
  127. Anne S. De Groot. **Oral Presentation to the FDA** - CBER Brown Bag Seminar January 29<sup>th</sup> 2010– Update on Tregitope. Ed Max, Amy Rosenberg, Host.
  128. Anne S. De Groot, Mark Buller, Sharon Frey, Steven Gregory, Steven Moss, Hardy Kornfeld, Jinhee Lee, Leonard Moise, William Martin. **T cell-driven Vaccines: Now more than Ever.** Oral Presentation, Vaccine Technology III, Nuevo Vallarta, 06/10.
  129. De Groot AS. **Importance of vaccines, rationale for new vaccine approach, history of ID-ED vaccines: Building “faster, safer” immunome-derived vaccines for infectious diseases, cancer and autoimmunity.** The University of Rhode Island 4<sup>th</sup> Vaccine Renaissance Conference. Oral presentation. Providence, RI, USA. 2010 Oct 21-23.
  130. Anne S. De Groot, **T cell-directed Vaccines: Now more than Ever.** Invited presentation – University of Florida Institute for Emerging Infectious Diseases. Janet Yamamoto, Host. November 2010.
  131. Anne S. De Groot, **T cell-driven Vaccines: Immunoinformatics.** Invited presentation – University of Michigan (Oliver He, Host). Division of Infectious Diseases. March 2011.
  132. Anne S. De Groot, **T cell-driven Vaccines: Validation in Vivo.** Invited presentation – University of Pennsylvania (David Weiner, Host). Vaccine Research Center. March 2011.
  133. Anne S. De Groot, **Moving the Epitope-Driven Approach Forward for Human and Animal Vaccines.** Invited presentation – University of Connecticut (Paulo Verardi Host). Division of Pathobiology. March 2011.
  134. Anne S. De Groot. **Tregitope Update. Oral Presentation to the FDA - CBER** Brown Bag Seminar January 2011. Ed Max, Amy Rosenberg, Hosts.
  135. Anne S. De Groot. **Oral presentation to European Medicines Agency (EMA) Update on the Relevance of T cell epitopes, Effector T cells and Regulatory T cells to Protein Immunogenicity, Risk Mitigation and Biomarkers** – April 2011.
  136. De Groot AS, Moise L, Ardito M, McClaine E, DuPont R, Tassone R, Haran J, Suner S, Martin WD. **Evidence from H1N1 supporting development of broad-spectrum vaccines against influenza.** National Foundation for Infectious Diseases (NFID) Fourteenth Annual Conference on Vaccine Research. Oral presentation. Abstract #S2. Baltimore, MD, USA. 2011 May 16-18.
  137. Anne S. De Groot/Leslie Cousens/Federico Mingozi/Nader Najafian/David Scott: **4<sup>th</sup> Tregitope Update Meeting** May 11, 2011, Immunogenicity Determinants and Correlates, Post-conference. Providence, RI. 2011
  138. De Groot AS, Cousens LP, Mazer B, Najafian N, Mingozi F, Elyaman W, Hui DJ, Levitz L, DuPont R, Messitt T, Khoury S, Su Y, Scott DW. **Tregitope mechanism of action and applications to autoimmunity.** Second International Forum on Immunoglobulin Research (IFIR 2011). Invited Oral Presentation. Barcelona, Spain. 2011 Sep 14-17.
  139. Anne S. De Groot. Tregitope – **Regulatory T-Cells Epitopes in Vaccine Delivery Design.** Host. Anne Hosmalin, MD, PhD., Research Director, CNRS Head, Antigen Presentation by Dendritic Cell Team. INSERM Unit 567, UMR CNRS 8104, Paris-Descartes University, Paris France. October 2011.
  140. De Groot A. iVax: **Extremely rapid online immunoinformatics tool for vaccine design.** 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference. Oral presentation. Abstract #1107. Las Vegas, NV, USA. 2011 Nov 14-18.

141. Anne S. De Groot. **Better, Faster Vaccines for Bacterial and Viral Threats**. Oral Presentation, Chemical and Biological Defense Science and Technology Conference, Las Vegas, Nevada, USA. November 2011.
142. Anne S. De Groot - **Genome-derived epitope driven vaccines for neglected tropical disease and emerging infectious diseases**. 5th International Eijkman Conference, Invited Plenary, Marsia Gustiananda, Host. Jakarta, Indonesia, November 9 2011.
143. Anne S. De Groot , **Epitope-driven Cancer Vaccines**, University of Honolulu, March 2012 (Miguel Carbone, Cancer Center Director, Host). March 24<sup>th</sup> 2012, Honolulu.
144. Anne S. De Groot – **New Vaccine Technologies for the Next Generation**. Rhode Island Science Teachers Association (RISTA) Plenary. March 2012.
145. Anne S. De Groot/Leslie Cousens: **FDA Brown Bag Lunch: Tregitope Update 2012**. –May 1 2012, Amy Rosenberg, Host.
146. Anne S. De Groot/Leslie Cousens: **6<sup>th</sup> Tregitope Update Meeting 2012**, April 20<sup>th</sup> 2012, Baltimore MD.
147. Immunogenicity, Biomarkers & PK/PD 2012 Berlin (Invited Speaker) Dates: Berlin 25-27 September 2012 Topic: T cell epitopes – The good, the bad, the Ugly. Location: Maritim proArte Hotel, Berlin, Germany.
148. Invited talk (URI, COP) “Is There No Balm in Bamako, Mali? Keeping Drug and Vaccine Development in Perspective. 1st International Conference of "Frontiers in Pharmaceutical Sciences: Global Perspectives" (Plenary) Dates: September 28-October 1<sup>st</sup> Location: URI/Kingston Campus. Sept 30<sup>th</sup> 2012. . Website: <http://www.uri.edu/pharmacy/frontiers/2012/index.html>
149. De Groot AS, Cousens LP, Najafian N, Mingozi F, Elyaman W, McClaine EM, Mazer B, Hui DJ, Khoury S, Su Y, Scott DW, Martin W. **Tregitope applications to tolerance induction in autoimmune diseases**. The American Association of Immunologists (AAI) Immunology 2012. Oral presentation. Abstract #1337905. Poster presentation #P1565. Boston, MA, USA. 2012 May 4-8. *J Immunol*. 2012 May;188 (Meeting Abstract Supplement):116.10.
150. Invited talk. Anne S. De Groot. **Tregitopes: Application to Autoimmune Disease**. Invited Plenary, Yehuda Shoenfeld, Organizers. Autoimmunity 2012, May 11, 2012, Granada Spain.
151. Invited talk. Anne S. De Groot, Leslie Cousens: **Treg epitopes defined using immunoinformatics; and Tregitope Mechanism of Action**. Alex Sette, La Jolla Allergy and Immunology Institute, May 23 2012.
152. Oral Presentation – Computational Vaccinology. ICIW 2012 (Workshop and Oral Presentations). Dates: October 6th-8<sup>th</sup> Location: The Embassy Suites, Orlando-Downtown, Orlando, Florida 32801. Website: <http://watson.cs.iastate.edu/>
153. Invited Speaker (CHI) De Groot, AS. 4th Immunogenicity Summit Bethesda, MD Topic: **Peptides that Act as T Regulators: Implications for Control of Immunogenicity and Application to Protein Therapeutics**. Location: Doubletree Hotel, Bethesda MD Website: <http://www.immunogenicitysummit.com/> Dates: 10-12 October 2012.
154. De Groot AS. **Faster Vaccines**. 6th Vaccine Renaissance (Institute for Immunology and Informatics) (Organizing) Dates: October 15-17 2012 Location: iCubed/URI Providence Campus Website: <http://www.immunome.org/conferences/vaccine-renaissance-conference/5th-annual-vaccine-renaissance-conference/>
155. Invited talk. De Groot AS, Moise L, Messitt T, Cousens L, Terry F, Martin W. **Genome-derived vaccines for infectious diseases, cancer, allergy and autoimmunity. Modern Genome Based**

- Vaccine Design 2012.** Oral presentation. Japanese Society for Vaccines. Invited Plenary. Yokohama, Japan. 2012 Nov 16.
156. Invited Speaker. De Groot AS. **H7N9, Stealth Virus.** Influenza Congress, Washington, DC. Dates: November 12-13<sup>th</sup>, 2012. Location: The Mandarin Hotel, Washington, DC. Website: <http://www.isni2012.org/>
157. Invited talk. De Groot AS. **Faster Vaccines.** The International Society of DNA Vaccines 20<sup>th</sup> Anniversary Meeting DNA Vaccines 2012. Oral presentation. San Diego, CA, USA. 2012 Dec 4-7.
158. Invited Speaker. **From Gene to Vaccine.** Washington Vaccine Forum, Washington DC. Dates: January 28th-30th **2013**. Location: Grand Hyatt, Washington DC. Website: <http://www.vaccine-forum.com/>
159. Invited Speaker. GTC Bio. 2nd Novel Immunotherapeutics Summit //Inaugural Immunogenicity / Immunotoxicity, San Diego, CA. **Tregitopes.** Dates: January 30th-February 1st 2012. <http://www.gtcbio.com/component/conference/?file=home&cn=Novel+Immunotherapeutics+Summit&cid=55>
160. Invited Speaker. **Immunogenicity.** IBC's Antibody Development & Production Conference, Huntington Beach, CA (Invited Speaker). Dates: February 25<sup>th</sup>-March 1<sup>st</sup> **Location:** Hyatt Resort and Spa, Huntington Beach, CA **Website:** <http://www.ibclifesciences.com/BDPWeek/overview.xml>
161. Invited Expert. De Groot, AS. **Innovation in Therapeutics: Drugs of the Future** MIT Sloan Expert Panel. Bioinnovations Conference, **2013**. February 21, **2013**.
162. Oral Presentation. De Groot AS, Cousens LP, Moise L, Najafian N, Mingozzi F, Elyaman W, Mazer B, Khoury S, Su Y, Scott DW, Martin W. **Antigen-specific tolerance induction by Tregitopes in vivo.** The American Association of Immunologists (AAI) Immunology 2013. Oral and poster presentation. Abstract #1644276. Honolulu, Hawaii, USA. **2013** May 3-7.
163. Invited talk: American Association of Pharmaceutical Scientists (AAPS). **Immunogenicity Screening, Deimmunization, Tolerance Induction for Biologics.** In the session Protein Engineering with Computational Immunoinformatics Approaches. 2013 AAPS National Biotechnology Conference (NBC). Invited presentation. San Diego, CA, USA. **2013** May 20-22.
164. Invited talk: Anne S. De Groot and Ted Ross (VGTI). **Influenza Vaccine Immunogenicity – The story of H1N1.** Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH/HHS. 20 March **2013**. Invited by Rachelle Solomon.
165. Invited Talk. Anne S. De Groot and Andres Gutierrez. **Immunogenicity Analysis of CHOP Contaminants in Therapeutic Protein Formulations** CHOPPI: Website for predicting the immunogenicity of CHO-derived Host Cell proteins. USP, Measurement of Residual Host Cell Protein and DNA in Biotechnology Products Workshop. June 3–4, **2013**. USP Headquarters, Rockville, Maryland
166. Invited talk from submitted abstract: De Groot, AS. **The Two-faced T cell epitope: Relevance to Vaccine Efficacy and Design.** 7<sup>th</sup> International Society of Vaccines meeting in Barcelona (Sitges), Spain, October 27-29
167. Invited Talk. VGTI Symposium. Vaccine & Gene Therapy Institute. **The Two-faced T cell epitope: Relevance to Vaccine and Biologics Efficacy and Design.** Port Saint Lucie, Florida. 13-15 November 2014.
168. Invited talk: American Society for Histocompatibility & Immunogenetics. ASHI 39th Annual Meeting in Chicago, Monday, November 18<sup>th</sup>, **2013**. **Tregitopes an Immunomodulation Powerhouse: Alternative to IVIG.**
169. Invited talk: CRWAD. With Andres Gutierrez. **MHC epitope mapping in humans and development of tools specific to domestic and livestock species** (Crystal Loving). Conference of Research Workers in Animal Diseases on December 9, **2013**. Mini-symposium “**Vaccine Design – Targeting the Immune System**”, sponsored by the American Association of Veterinary

- Immunologists (AAVI).
170. Invited talk: Anne S. De Groot: **FDA Brown Bag Lunch: The Two Faced T cell epitope: Implications for Immunogenicity.** October 25<sup>th</sup>, **2013**, Amy Rosenberg, Ed Max, FDA, Host.
  171. Invited talk: **Novozymes.** Dan Shelly, Host. **The Science and potential of Tregitope-Albumin Fusions to induce tolerance to protein drugs, transplants, and blood replacement therapies, as well as for the treatment of autoimmune diseases and allergies.** Nottingham, England, December 2014.
  172. Invited talk: **GTC Biologics:** Protein Aggregation Biological Activity and Immunogenicity. Session Chair: Melody Sauerborn, TNO Triskelion BV. **T-cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation.** San Diego, January, 2014.
  173. Invited talk: **Rachel Caspi Laboratory: Tregitope: The Immune System Off Switch and ...Testing the Limits of Epitope-mapping tools: Can we predict Tolerance?** Friday, March 14, 2014. Invited by Rachel Caspi. Presentation to Immunology group at NIAID.
  174. Invited talk: Anne S. De Groot. **Influenza Vaccine Design: Role of Cross-Reactivity to “Self” and “Other” when Designing Vaccines and Therapeutics.** Friday, March 14, 2014. Invited by **David Scott, Ph.D. VP of Research**, USUHS Department of Medicine.

#### **Invited Presentations (Epidemiology/HIV/Women/Prison)**

1. **Condoms and HIV Transmission**, Member of Panel, Falmouth, Massachusetts Public School Board Panel 07/92.
2. **Battering and the Cycle of Violence**; speaker on the panel "Locked up and Locked out; Women in Prison," Criminal Justice Institute conference, Harvard Law School. 12/93.
3. **Sexual Abuse and HIV Risk Taking among Incarcerated Women** HIV infection in Women, 1st National Meeting in Washington DC, 02/95; Women's Health Conference, Women & Infants Hospital, 09/94, Providence RI.
4. **HIV in Incarcerated Women:** HIV Update, and Rhode Island Hospital Nursing Update, 03/94, and New England HIV in Prisons Conference, Wesleyan College, 05/94.
5. **Sexual Abuse and HIV Risk Taking among Incarcerated Women** Invited Speaker. Women's Health Conference, Women & Infants Hospital, Providence RI, 09/94.
6. **HIV in Prisons:** Breakout group leader at the conference HIV Update: Current State of the Art, Brown University AIDS program conference, Butler Hospital, Providence, Rhode Island, 01/94.
7. **Risks for HIV infection among Incarcerated Women**, Invited Speaker. Yale AIDS Colloquium Series (YACS, Dr. Rick Altice, host) New Haven CT, 10/95.
8. **TB in Prisons workshop leader**, Invited Speaker. New England HIV in Prisons Conference (and conference co-organizer)Springfield MA, 10/95.
9. **HIV infection in Incarcerated Women: Priorities for Research**, Invited Speaker. Clinical AIDS Research; PRIM&R, Boston MA, 11/95.
10. **The Framingham model and Health Services for HIV seropositive women**, Invited Speaker. National Correctional Health Care conference, Washington DC, 11/95.
11. **Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls (HEPA filters and UV lights)**, Invited Speaker. National Correctional

- Health Care conference, Washington DC, 11/95.
12. **HIV infection in Women**, Invited Speaker. Harvard AIDS Institute, Changing Times, Changing Strategies, AIDS in New England, 04/95.
  13. **Sexual Abuse and HIV Risk Taking among Incarcerated Women**, Invited Speaker. HIV infection in Women, 1st National Meeting in Washington DC, 02/95.
  14. **Sexual Abuse and HIV Risk Taking among Incarcerated Women**, National Drug Abuse Treatment Association conference, Newport RI, 11/95.
  15. **Prisons: Inside/Out** Departments of Legal Studies, Political Science, and Women's Studies, UMass Amherst. Invited speaker, panel on Economics of Prison and Sentencing Issues, 03/96.
  16. **Second Generation HIV/AIDS behind Bars** Invited speaker on panel with members of NORA, CDC, Federal Bureau of Prisons. NCCHC conference, Nashville Tennessee, 10/96.
  17. **Sexual abuse and HIV Risk taking**, Invited Speaker. Suffolk County Jail, Massachusetts DPH HIV Case Managers meeting 01/96 and Planned Parenthood open seminar, Boston, MA, 04/96.
  18. **1996 Prevention Summit, HIV Prevention Planning Co-Chairs Meeting**, CDC, Bethesda, Maryland, Panel, invited speaker: Effective Interventions to prevent HIV in Correctional Facilities, Atlanta, GA, 05/96.
  19. **HIV and incarcerated women: Risks, Models of Care**, Invited Speaker. APHA panel on Prisons and Jails (Socialist Caucus) APHA meeting, New York City, 11/96.
  20. **Closed Roundtable on HIV/Prison**, Invited Speaker. **Corrections Responds to HIV disease among Incarcerated Women**, Correctional HIV Consortium Winter Update, San Pedro, California, 01/97.
  21. **Intensive workshop on HIV Behind Bars: Providing Education, Advocacy, Care and Services (Intensive workshop #1)** Invited Speaker. 9th Annual AIDS Update Conference, San Francisco, California, 03/97.
  22. **Care and Treatment in Prisons and Jails (Panel #406)**, Invited Speaker. 9th Annual AIDS Update Conference, San Francisco, California, 03/97.
  23. **State of the Art Workshop, Living with HIV behind prison walls: perspectives from a patient and her physician**, Invited Speaker. Women and HIV infection Conference, Los Angeles, California, 10/97.
  24. **HIV infection among incarcerated women: Clinical Care**, Invited Speaker. New England School of Law, Symposium on the Treatment of Women Prisoners Boston, MA, 01/98.
  25. **HIV infection among incarcerated women**, Invited Speaker. New England Medical Center series for HIV infected Women (sponsored by AIDS Action and the New England Medical Center) **Gender Politics of HIV/AIDS in Women** Boston, MA 06/98.
  26. **What's different about Women living with HIV in Corrections**, Invited Speaker. (AIDS track talk on HIV infection among incarcerated women), National Commission on Correctional Health Care (National Meeting, 11/98).
  27. **HIV Management in the Prison Setting: An Update**, Invited Speaker. NJ AIDS Education and Training Center and Correctional Medical Service, Newark, New Jersey, 12/98.
  28. **Management of the HIV infected inmate**, Invited Speaker. Delaware AIDS Council Annual Meeting, Wilmington Delaware, 11/98.
  29. **Management of HIV in Correctional Facilities** to HIV providers on site

- South Carolina Women's Facility, Columbia, South Carolina
  - Central Florida Receiving Facility, Orlando Florida, 08/98, 11/98, 06/99, 02/01.
  - Delaware Department of Corrections, at the Delaware AIDS Council, 11/98.
30. Policy Action Network Briefing at the US Senate, Russell Office Building for Senate Staffers: **Breaking the Wall of Silence: Women, HIV/AIDS, and the Prison System**, Invited Speaker. 02/99.
  31. **Prisoner Research** Invited Speaker. CCG Scientific Agenda Subcommittee conference call. Jeff Taylor, Chair CCG Scientific Agenda Subcommittee ACTG 04/00.
  32. **HIV infection in Incarcerated Women** Invited Speaker. (CME lecture to physicians and health care practitioners attending HIV Update Course). University of Texas Medical Branch (Galveston Texas). 10/00, 08/01, 10/01.
  33. **HIV Behind Bars** Director, CME accredited course for Correctional HIV providers, 06/01, organized by Montefiore Medical Center.
  34. **HIV Management of Incarcerated Women**, Invited Speaker, Federal Bureau of Prisons Annual Nursing Conference, Raleigh, N.C., 04/02.
  35. Organizer and Plenary Speaker, **Real Life Examples: Managing Infectious Disease in Corrections**. NCCHC annual conference, HEPP Preconference Symposium, 10/02.
  36. **Post Exposure Prophylaxis of HIV infection**. HIV Minifellowship. University of Texas Medical Branch (David Paar, Host). Galveston, TX. 02/03.
  37. Organizer and Plenary Speaker, "**Texas MiniFellowship**" for **Correctional HIV Providers**, 09/03. Providence, Rhode Island,
  38. Organizer and Plenary Speaker, **Infectious and Transmissible Diseases in Correctional Settings**. NCCHC 10/03. Austin Texas. HEPP Report pre-conference symposium.
  39. TB in Corrections. Prevention and Treatment of Infectious Disease in Corrections. **What Corrections-Based Staff Need to Know**. 12/03. (RIDOC and RI Brotherhood of Correctional Officers)
  40. Emerging Issues in the Management of HIV Disease in Women (Rush U. Medical Center): The **Forgotten Many: HIV –seropositive Women in Prison, IDU and Adolescents**. Lecture and preparation of a monograph. 01/04. (Kim Smith MD, Rush UMC, host).
  41. Incarcerated Women and HIV. Half-day seminar (3 lectures). **Women and HIV Overview, Mother to Child Transmission Prevention**, and **HIV: African Realities**. UTMB Galveston, 03/04. (David Paar, MD, host).
  42. Incarcerated Women and HIV. **Women and HIV Overview, Mother to Child Transmission Prevention**. UTMB Galveston, 06/05. (David Paar, MD, host).
  43. Incarcerated Women and HIV. **Women and HIV Overview**. UTMB Galveston, 06/06. (David Paar, MD, host).
  44. Incarcerated Women and HIV. **HIV in Women Conference; Texas-Okla. AETC** Dallas, 04/08.  
(no further work in HIV/Prison since April 2008 – no further talks)

**Grants: Principal Investigator (NIH and Foundation grants for research) (Not Updated 2014)**

**Total NIH funding to date: >\$26 Million Cumulative Directs and Indirects with U19 Award (\$13M)**

<b>Currently Funded Research</b>		
2R44DK081261-03A1 ( PI A.S. De Groot) 04/01/2012- 03/31/2014		
NIDDK Phase II SBIR: \$1.5M Dir/Indir. <b><i>Preclinical studies of Tregitope Delivery and Mechanism of Action in T1D</i></b>		
The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials.		
1R43HL114308-01 (PI A.S. De Groot)		04/01/2012-03/31/2014
SBIR Phase I – FVIII-ASATI : \$775K <b>Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A.</b> The goal of this new SBIR program is to develop a tolerizing FVIII molecule that will combine replacement therapy and FVIII-specific tolerance induction to prevent hemophiliacs from developing neutralizing antibody ‘inhibitors’ against the very therapy they need.		
<b>1R21AI090359-01A1</b>	<b>PI: A. S. De Groot</b>	5/01/2011 – 4/30/2013
<b>NHLBI SBIR Phase I \$750K Dir/Indir. Title: <i>Novel H1N1 influenza protection via cross-reactive immunity</i></b>		
The specific aims for this project are to: (1) analyze the HA and NA sequences of known isolates of H1N1 and design highly conserved “immunogenic consensus sequence” (ICS) Class II restricted T cell epitopes; (2) validate the ICS epitopes designed in AIM1 by demonstrating promiscuous MHC binding in-vitro and antigenicity in ex-vivo T cell restimulation assays using peripheral blood leukocytes from TIV exposed, seasonal influenza-exposed and novel H1N1-exposed human subjects.		
Finally, in collaboration with Dr. Richard Webby, we plan to (3) evaluate the effect priming with ICS epitopes has on immunogenicity and protective efficacy in HLA transgenic mouse vaccinated with TIV and challenged with novel H1N1.		
We expect to find that antibody titers are higher and manifestations of influenza are attenuated in mice primed with the cross-reactive epitopes, compared to mice not primed. We expect the results of these studies to demonstrate that conserved influenza sequences, which are important to viral fitness, may also be of immunological value in that they may contribute to protection against morbidity and to universal influenza vaccine design, leading to re-evaluation of alternative approaches to “priming” influenza immune responses, attenuating illness and preparing for the next pandemic.		
<b>1U19AI082642-01</b>	<b>PI: A. S. De Groot</b>	7/20/2009 – 6/30/2014
\$13M Program Project in Collaborative Centers for Human Immunology Program, NIAID		
Title: <i>Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)</i>		
The goal of this application is to promote the use of immunoinformatics tools to accelerate the design and development of vaccines for emerging infectious diseases and biowarfare agents. Dr. De Groot is the overall PI of this project.		
1R43HL088834-01	<b>PI: A. S. De Groot</b>	5/01/2007 – 4/30/2011
Title: <i>Epitope-driven deimmunization of Factor VIII</i>		
The goal of this project is to modify the constituent epitopes of FVIII so that it is a less immunogenic and more effective therapy. 12,000 Americans have the blood clotting disorder Hemophilia A, and as such are susceptible to a host of complications from chronic bleeding of the joints to life threatening blood loss due to traumatic injury. This SBIR describes a plan to produce an improved clotting protein (Factor VIII) that could be used to treat hemophiliacs since the current treatment is often rejected by the body. The reengineered protein will be evaluated in mice that have hemophilia as well as in mice that have a human-like immune system. In the first phase of the projects, we demonstrated that deimmunization does work as expected; further funding in the form of an SBIR Phase II or I-II will be sought. The technology is currently being evaluated by a large Pharma for incorporation into their FVIII therapy.		
1R43AI075830-01	<b>PI: A. S. De Groot</b>	9/01/2007 – 8/31/2011
Title: <i>Optimization of a Multivalent Tuberculosis Vaccine</i>		
The goal of this project is to optimize methods of adjuvanting and delivering (dose, route) an epitope based vaccine for TB.		
Unfunded extension.		
<b>1R43DK081261-01</b>	<b>PI: A. S. De Groot</b>	8/01/2008 – 7/31/2010

<i>(SBIR Phase II Submitted and under review)</i>		
<i>Title: T1D Tolerance Induction with Natural Treg Epitopes</i>		
<i>The purpose of this project is to develop a therapeutic to treat and prevent Type 1 Diabetes. NIDDK supported EpiVax through an SBIR grant to reach proof-of-principle for a drug that will focus on the natural “regulatory T cells” and their protective role in the diabetes patient. The studies are anticipated to show that the drug reduces harmful immune responses to insulin-producing cells, preserving the body’s ability to make its own insulin. The approach used by EpiVax is called “Antigen-Specific Adaptive Tolerance Induction (ASATI™)”; it specifically targets and reduces undesirable immune responses. A study that will explore the formulation of the epitopes is currently being supported by NIDDK. The latter program (PTP) is highly competitive, and we credit our SBIR with the ability to secure this translational funding from the NIH.</i>		
<b>1R21AI078800-01</b>	<b>PI: A.S. De Groot</b>	9/30/2008 – 8/31/2011
<i>Title: Optimization of HIV Vaccine Subunit Delivery</i>		
The goal of this project is to optimize delivery of a multi-epitope HIV vaccine		
<b>Funded Supplements</b>		
<b>1U19AI082642-01 S1</b>	<b>PI: A. S. De Groot</b>	12/1/2009 – 04/30/2011
<i>Title: Translational Immunology Research and Accelerated [vaccine] Development (TRIAD) (Parent)</i>		
<i>iVAX - Vaccine and Diagnostic Design Toolkit for CCHI funded programs (Discretionary Funds) (Supplement)</i>		
The goal of this project is to make a set of tools and techniques accessible to CCHI funded investigators		
<b>1U19AI082642-01 S1</b>	<b>PI: A. S. De Groot</b>	2010 – 06/30/2011
<i>Title: Translational Immunology Research and Accelerated [vaccine] Development (TRIAD) (Parent)</i>		
<i>NTD@TRIAD - Application of TRIAD Toolkit (iVAX) to NTD Vaccine Research and Development</i>		
The goal of this project is provide iVAX tools and techniques training to researchers pursuing NTD vaccines.		
<b>3R21AI078800-02 S2</b>	<b>PI: A. S. De Groot</b>	9/27/2011 – 8/31/2012
<i>Title: Optimization of HIV Vaccine Subunit Delivery (Supplement)</i>		
The goal of this project is to optimize delivery of a multi-epitope HIV vaccine		
<b>Previously Funded</b>		
<b>1R21NS054781-01</b>	<b>PI: A. S. De Groot</b>	3/1/2007 - 2/28/2010
NINDS		
<i>Title: Development of De-Immunized Botulinum Neurotoxin Type A for Dystonia</i>		
The goal of this project is to develop safe and effective De-immunized botulinum neurotoxin Type A for patients diagnosed with Dystonia.		
<b>5R43A1058326-02</b>	<b>PI: A. S. De Groot</b>	9/01/2004 – 8/31/2007
NIH/NIAID: Small Business Biodefense Program (SBIR Phase I)		
<i>Title: A Genome-Derived, Epitope-Driven Tularemia Vaccine</i>		
The goal of this project is to develop a vaccine of highly immunogenic <i>F tularensis</i> epitopes. A Phase II application has been submitted and is currently under review.		
The goal of this project is to develop a vaccine of highly immunogenic <i>F tularensis</i> epitopes. A Phase II application has been submitted and is currently under review. The second-generation vaccine is a viable vaccine candidate; this product will be further developed with in collaboration with the Department of Defense (NMRC at Walter Reed) and brought to the clinic as soon as possible. This vaccine would be safer than current vaccines for tularemia and suitable for use in civilian populations as part of strategic defense against WMD.		
<b>7R01AI050528-04</b>	<b>PI: A. S. De Groot</b>	5/01/2002 – 4/30/2008
NIAID		
<i>Title: Epitope Driven HIV Vaccine Development</i>		
The goal of this project is to develop a vaccine of highly immunogenic conserved HIV epitopes.		
<b>5R43AI058376-02</b>	<b>PI: A. S. De Groot</b>	5/26/2005 – 5/31/2009
NIH/NIAID (SBIR Phase I)		
<i>Title: Novel Smallpox Vaccine Derived from VV/VAR Immunome</i>		
The goal of this project is to develop a novel and safer smallpox vaccine derived from immunogenic T cell epitopes conserved in both VV and Var proteomes. A Phase II application has been submitted and is currently under review.		
Whole organism vaccines provide more information than the immune system needs for protection, thereby presenting unnecessary safety risks for activation of undesired immune reactions. Whole subunit vaccines may not provide adequate information and therefore fail to protect. A genomes-to-vaccine approach aims to identify the		



minimal, essential information from multiple antigens that will achieve protection, while avoiding unintended and dangerous effects. In this SBIR we proposed to develop a safe, new smallpox vaccine based on T cell epitopes conserved between the genomes of vaccinia virus (VV) and Variola (VAR). The initial study showed 100% protection by the vaccine. The next phase of this work is underway – a strategic collaboration with USAMRIID (Department of Defense). This type of vaccine (epitope-driven) is anticipated to have fewer side effects than the existing smallpox vaccine (DryVax) and would be safe for use in lower risk populations such as civilians, as compared to the existing smallpox vaccine.

<b>5R43A1058326-02</b>	<b>PI: A. S. De Groot</b>	9/01/2004 – 8/31/2007
<p>NIH/NIAID: Small Business Biodefense Program (SBIR Phase I)  <i>Title: A Genome-Derived, Epitope-Driven Tularemia Vaccine</i>  <i>The goal of this project is to develop a vaccine of highly immunogenic F tularensis epitopes. A Phase II application has been submitted and is currently under review.</i></p>		
<b>7R01AI050528-04</b>	<b>PI: A. S. De Groot</b>	5/01/2002 – 4/30/2008
<p><i>Title: Epitope Driven HIV Vaccine Development</i>  <i>The goal of this project is to develop a vaccine of highly immunogenic conserved HIV epitopes.</i></p>		
<b>5R43AI065036-02</b>	<b>PI: A. S. De Groot</b>	5/26/2005 – 5/31/2008
<p>NIH/NIAID (SBIR Phase I)  <i>Title: A Genome-Derived, Epitope-Driven H. Pylori Vaccine</i>  <i>The goal of this project is to develop safe and effective H pylori vaccine derived from conserved immunogenic epitopes. Despite considerable effort, an effective Helicobacter pylori vaccine remains elusive. Advances in predictive in silico modeling and epitope-based vaccination afford novel approaches to H. pylori vaccine development. The goal of this SBIR Phase I research program was to develop a T-cell epitope-based, therapeutic vaccine against H. pylori and to when delivered mucosally as a multi-epitope DNA vaccine, can be shown to protect from H. pylori infection and gastric cancer. Initial studies carried out with SBIR funding resulted in the development of a viable vaccine candidate; this product will be out-licensed to a strategic partner and brought to the clinic as soon as possible.</i></p>		
<b>JDRF Industry grant</b>	<b>PI: A. S. De Groot</b>	12/01/08 – 11/31/2009
<p>JDRF  <i>Title: Antigen-Specific Tolerance Induction (ASATI) for the prevention and treatment of T1D</i>  The goal of this project is to develop a treatment for Type 1 Diabetes.</p>		
<b>Collaborations</b>		
<b>1R21AI078355-01A2</b>	PI: L. Moise	12/01/2009 – 11/30/2011
<p>NIH/NIAID  <i>Title: Novel Function of Complement C3d as a Helper T-cell Target.</i>  The goal of this project is to investigate a newly discovered auxiliary pathway of immune activation.</p>		

#### Support for Clinica Esperanza/Hope Clinic: Current

<b>United Way of Rhode Island</b>		<b>PI: A.S. De Groot</b>	<b>05/15/2014-2015</b>
CHEER: Operational Support			
<b>United Way of Rhode Island</b>	<b>\$15,000</b>	<b>PI: A.S. De Groot</b>	<b>05/15/2013-2014</b>
CHEER: Operational Support			
<b>Rhode Island Department of Health</b>		<b>PD: A.S. De Groot</b>	<b>01/01/12- 12/31/2013</b>

**Rhode Island Department of Health                      PD: A.S. De Groot                      01/01/14- 12/31/2014**

Centers for Health Equity and Wellness: A Place to be Healthy

This funding provides operational support for Clinica Esperanza in relation to the establishment of five sites in Providence where the health and wellness intervention “Vida Sana” will be performed by CEHC Navegantes.

**RI Community Foundation                                      PI: A.S. De Groot                                      08/29/2012-09/01/2013**

HIP Healthcare Innovation Partnership

This Strategy Grant provides support for staff time to focus on developing the proposed HIP@URI IPCOR Healthcare Innovation Partnership (HIP@URI IPCOR), program and piloting the proposed innovations.

**American Communities Trust                                      PI: A.S. De Groot                                      08/02/2011–8/22/2014**

Multiple unrestricted awards have supported CEHC activities related to the Patient Integrated Medical Home and activities related to providing health services for uninsured residents of the state of Rhode Island.

**American Medical Association Foundation                      PI: A.S. De Groot                                      08/22/2012–08/22/2013**

Vida Sana Program

This grant provides support for an outreach program to improve healthy behaviors and reduce chronic disease at five locations in Providence. The program will terminate in August 2013.

**Blue Cross Blue Shield of RI                                      PI: A.S. De Groot                                      01/13/2012–11/1/2014**

BCBS CHEER Project - \$50,000/year in 2012, 2013, and (pending) 2014

This funding provided support to develop a walk in clinic for non-urgent care for the uninsured; the program leverages the clinic site and volunteer hours to reduce ER costs for local patients affected by health disparities.

**City of Providence    PI: A.S. De Groot    7/1/2008 - 6/30/2014**

Community Development Block Grants: Yearly Awards: FY 34-38 (\$20,000 per year)

This grant provides ongoing support (competed annually) for general operating procedures, for continuity of care for uninsured patients, and to perform health screenings for the uninsured.

**Support for Clinica Esperanza/Hope Clinic: Previous**

**DOH Minigrant    PI: A.S. De Groot    9/23/2011- 3/01/2012**

Centers for Health Equity and Wellness

This Grant provides support to establish a collaborative relationship between AIWA (a local North African/Islamic Wellness Association to assist uninsured African Refugee population with Free Health Services

**Blue Cross Blue Shield    PI: A.S. De Groot    03/01/2010- 02/28/2012**

This (Blue Angel Community Grant) Grant provided support for the development of the Navegantes program for uninsured/underserved populations. CEHC promoted and evaluated the use of community health workers to address disparities in health status for minority populations.

**Rhode Island Foundation    PI: A.S. De Groot    01/14/2011-01/13/2012**

Rhode Island Foundation

This Grant provided support for general operating procedures and for Un Lugar por tu Salud/A place to be healthy- Health Care access for the Uninsured.

**Rhode Island Foundation    PI: A.S. De Groot    10/13/2011-10/12/2012**

**PIMHA Program**

This Grant provided support to programmatic expenses related to the Patient Integrated Medical Home and Advocacy (PIMHA) project.

**Previous Grants (Chronological)**

01/01/92-06/30/92. **Reactivation Tuberculosis in HIV Infection**

**NIH: K08** AI 01068.

Total Direct Costs \$68,000, Indirect Costs \$40,500.

PI: De Groot (Brown University)

1/1/93-12/31/93 Rhode Island Foundation (title not available)

**Rhode Island Foundation** RIF 4238.

Total Direct Costs \$4,822 (no indirects).

PI: De Groot (Brown University)

07/01/92-06/30/94 **Natural and predicted antigens for TB immunotherapy**

**NIH: R01** AI 35271

Total Direct Costs Year 1 (continuation of K-08) Direct Costs \$174,813, Year 2 \$171,904; Indirects Year 1, \$40,366, Year 2 \$43,676.

PI: De Groot (New England Medical Center and Brown University)

7/1/93-6/30/94 **Heiser Program for Research in Leprosy and Tuberculosis**

**Heiser Foundation.**

Total Direct Costs \$16,659; Indirect Costs \$3,332.

PI: De Groot (Brown University)

1/1/94-12/31/94 Rhode Island Foundation (title not available)

**Rhode Island Foundation** RIF 3192

Total Direct Costs \$4,840 (no indirects).

Gabriel Meister PI, De Groot Co-investigator (Brown University)

9/01/95-7/01/95 **Recognition of putative TB vaccine epitopes by sub Saharan Africans**

**NIH: R03** TW00552-03 S1USAID Supplement.

Total Direct Costs \$ 20,000; Indirect Costs \$0.

PI: De Groot (Brown University)

8/21/97-5/31/99 **Sequencing the Mtb Genome**; Supplement EpiMatrix analysis of Mtb Genome

**NIH: R01** AI 40125

Total Direct Costs \$82,694; Indirect Costs \$41,381.

PI: De Groot (Brown University)

10/1/98-6/30/99 **Epitope-based Vaccines and Therapeutics, accelerating design and delivery**

**Rhode Island Center for Cellular Medicine** Phase I grant.

Total Direct Costs to TBHRL: \$75,000; Indirect Costs \$24,894

PI: De Groot, M. Gonzalez Co-investigator at TBHRL(Brown University)

10/01/95-09/30/99 **TB peptide epitope project, MRC Laboratories, The Gambia**

**NIH: R03** TW00552

Total Direct Costs \$68,000; Indirect Costs \$40,500.

PI: De Groot (Brown University)

0/1/99-03/1/00 **Epitope-driven HIV vaccine targeting dendritic cells**

**NIH: SBIR** Phase 1 R43 AI 46212. Subcontract to Brown.

Total Direct Costs to TBHRL: \$29,684; Indirect Costs \$16,920

PI: De Groot, Dr. M. Gonzalez Co-investigator at TBHRL (Brown University)

03/01/00-12/31/00. CFAR Pilot Project. **Validation of candidate HIV vaccine T cell epitopes**

**NIH: CFAR** Pilot Project

Total Direct Costs \$13,005. 30,000; Indirect Costs 7,500

PI: De Groot, Dr. M. Gonzalez Co-investigator at TBHRL (Brown University)

10/01/99-09/30/01 **A Cross-Clade Approach to HIV Vaccine Development**

**NIH: R21** AI 45416

Total Direct Costs \$446,047; Indirect Costs \$147,383

PI: De Groot (Brown University)

07/01/01-12/30/01 **Diagnostic Reagents for Emerging Infectious Diseases**

NIH/NIAID: **SBIR** Phase I to EpiVax

TBHRL Total Direct Costs \$40,000; Indirect Costs \$22,000 (total grant \$100,000)

PI: De Groot (Brown University) (Formerly PI at EpiVax; current PI at EpiVax is Bill Martin)

4/1/98-03/31/02 **HIV-1/HIV-2 Epitope project, The Gambia, West Africa**

**NIH: R03** TW00973

Total Direct Costs \$70,569; Indirect Costs \$41,431.

PI: De Groot (Brown University)

**7/0/97-06/30/02 HIV Evolution and Cellular Immune Response**

**NIH: R01** AI 40888

Total Direct Costs \$899,249; Indirect Costs \$283,029.

PI: De Groot (Brown University)

**12/30/01-08/30/02 Epitope-driven HPV Vaccine Targeting Dendritic Cells**

PI: De Groot (Brown University) (PI at EpiVax is Bill Martin)

NIH/NCI: **SBIR** Phase I to EpiVax

TBHRL Total Direct Costs \$67,382; Indirect Costs \$32,708 (total grant to TBHRL \$100,090)

**03/01/99-04/30/03. Immunoregulatory Defects in Hemophilia**

**NIH: R01** HL 042257

Year Two Total Direct Costs \$13,416; Indirect Costs \$8,049

PI: John Sullivan, UMass Worcester, De Groot, subcontractor (Brown University)

**05/01/03 – 08/01/03 GAIA Vaccine Project –Bamako, Mali West Africa**

PI Marcon (Brown) / Koita (FAST, Bamako Mali)

Campbell Foundation (to A. De Groot at GAIA Vaccine Foundation)

Total Direct and Indirect Costs \$75,000.

**3/1/00-03/1/03 Bringing Epitope Driven Vaccines into Phase I Trials**

Sequella Global TB Foundation **SGTBF Core Scientist Award**

PI: De Groot (EpiVax)

Total Direct Costs \$900,000 to EpiVax

TBHRL Subcontract: Total Direct Costs: \$300,000 (expected/3 years); Indirect \$150,000.

**03/01/04-03/01/05 Collaborative for Vaccine Research and Design (CVRD)**

PI De Groot (Brown)

Office of the Vice President of Research, Brown University

Research seed Funding (\$75,000).

**9/1/2004 – 8/31/2007. A Genome-Derived, Epitope-Driven Tularemia Vaccine**

**NIH: 5R43A1058326-02**

**PI: A.S. De Groot**

Total Direct Costs: \$716,957 Indirect Costs: \$114,965

5/01/2002 - 4/30/2008. **Epitope Driven HIV Vaccine Development**

*NIH: 7R01AI050528-04*

**PI: A.S. De Groot**

05/26/2005 - 05/31/2008. **A Genome-Derived, Epitope-Driven H. Pylori Vaccine**

*NIH: 5R43AI065036-02*

**PI: A.S. De Groot**

05/26/2005 - 05/31/2009. **Novel Smallpox Vaccine Derived from VV/VAR Immunome**

*NIH: 5R43AI058376-02*

**PI: A.S. De Groot**

**Other Grants (Co-investigator or subcontract)**

1993-1994 **TB Cure Rate at a Public Hospital in Massachusetts**

(mentor for Massachusetts Nursing Association Award/ Nellie Castillo R.N.) (New England Medical Center)

1992-1993 CPCRA Study of **TB prophylaxis for HIV-seropositive patients**

(TB/PPD+, 004) (subcontractor to Boston Department of Health and Hospitals/CDC) (NEMC)

1998-2002 **CD8<sup>+</sup> T-Cell Response in Resistance to Tuberculosis**

PI Dr. Yuri Bushkin, Public Health Research Institute, NYC, NY (Brown University)

**Patents**

- 1) Brown University Research Foundation reference 1994-14; **"HIV Vaccine Candidate Peptides"** This application claims an HIV vaccine and includes 672 peptide sequences. Filed as a provisional July 10, 1998 (60/092,346) and as a full utility application July 9, 1999 ( 09/351,036). Most recent action was a response to USPTO on July 10, 2001. No foreign filings. Inventors are Meister, Roberts, Berzofsky and DeGroot.
- 2) Brown University Research Foundation reference 1998-22; **"Human T Cell Response to MHC-Binding Motif Clusters"** This application claims a TB vaccine and includes a list of 28 peptides. Filed as a provisional March 20, 2000 (60/190.834) and as a full utility application ( 09/813,333) March 20, 2001. Filed as PCT (foreign) application on March 20, 2001. Inventor is DeGroot.
- 3) Brown University Research Foundation reference 1998-34; **"A Regional HIV Vaccine for India"** Filed as a provisional application (60/115,145) on January 8, 1999. Combined with (1) above when utility application was filed.

- 4) Brown University Research Foundation reference 1999-09: **"A "World-clade" HIV-1 Vaccine"** Filed as a provisional application (60/130,677) on April 23, 1999. Combined with (1) above when utility application was filed.
- 5) Brown University Research Foundation reference 2000-32; **"Methods of Determining West Nile Virus Epitopes and Method of Using the Same"** Filed as provisional application (60/272,132) on 02/2001. 20050048073 - Methods of determining west nile virus epitopes and method of using the same.
- 6) USPTO Patent Application 02721225.7 2119 US0206314; Date of Filing 01 03 02 **Immunogenic HIV peptides for use as reagents and vaccines.** (Janet McNicoll, CDC).
- 7) USPTO Patent Application 20090018067, Regulatory t cell epitopes, compositions and uses thereof. **Issued Feb 11, 2011**

### University Teaching Roles

#### **Undergraduate/Graduate Courses**

Brown U. Medical School	Pathology of Infectious Diseases	1997, 1999.
Bio 160 Brown U.	Vaccines for Infectious Disease with Paul Knopf, Ph.D.	Co-course leader Spring 1995, 1997, 1999, 2000, 2004, 2005, 2006, 2007
MTC594, URI	Vaccines for Infectious Disease with Lenny Moise, Ph.D.	Course Leader Spring 2008, 2009, 2010, 2011, 2012, 2013
Biotechnology	Vaccine Development	For Prof. Lysaght/Hawrot 1998, 1999, 2001, 2002, 2003, 2004 2005, 2006, 2007, 2008
Immunology (Bio 53)	HIV vaccine development	For Prof. Knopf Fall 1998-2002, For Prof. Yap, Fall 2003, 2005, 2006, 2007, 2008
Women's Health		HIV among women in prison For Prof. Lapan Fall 1997

**FLASC Summer Fellowship**

Wendee Gozansky, M.D. MPH Tufts University Class of 1995,

Epidemiology of Toxoplasma  
Reactivation In HIV seropositive  
patients

**Schwietzer Fellowship**

Lisa A. Pratt, Class of 1997 M.D., MPH Tufts University

Discharge planning for HIV +  
Incarcerated women

**Brown University Undergraduate Senior Honors Thesis, Primary Mentor**

<b>Jessica Stevens</b>	1994	HIV/Women Epidemiology Res.
<b>Kimberly Fisher</b>	1994	HIV Immunology Res.
<b>Caroline Roberts</b>	1994	HIV/Vaccines Immunology
<b>Brian Edelson</b>	1995	TB/Vaccines Immunology Howard Hughes Fellow
<b>Tamar Renaud</b>	1995	Prisons Epidemiology Howard Hughes Fellow
<b>Stephanie Gampper</b>	1996	TB/HIV Epidemiology Research Undergraduate Teaching and Research Award
<b>Lieschen Quiroz</b>	1996	TB/Vaccines (Philippines) Undergraduate Teaching and Research Award
<b>Michelle Ferdinand</b>	1996	HIV Epidemiology Research
<b>Neal Muni</b>	1996	Biotech Applications
<b>James Robert Schafer</b>	1997	HIV vaccine research Saihou Sabelleh HIV Res. Fellowship
<b>Igor Brichkov</b>	1998	TB vaccine research
<b>Jean David Barnea</b>	1998	HIV vaccine research (India)
<b>Tony Breu</b>	2000	TB vaccine research (summer )
<b>Natasha Chinai</b>	1998-2001	HIV vaccine research



		India/ HIV2)
		Summer Howard Hughes Fellow
<b>Kara Chew</b>	2000-2001	TB vaccine research
		UTRA 2000
<b>Brian Tuch</b>	2000-2001	HIV evolution, UTRA 2000
<b>Andrew Girvin</b>	2000-2001	DNA vaccines, UTRA 2000
<b>Ankanksha Mehta</b>	2001-2002	DNA vaccines UTRA 2001
<b>David Heller</b>	2001-2002	HIV evolution, UTRA 2001
<b>Basim Khan</b>	2001-2002	Dendritic Cells UTRA 2001
<b>Nicole Pattamanuch</b>	2002-2003	Dendritic Cells/HPV
<b>Rebecca Doctors</b>	2002-2003 UTRA 2004	EBV epitopes/UTRA 2002,
<b>Shirley Chan</b>	2003-2005	Testing a DNA based HPV vaccine. UTRA 2002,03
<b>Sangeeta Tripathi</b>	2003-2004	KAP related to Vaccines, Bamako, Mali
<b>Delphine Huang</b>	2004	MTCT in Bamako, Mali
		Barbara Anton Internship Grant. (Pembroke Center)
<b>Sara Kimball</b>	2004-2005	EBV epitope mapping
<b>Shuyi Zhang</b>	2004-2005	Listeria-vectored vaccines
<b>Jessica Beckerman</b>	2004-2005	KAP related to Vaccines, Bamako, Mali (Royce)
<b>Caitlin Cohen, Brendan Pelsue, Alexa Lafaunce</b>	2005-2006	KAP study in Bamako Markets Bamako, Mali (Royce)
<b>Erica Trauba, Rebecca Fox, Alexandra Dick.</b>	2005-2006	Oral History Project, Sikoro Women's Group, Bamako Mali
<b>Kathleen Bernard</b>	2005-2006	Standard of Care in Prisons Comparison to Community SOC Providence (IDCR) 2006
<b>Madeline DiLorenzo</b> (Brown 2008)		Smoke Fellowship Five Finger Peer Ed Program Bamako, Mali 2006
<b>Bay Hudson</b> (Harvard 2007)		Five Finger Peer Ed Program Bamako, Mali 2006
<b>Erica Trauba, Hong Troung, Megan Billman, Fiona Heckscher</b> (Brown 2008)		HIV testing and Counseling Bamako, Mali 2006
<b>Jared Meshekow and Victoria Albina</b> (BU, 2008)		Electronic Medical Records

	(Labtracker Project) Sikoro Clinic, Bamako, Mali, 2006
<b>Katie Fletcher</b> (Mt Holyoke, 2007)	Immunoinformatics and Immunology Internship EpiVax, Inc.
<b>Binny Chokshi</b> , Brown -08 (Columbia Med School)	TB Bolo Project Bamako Mali
<b>Olivier Bardol</b> (University of Bordeaux Med Student)	HIV Adherence Hope Center Clinic Bamako Mali
<b>Tobias Cohen</b> (Brown 2009 – became EpiVax employee -2010)	Looking for Tregitopes In EBV
<b>Sanjay Trehan</b> (Brown 2009)	Immunoinformatics, Heterologous Immunity
<b>Katie Harty</b> (Brown 2009)	Business Development Intern <b>EpiVax, 2009</b>
<b>Julie Caplow</b> (Brown 2009), <b>Lauren Pischel</b> (Brown 2011)	TB Knowledge, attitudes and practices in <b>Sikoro, Mali. 2009</b>
<b>Lauren Levitz</b> (Brown U. 2010)	C3d and auto-immune response
<b>Emily Kossow</b> (Wesleyan 2011), <b>Tonhu Huang</b> (Concord Academy)	HPV knowledge, attitudes and practices in <b>Sikoro, Mali. 2010</b>
<b>Christina Gomez Mira</b> (University of Texas, Medical School)	Evaluation of MTCTP program, <b>Sikoro, Mali, 2010</b>
<b>John Rozenhal</b> (Brown 2009 – became URI employee)	GAIA AIDS Vaccine Research
<b>Natasha Rybart</b> (Med/Peds Resident, Brown University)	Evaluation of MTCTP program, <b>Sikoro, Mali, 2010</b>
<b>Julia Toffoli</b> (Columbia Masters in Public Health, 2011)	Evaluation of MTCTP program, <b>Sikoro, Mali, 2011</b>
<b>Nick Platt</b> , American University of Paris, undergraduate	Evaluation of HIV Care program, <b>Sikoro, Mali, 2011</b>
<b>Salman Khan</b> , MSIV Brown U. Medical School	<b>Comm. Health Clerkship, 2011</b>
<b>Danielle Poole</b> (Brown Masters in Public Health, 2012)	<b>HPV KAP and WTP, Sikoro, Mali</b>
<b>Andres Nunez Gutierrez</b> , University of Cayetano Heredia	<b>iCubed URI, 2011-present</b>
<b>Tania Medieros</b> , Masters in Public Health	<b>HPV KAP at CEHC, 2011</b>
<b>Jeff Chau</b> , Macayla Landi, Melissa Reilly, URI Pharmacy	<b>HPV KAP at CEHC, 2012</b>

Farzana Kibria, Jillian Peters, Carmen Shulman,

AHA HTN project CEHC, 2013

**Foreign Study Fellowship, Brown University Independent Study, Primary Mentor**

<b>Krista Dong</b>	PLME 2000	TB/Vaccines Immunology The Gambia, W. Africa, 1995
<b>Tevis Howard</b>	Class of 2007	Kenya – Malaria - 2006

**Fogarty AIDS Research Training Program (International Health Institute) Trainees**

<b>Mario O. Santiago</b>		U. Philippines 1995 HIV evolution/ EpiMer Algorithm
<b>Julius Hafalla</b>		U. Philippines 1995 TB vaccines; MHC PCR/ EpiMer
<b>Winston Banya</b>		MRC Research Labs 1998 HIV 2 vaccine development
<b>Ousmane Toure</b>	(Visiting Fellow from Tulane U)	AIDS Vax Conservation in Mali

**Other Visiting Fellows**

<b>Constanze Weber</b> , Ph.D. Candidate	University of Frieberg 2008-09 Hendrik Veelkens, Sponsor Dec205 Deimmunization project
<b>Ben Aboubacar</b> , M.D. Takemi Fellowship (Did not complete)	HIV/AIDS Care in Bamako Mali
<b>Kotou Sangare</b> (LBMA, FAST, Bamako Mali)	GAIA Vaccine Research 2009

**Neglected Tropical Disease Fellows**

**2011, 2012, 2013**

**Organizational responsibilities: panels and conferences**

- (NCCHC 1) 2nd Generation AIDS behind Bars**, at the National Commission on Correctional Health Care Conference, San Antonio, Texas, Nov 9, 1997: Set agenda, invited speakers, hosted.
- NE Regional Symposium on HIV infection among incarcerated women** Brown AIDS Program/ NEAETC Providence RI, Nov 5, 1997. Course Director. Raised funding, set agenda, invited speakers, hosted, published proceedings.
- Current Strategies for the Management and Prevention of HIV in Corrections**, HEPP (HIV Education/ Prison Project) at the Brown AIDS Program /Yale HIV/Prison Program, New York City, NY October 20-21 1998: Course Director (with Dr. Rick Altice). Raised funding, set agenda, invited speakers, hosted.
- HIV Treatment Update for Prisons and Jails**, HEPP (HIV Education/ Prison Project) at the Brown AIDS Program/NEAETC, Cambridge, MA, March 11, 1998: Course Director. Raised funding, set agenda, invited speakers, hosted.
- Clinical Trials in Correctional Settings**, HEPP (HIV Education/ Prison Project) at the Brown AIDS Program, Yale HIV/Prison Program and Center for Interdisciplinary Research on AIDS, Course Director. October 12-14, 1999. Raised funding, set agenda, invited speakers, hosted.
- (NCCHC 2) 2nd Generation AIDS behind Bars**, at the National Commission on Correctional Health Care Conference, Fort Lauderdale, Florida, Nov 6 1999: Set agenda, invited speakers, hosted.
- (NCCHC 3) HIV/AIDS behind Bars**, at the National Commission on Correctional Health Care Conference, St. Louis, MO, Sept 7-9 2000: Set agenda, invited speakers, hosted.
- TB Vaccine 2000**. Sequella Global TB Foundation, November 3- 5, 2000. Set agenda, invited speakers, hosted.
- (NCCHC 4) Bridging the Gap**, at the National Commission on Correctional Health Care Conference, Albuquerque, New Mexico, Nov 10, 2001: Set agenda, invited speakers, hosted.
- (NCCHC 5) Real Life Examples, Managing Infectious Diseases in Corrections**, at the National Commission on Correctional Health Care Conference, Nashville Tennessee, October, 2002: Set agenda, invited speakers, hosted.
- (NCCHC 6) Managing Infectious and Contagious Disease in the Correctional Setting**. at the National Commission on Correctional Health Care Conference, sponsored by HEPP Report (Infectious Diseases in Corrections), Brown University AIDS Program. Austin, Texas, October 4, 2003. Set agenda, invited speakers, Hosted.
- (NCCHC 7)** at the National Commission on Correctional Health Care Conference, sponsored by HEPP Report (Infectious Diseases in Corrections), Brown University AIDS Program. New Orleans, October 2004. Set agenda, invited speakers, Hosted.
- Rencontre des Specialistes VIH/SIDA a Bamako**. GAIA Vaccine Foundation / Fondation Merieux Jan 7, 8 2004. Organization, Invitation, Hosting, and Support (GAIA VF).
- Rencontre des Specialistes II**. GAIA Vaccine Foundation / Fondation Merieux Jan 11,12 2005 Organization, Invitation, Hosting, and Support (GAIA VF).
- 2<sup>nd</sup> International IIMMS Symposium** Sponsors: Brown University and Boston University. Held at Boston University, March 8,9,10 2005. Organization, Invitation, Hosting, and Support (IIMMS/CVRD)
- 1<sup>st</sup> Annual Vaccine Renaissance, Rhode Island**. June 7,8, 2005. Sponsored by the Collaborative for Vaccine Development, Brown University and Tech Collective. Organization, Invitation, Hosting, and Support (CVRD)

- (NCCHC 8)** at the National Commission on Correctional Health Care Conference, sponsored by Infectious Diseases in Corrections. Denver, October 2005. Set agenda, invited speakers, Hosted.
- 3eme Journees de VIH Bamako.** GAIA Vaccine Foundation / Esther/Solthis. Jan 16, 17, 18, 2006 Organization, Invitation, Hosting, and Major Financial Support (GAIA VF).
- WCVII 2006 Montreal.** New Vaccines and Immunotherapeutics. The Fourth World Congress on Vaccines, Immunisation, and Immunotherapy. Board of Scientific Advisors.
- 2nd Annual Vaccine Renaissance, Rhode Island.** June 7-9, 2006. Sponsored by the Collaborative for Vaccine Development, Brown University and Tech Collective. Organization, Invitation, Hosting, and Support (CVRD).
- WCVII 2007 Dubai.** New Vaccines and Immunotherapeutics. The Fifth World Congress on Vaccines, Immunisation, and Immunotherapy. Board of Scientific Advisors.
- (NCCHC 9)** at the National Commission on Correctional Health Care Conference, sponsored by Infectious Diseases in Corrections. Atlanta, October 2006.
- 4eme Journees de VIH Bamako.** GAIA Vaccine Foundation / Esther/Solthis. Jan 17, 18, 19, 2006 Organization, Invitation, Hosting, and Major Financial Support (GAIA VF).
- WCVII 2008 ITALY.** New Vaccines and Immunotherapeutics. The Sixth World Congress on Vaccines, Immunisation, and Immunotherapy. Board of Scientific Advisors.
- Vaccine Renaissance III.** Anne S. De Groot, Denice Spero, co-organizers, Institute for Immunology and Informatics. Providence, RI October, 2009.
- Immunogenicity (PEGS Boston) Anne S. De Groot, Invited speaker and session organizer.** Testing for Immunogenicity. Christina Lingham, host. PEGS Boston (CHI), February 12th 2009. Boston.
- Vaccine Technologies III (Barry Buckland, others, Organizing Committee); Engineering Conferences International;** Mexico, June 2010
- Vaccine Renaissance IV** Anne S. De Groot, Denice Spero, co-organizers, Institute for Immunology and Informatics. Providence, RI October, 2010
- Immunogenicity: Determinants and Correlates.** Anne S. De Groot, Denice Spero, Naren Chirmule (Amgen), Bonnie Rup (Pfizer), Eric Furfine (Eleven, Boston), Eric Wakshull (Genentech), co-organizers, Institute for Immunology and Informatics. **May 2011, Providence RI.**
- Computational Vaccinology Workshop,** Co-organizer with France Terry, EpiVax, Oliver He, University of Michigan, David Koelle, University of Washington, Bill Kwok, Benaroya Institute. **International Vaccine Society World Congress on Vaccines, Seattle Washington, October 2011.**
- Vaccine Renaissance V** Anne S. De Groot, Denice Spero, co-organizers, Institute for Immunology and Informatics. Providence, RI October, 2011.
- Applied Immunoinformatics for Neglected Tropical Diseases. June 2012, Providence RI.**
- Vaccine Renaissance VI** Anne S. De Groot, Denice Spero, co-organizers, Institute for Immunology and Informatics. Providence, RI October, 2012.
- Vaccine Renaissance VII** Anne S. De Groot, organizer, Institute for Immunology and Informatics. Providence, RI October, 2013.
- ICoVax3 (with ISV, Sitges, Spain) 2013**
- Vaccine Renaissance VIII** Anne S. De Groot, organizer, Institute for Immunology and Informatics. Providence, RI October, 2014.



**Journal Reviews (Ad Hoc)**

Journal of Infectious Diseases	1994, 2009
Human Immunology	1995
AIDS	1995
Tubercle (International Union Against TB and Lung Disease)	1997
Nature Biotechnology	1999-2006
Bioinformatics	2000-2006
Proteins: Structure, Function and Genetics	2001
AIDS Reader	2001-2008
AIDS Education and Prevention	2001
Trends in Genetics	2002
Emerging Infectious Diseases	2002-2010, 2013
Trends in Immunology	2003
Immunogenetics	2005
Viral Immunology	2005
Medicine and Health Rhode Island	2007 (Guest Editor)
Lancet	1999- present
Vaccine	2000- present
Clinical Immunology	2009- present
PLOS-One	2010 - present
Human Vaccines and Immunotherapy	2010- present
Immunome Research	2008- present

**Grant Reviews, NIH Study Sections**

Special Review Committee for NIAID: National Cooperative Drug Discovery Group for the treatment of Opportunistic Infections and AIDS	June 1993 / March 1994
Review Committee, Program Project U19 AI 40972 (Heifits, PI)	1998-2000
Global Challenges (Gates Foundation)	2007
Welcome Foundation (Parasitology)	2008

### Press Articles and Interviews

**Clad Against All Clades: Can vaccinomics build a world HIV vaccine?** *The Scientist* Interview by Tom Hollon, September 18, 2000

**The Price of Punishment** *National Public Radio* Interview by Jennifer Schmidt, WBUR Prison Series, (WBUR, Boston) interview on Hepatitis C in Prison. December 20, 2000.

**The Zealot.** *Inc. Magazine* Interview by Thea Singer. Start Up Issue, January 2001.

**R.I. lab veers from convention in AIDS study.** *Providence Journal.* Front Page Interview by Felice Freyer, May 18, 2001

**Brown scientist at work on AIDS vaccine.** *Providence Journal Providence, R.I.* May 14, 2002. Felice Freyer, May 14, 2002.

Interview "**Amazing Women**". WPRO, (FM Radio Talk Show) October 26, 2003. Deb Ruggiero, Host.

**"Best and the Brightest 2003"** (Science and Industry). *Esquire Magazine*, December 2003. "My AIDS Vaccine" as told to Rebecca Dorr.

**"The Code Breaker"**. *Rhode Island Monthly Magazine.* Profile by Ellen Lieberman. June 2004.

**"Amazing women"** *Women in Science.* March 23, 2005. PBSRI Interviewed by Deb Ruggiero about President Summer's remarks on Women in Science.

Featured in *University Magazine: Smith College Alumnae Quarterly* (2010); *University of Rhode Island Quandrangles* (2011).

### Press Quotes and Brief Interviews

#### **New Rules Offered For Inmate Medical Tests. New York Times. October 16, 1999**

A panel member, Dr. Anne S. De Groot, said prisoners with AIDS must be given access to cutting-edge clinical tests but also protected from possible abuses. The panel recommended that prisons where research is done must have quality medical care already available, so inmates do not feel coerced into research programs simply to get proper care.

**Published: October 16, 1999 Computers Aid Vaccine Design, Science Magazine,** Featured interview in story by Michael Hagmann, *Science* 2000 October 6; 290: 80-82. (in News)

**A Health Danger From a Needle Becomes a Scourge Behind Bars** *New York Times,* Front Page. Featured interview in story by David Rohde. August 6th, 2001.

**TB in prison.** *TB Monitor.* Featured interview in story Alice Alexander. Fall 2000.

**HIV Testing of State Prisoners Not Mandatory.** *Indianapolis Star* (10.21.01) - Wednesday, October 24, 2001 Mike Ellis

**Hepatitis C has higher incidence among inmates. Many prisons opting to withhold treatment.** September 5, 2001 Associated Press

**A Health Danger From a Needle Becomes a Scourge Behind Bars.** *New York Times* (New York Report) August 6, 2001. David Rhode



**Hepatitis C Spreads Mostly Unchecked in Prisons.** Reuters. April 5 2001. Alan Elsner, National Correspondent.

**HIV Testing of State Prisoners Not Mandatory.** Indianapolis Star (10.21.01): Mike Ellis.

**Alabama Prison at Center of Suit Over AIDS Policy.** *New York Times* (National News Section). October 26, 2003. Adam Liptak.

**Top For 2003 (Providence Monthly's third annual ten people you don't know now, but soon will).** *Providence Monthly*, 2003.

Can HIV Care Click in the Clink? *Poz Magazine*. April 2004.

**Mass Biotech News** // Biotechnology publications – Press reports about **Smallpox, Tularemia** vaccines 2004-2007.

**Boston Herald story on not-for profit work of Professor Annie De Groot , October 2009“ The power of one”** <http://tinyurl.com/herald-story>

**Providence Business News: URI's De Groot wins \$13M NIH grant, July 28, 2009**

Aug 2, 2009 A \$13 million National Institutes of Health grant awarded to vaccine researcher Anne S. De Groot is expected to move a slew of projects from the basic-science stage to preparations for clinical trials, advancing the fight against tick-borne diseases, hepatitis C, ulcers and more <http://tinyurl.com/I-Cubed2009>

**Institute for Immunology and Informatics** – opening of the new Institute, story in the Providence Journal: <http://tinyurl.com/13M-Validation-Epi-Technology>

**Providence Journal article on L. J. De Groot and A. S. De Groot - Father Daughter Collaboration at URI** <http://tinyurl.com/father-daughter-2009>

**Modeling the bug, the host, the world: Computational Biology catches the FLU**, by Katherine Miller 16 BIOMEDICAL COMPUTATION REVIEW Summer 2006 . Article describing our work on influenza (and the work of others who are using computational biology to model the flu:

<http://www.biomedicalcomputationreview.org>

**Providence Business News: Dec 2, 2009 EpiVax signs deal with drug giant Roche** . EpiVax Inc. said Tuesday it has signed a research deal with the giant Swiss drugmaker Roche Holding AG to evaluate the biotechnology firm's main product candidate.

**Providence Business News: Feb 26, 2011 Research taking bite out of tick-borne diseases**

A \$200,000 grant from the R.I. Science and Technology Advisory Council allows University of Rhode Island researchers to work on continued development of an anti-tick vaccine, but now the vaccine would be delivered through the use of a transdermal patch. . . .

**Providence Business News: Feb 19, 2011 Rewarding innovation in vaccine research**

A nearly \$200,000 grant from the Rhode Island Science and Technology Advisory Council allows researchers, including EpiVax Inc. founder Annie De Groot, above, to continue work on an anti-tick vaccine delivered through the use of a transdermal patch. De Groot has been working with University of Rhode Island researchers on the vaccine, which remains years away from the marketplace. The grant allows Isis Biopolymer Inc. to join in the project, to help develop a delivery system for the vaccine. more

**Providence Business News Jan 25, 2011: EpiVax receives \$458,000 NIH grant** to develop universal influenza vaccin. EpiVax Inc. said Tuesday it has received a \$458,000, two-year grant to develop a universal influenza

**Providence Business News Nov 13, 2010 PROVIDENCE – Clinica Esperanza has new Providence home.** With the help of numerous volunteers, Clinica Esperanza/Hope Clinic moved into permanent space at 60 Valley St. on Nov. 5.

**Providence Business News: July 18, 2010 - URI hires 14 researchers for vaccine fellowship from stimulus act grant.** Biotech entrepreneur and researcher Anne De Groot has won a \$212,000 grant through the American Recovery and Reinvestment Act, allowing her University of Rhode Island lab to hire 14 students and recent graduates as summer research fellows. . . .

**Providence Business News: May 26, 2010 Pharma scientists give award to EpiVax.** EpiVax Inc. has received the Innovation in Biotechnology award from the American Association of Pharmaceutical Scientists for the company's research on Tregitopes, or t-cell epitopes. . . .

**Blog: Thinking Out Loud**

**Twitter @AnnieDMobile**